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1. INTRODUCTION 
1.1. Insulin  
Insulin is the most potent anabolic hormone and is essential for 
appropriate tissue development and growth as well as the 
maintenance of whole-body glucose homeostasis (Chang et al., 
2004). Insulin is secreted by the β cells of the pancreatic islets of 
Langerhans in response to increased circulating levels of glucose and 
regulates glucose homeostasis by reducing hepatic glucose output via 
decreased gluconeogenesis and glycogenolysis and increasing the 
rate of glucose uptake into muscle and adipose tissue (Rinderknecht 
and Humbel, 1978, Burks and White, 2001) 
Human insulin contains 51 amino acids (molecular weight 5700 
daltons) and is structurally homologous to insulin-like growth factors 1 
and 2 (IGF1 and 2) and also to the ovarian hormone, relaxin (Bell et 
al., 1980, Dull et al., 1984, Nussey S, 2001). It is synthesized in the β 
cells of the pancreatic islets. The gene for insulin codes for pre-
proinsulin which is made up of a signal sequence, and the B chain, 
connecting (or C) peptide and A chain (Figure 1). The A and B chains 
are joined together by two disulfide bonds between common cysteine 
amino-acid residues. The C peptide is essential to the formation of 
these disulfide bonds and is cleaved in the Golgi apparatus leaving 
the joined A and B chains which form the active insulin molecule 
(Duckworth, 1988) The cleaved C peptide is co-secreted with insulin, 
a point of great clinical importance. Previously considered to have no 
physiological role, C peptide is now recognized to have G-protein-
coupled cellular receptors and is likely to have some function in 
regulating blood flow and renal function (Philippe, 1991). 
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Figure 1: Synthesis of insulin.  
1. Structure of the insulin gene, 2. Mature messenger RNA after exicision of the introns, 
3. Structure of proinsulin after cleavage of the signal sequence from pre-proinsulin, 4. 
Cleavage of the C peptide leaving biologically active insulin, 5. Packaging of insulin and 
C-peptide in secretory granules for storage and release (Nussey S, 2001). 
 
When β cells are appropriately stimulated, insulin is secreted by 
exocytosis and diffuses into the blood of islet capillaries. Insulin is 
secreted in pulses and has a t1/2 in the systemic circulation of 
approximately 3 minutes (Rubenstein et al., 1972, Lang et al., 1979). 
About 50% is removed by the liver. This is known as the ‘first-pass’ 
effect (i.e. the first time insulin passes through the liver). Insulin that 
has escaped the liver's inactivating activity exerts important regulatory 
actions on peripheral tissues. C peptide is released in a 1:1 ratio with 
insulin and since it is not significantly removed by the liver, has a t1/2 of 
30 min. For this reason, the measurement of C-peptide has been used 
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as an index of insulin secretion (Rubenstein et al., 1972, Horwitz et 
al., 1975). 
1.1.1. Physiological effects 
Insulin regulates energy metabolism by stimulating cells in peripheral 
tissues to incorporate glucose from the blood and stimulating the 
storage of glycogen in the liver and muscle and lipids in adipose 
tissue. The ultimate effector system for regulating glucose disposal is 
the translocation of vesicles containing glucose transporters (GLUT) 
to the plasma membrane to increase the rate of cellular glucose 
transport (Suzuki and Kono, 1980). When insulin is absent, glucose is 
not taken up by body cells and the body begins to use fat as an 
energy source. The hyperglycemia observed in diabetes results from 
impairments in insulin secretion, insulin action, or a combination of 
both (Kahn et al., 1993, Kahn, 1998).  
The action of insulin in controlling the overall flow of fuels is 
summarized in Table 1. In the liver, insulin promotes glycogen 
synthesis by stimulating glycogen synthetase and inhibiting glycogen 
phosphorylase although it has no direct effect on the GLUT 2 and, 
hence, the uptake of glucose into hepatocytes (Board et al., 1995). In 
contrast, insulin induces a rapid uptake of glucose in muscle and fat 
tissue by recruiting intracellular GLUT 4 and, thus, increasing their 
cell-surface expression (Klip and Pâquet, 1990). As a consequence, 
muscle converts glucose to glycogen. In adipose tissue, glucose is 
converted to fatty acids for storage as triglyceride. Insulin also 
stimulates the uptake of amino acids into muscle. At the same time, 
insulin suppresses mobilization of fuels by inhibiting the breakdown of 
glycogen in the liver, the release of amino acids from muscle and the 
release of free fatty acids from adipose tissue. This explains, in part, 
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why patients with Diabetes Mellitus (DM) lose weight although they 
have normal or increased appetite (Woods et al., 1979, Ikeda et al., 
1986, Schwartz et al., 1992, Baskin et al., 1999, Burks et al., 2000). 
INSULIN ACTION 
Liver Muscle Adipose tissue 
+ glycogen 
synthesis + glucose uptake + glucose uptake 
+ glycolysis + amino acid uptake 
+ free fatty acid 
uptake 
- glycogenolysis - proteolysis - lipolysis 
- gluconeogenesis   
- ketogenesis   
 
Table 1: Effects of insulin on the flow of fuels in the body.  
(+) stimulates and (-) inhibits. 
1.1.2. Insulin receptor 
Insulin action is initiated through binding and activating its cell surface 
receptor (IR), which consists of two α subunits and two β subunits that 
are disulfide linked into an α2β2 heterotetrameric complex (Pessin 
and Saltiel, 2000).  IGF1 signals via the type 1 IGF1 receptor (IGF1R), 
a widely expressed cell-surface heterotetramer, highly similar to the 
IR, which possesses intrinsic kinase activity in its cytoplasmic domains 
(Favelyukis et al., 2001).  Insulin binds to the extracellular α subunit of 
the IR/IGF1R and modifies the α subunit dimer which mediates trans-
autophosphorylation between the membrane-spanning β subunits 
(White, 1997).  This activates the intrinsic tyrosine kinase activity of 
the intracellular β subunit of the receptor which then leads to tyrosine 
phosphorylation of a variety of docking proteins.   
Interestingly, unlike other receptor tyrosine kinases that bind directly 
to the cytoplasmic tails of downstream effectors, the IR and the IGF1R 
 utilize insulin receptor substrate (IRS) proteins to mediate the binding 
of intracellular effectors 
of the IR/IGF1R is tightly regulated, as unchecked activation or 
inactivity would lead to profound metabolic consequences. Ligand
stimulated internalization and degradation of the IR is a common 
feature of most insulin
obesity and type
third member of the insulin receptor family is insulin receptor
receptor (IRR).  Despite similar homology, IRR is still an orphan 
receptor with obscure function and is expressed in few tissues 
(Klammt et al., 2005
IGF1R is the C
(Hanke and Mann, 2009
Figure 2: 
Each receptor is 
dimers are derived from separate genes and the IR has two splice variants, IR
Therefore, combinations of the single α
bind to several 
extracellular portion of the receptor while the β subunit spans the membrane and its 
cytoplasmic portion interacts with IRS proteins
 
 2 Diabetes 
).  The main difference compared to the IR and 
-terminal region which lacks at least 50 amino acids 
Structure of Receptors for insulin, IGF1, and IGF2.   
composed of a
hybrid receptors, albeit at different affinities. The α subunit is the 
(Ullrich and Schless
-resistant, hyperinsulinemic states, including 
Mellitus (T2D)
). 
 α2β2 heterotetrameric complex.
-β dimers exist and insulin, IGF1, and IGF2 can 
. 
inger, 1990
 (Friedman et al., 1997
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1.1.3. Insulin signal transduction 
Once activated, the IR phosphorylates a number of important proximal 
substrates on tyrosine, including members of the insulin receptor 
substrate family (IRS1/2/3/4), the SHC adapter protein isoforms, 
signal-regulatory protein (SIRP) family members, growth factor 
receptor bound protein 2 associated protein 1 (GAB1), Casitas B-
lineage lymphoma (CBL) , and SH2B adaptor protein 2 (APS) 
(Pawson and Scott, 1997, White and Yenush, 1998, Nelms et al., 
1999). Tyrosine phosphorylation of the IRS proteins creates 
recognition sites for additional effector molecules containing Src 
homology 2 (SH2) domains (Burks and White, 2001, Rui and White, 
2003). These include the small adapter proteins growth factor receptor 
bound protein 2 (GRB2) and non-catalytic region of tyrosine kinase 
adaptor protein (NCK), the SHP2 protein tyrosine phosphatase and, 
most importantly, the regulatory subunit of the type 1A 
phosphatidylinositol 3 kinase (PI3K) (Figure 3).  
Two classes of serine/threonine kinases are known to act downstream 
of PI3K (Coffer et al., 1998), namely the serine/threonine kinase AKT, 
also known as protein kinase B (PKB) or thymoma viral proto-
oncogene 1, and the atypical protein kinase C isoforms z and l 
(PKCz/l) Each IRS protein contains a highly conserved NH2-terminal 
pleckstrin homology (PH) domain followed by a phosphotyrosine- 
binding (PTB) domain, which together couple IRS proteins to the 
activated insulin or IGF1 receptors (Myers et al., 1998, Yenush et al., 
1996). IRS proteins contain 8–18 potential tyrosine phosphorylation 
sites in various amino acid sequence motifs, which bind after 
phosphorylation to the SH2 domains in effector proteins, including the 
regulatory subunit of the lipid kinase PI3K, GRB 2, NCK, and SHP2 
(Myers Jr and White, 1996, Sun et al., 1995). Products of PI3K 
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activate a network of serine-threonine kinases implicated in the action 
of insulin on glucose transport, glycogen synthesis, protein synthesis, 
antilipolysis, and the control of hepatic gluconeogenesis (White, 2006) 
(see Figure 3).  
Activated AKT induces glycogen synthesis, through inhibition of 
glycogen synthase kinase 3 beta (GSK3β), protein synthesis via 
mammalian target of rapamycin serine/threonine kinase (mTOR) and 
downstream elements (Engelman et al., 2006), and cell survival, 
through inhibition of several pro-apoptotic agents (BCL2-associated 
agonist of cell death (BAD), forkhead family transcription factors, GSK 
3). PI3K and AKT play critical roles in GLUT4 translocation 
(Fasshauer et al., 2000). Stable expression of a constitutively active 
membrane-bound form of AKT in 3T3L1 adipocytes results in 
increased glucose transport and persistent localization of GLUT4 to 
the plasma membrane (Hill et al., 1999). Conversely, expression of a 
dominant interfering AKT mutant inhibits insulin-stimulated GLUT4 
translocation.PKCz is also activated by polyphosphoinositides, which 
accumulate in insulin-treated cells; PKCz is, therefore, also sensitive 
to pharmacologic PI3K inhibitors, such as wortmannin (Fasshauer et 
al., 2000). Expression of PKCz or PKCl is also reported to induce 
GLUT4 translocation, whereas expression of a dominant-interfering 
PKCl inhibited GLUT4 translocation.  
 
Insulin promotes the uptake of fatty acids and the synthesis of lipids, 
whilst inhibiting lipolysis (Kahn, 2001). Lipid synthesis requires an 
increase in the transcription factor steroid regulatory element-binding 
protein 1c (SREBP1c) (Shimomura et al., 2000). However, the 
pathway leading to changes in SREBP expression are unknown. 
Insulin inhibits lipid metabolism through decreasing cellular 
concentrations of cyclic adenosine monophosphate (cAMP) by 
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activating a cAMP specific phosphodiesterase in adipocytes (Kubota 
et al., 1999, Kahn, 2001). Insulin signaling also has growth and 
mitogenic effects, which are mostly mediated by the AKT cascade as 
well as by activation of the RAS/RAF/mitogen-activated protein (MAP) 
kinase (RAS/MAPK) cascade. A negative feedback signal emanating 
from AKT, PKCΖ, p70 S6K and the MAPK cascades results in serine 
phosphorylation and inactivation of IRS signaling (White, 2003).  
 
Figure 3: A simplified view of insulin/IGF1 signaling through IRS proteins.   
Activation of the receptors for insulin and IGF-I results in tyrosine phosphorylation of the 
IRS proteins. The IRS proteins then recruit PI 3-kinase, Grb2/son of sevenless (SOS), 
and SHP-2. The Grb2/SOS complex mediates the activation of p21ras, thereby 
activating the ras/raf/mitogen-activated protein (MAP) kinase kinase (MEK)/MAP kinase 
cascade. SHP-2 feeds back to inhibit IRS protein phosphorylation by directly 
dephosphorylating the IRS protein and may transmit an independent signal to activate 
MAP kinase. The activation of PI 3-kinase by IRS protein recruitment results in the 
generation of PI-3,4-diphosphate (PI3,4P2) and PI-3,4,5-triphosphate (PI3,4,5P3). In 
aggregate, PI3,4P2 and PI3,4,5P3 activate a variety of downstream signaling kinases, 
including the mammalian target of rapamycin (mTOR), which regulates protein 
synthesis via PHAS/p70 S6 kinase (p70S6k). These lipids also activate 
phosphoinositide-dependent kinase (PDK) isoforms. The PDKs (PDK1, PDK2) activate 
protein kinase B (PKB or AKT), which mediates glucose transport in concert with the 
atypical PKC isoforms. AKT also regulates glycogen synthase kinase 3 (GSK-3) in 
glycogen synthesis, and a variety of regulators of cell survival. (White, 2002). 
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1.1.4. Insulin Receptor Substrates 
The Insulin Receptor Substrate (IRS) proteins are a family of 
cytoplasmic adaptor proteins that were first identified based on their 
role in insulin signaling. At least 11 intracellular substrates of the 
IR/IGF1R have been identified and at least four of these belong to the 
IRS family of proteins  (Taniguchi et al., 2006). The first family 
member to be identified, IRS 1, was initially characterized as a 185kD 
phosphoprotein that was detected in anti-phosphotyrosine 
immunoblots in response to insulin stimulation (White et al., 1985). 
IRS 2 was discovered as an alternative insulin receptor substrate, 
initially named 4PS, in insulin-stimulated cells derived from from Irs1-/- 
mice (Patti et al., 1995, Sun et al., 1995). 
IRS 1 appears to be ubiquitously expressed. IRS 2 was identified as a 
component of the interleukin 4 (IL4) signaling pathway, but it is now 
known to be expressed in nearly all cells and tissues (Boura-Halfon 
and Zick, 2009). IRS 3 is predominantly expressed in adipose tissue, 
and it was purified and cloned from rat adipose tissue (Lavan et al., 
1997). However, IRS3 has not been detected in humans (Björnholm et 
al., 2002). IRS 4 was purified and cloned from HEK293 cells, where it 
is the major IRS protein. IRS 4 is expressed predominantly in the 
pituitary, thymus, and brain (Fantin et al., 1999).  
Despite their significant structural homology (Figure 4), it is clear from 
the genotypes of knockout mice that the IRS proteins have non-
redundant physiological functions. Irs1-/- mice are born small and 
remain so throughout their lives, implicating a role for this IRS protein 
in somatic growth regulation (White, 1997, Withers et al., 1998). A 
similar contribution of the IRS homolog Chico to the regulation of cell 
size and growth in Drosophila has been observed (Böhni et al., 1999). 
Mice deficient for Irs1 develop insulin resistance but do not progress 
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to diabetes because they maintain normal pancreatic β-cell numbers. 
Irs2-/- mice are normal in size but have brain defects, the result of a 
50% decrease in neuronal proliferation. In contrast to Irs1-/- mice, 
IRS2-deficient mice develop early-onset diabetes due to a 
combination of peripheral insulin resistance and a loss of β-cell 
function (Withers et al., 1998, Burks and White, 2001). Irs2-/- females 
are also infertile, which together with evidence from insulin-signaling 
in Drosophila and C. elegans, supports a conserved mechanism for 
integrating reproduction and metabolism (Burks et al., 2000). Irs4-/- 
mice are phenotypically normal, with only mild growth, reproductive 
and insulin sensitivity defects (Mardilovich et al., 2009). Thus, 
IRS1/IRS2 are not redundant and appear to regulate unique signals in 
various tissues, whereas in certain tissues two IRS proteins might 
reinforce each other as in the case of IRS1/IRS3 in adipocytes (White, 
2002). A summary of phenotypes resulting from deletion of IRS 
proteins is presented in Table 2. 
 
Table 2: Murine phenotypes produced by IRS protein deficiency (Burks and 
White, 2001). 
1.1.4.1. Structure and isoforms 
Alignment of the amino acid sequences of the IRS proteins reveals 
important similarities and differences (Figure 4). Mammalian IRS1,2,3, 
and IRS4, and the Drosophila ortholog Chico contain an NH2-terminal 
PH domain adjacent to a phosphotyrosine-binding domain (Burks et 
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al., 1998). The PH domain possibly directs IRS proteins to the 
membrane in proximity to the IR/IGF1R and the PTB domain binds to 
phosphotyrosine 960 located in a NPXY (Asparagine-Proline-
Unspecified-Tyrosine) motif of the juxtamembrane region of the 
IR/IGF1R (Biddinger and Kahn, 2006) but hindrance of these 
interactions by serine/threonine phosphorylation negatively affects 
insulin signalling (Voliovitch et al., 1995). The structures of these 
domains are remarkably similar, and both facilitate recruitment of IRS 
proteins to the activated insulin and IGF-1 receptors. Deletion of both 
domains almost completely prevents tyrosine phosphorylation, even 
when insulin receptors are expressed at high levels (Burks et al., 
1997). PH domains can be exchanged among IRS proteins without 
noticeable loss of bioactivity, but chimeric IRS proteins composed of 
heterologous PH domains that are known to bind phospholipids are 
not phosphorylated by the insulin receptor (Burks et al., 1997). The 
center and C-terminus contain up to 20 potential tyrosine 
phosphorylation sites that after phosphorylation by the IR/IGF1R, bind 
to intracellular adaptor molecules that contain Src-homology-2 (SH2) 
domains, such as the p85 regulatory subunit of PI3K or GRB2. 
Serine/Threonine phosphorylation adjacent to tyrosine 
phosphorylation sites impedes binding of the SH2 domains of IRS 
proteins, thus inhibiting insulin signalling (Boura-Halfon and Zick, 
2009). More distantly related IRS family members IRS 5 and IRS 6, 
also known as DOK4 and DOK5 (Cai et al., 2003, Favre et al., 2003), 
share homology in their N-termini, but have truncated C-termini 
(Figure 4).  
IRS2 contains a unique region of undefined structure that binds to the 
phosphorylated regulatory loop of the insulin receptor kinase called 
the kinase regulatory loop-binding (KRLB) domain (Sawka-Verhelle et 
al., 1997). Phosphorylation of tyrosine residues in the KRLB domain 
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by the insulin receptor inhibits IRS2 binding to the receptor, 
suggesting a novel mechanism regulating
receptor and IRS2 that might distinguish the signal of IRS2 from IRS1. 
There are also multiple amino acid sequence differences between 
IRS1 and IRS2 that might create unique interaction sites for other 
partner proteins to fi
2003). 
 
Figure 4: Structure of 
Interaction domains of the IRS proteins are indicated. PH (blue), pleckstrin 
domain; PTB (red), phosphotyrosine binding domain; KRLB (pink), kinase regulatory 
loop binding domain; PI3K (orange), region containing multiple PI3K binding motifs; 
Grb-2 (green), Grb
contain unique regions in their C termini (purple).
Regulatory-Loop Binding, 
to control the extent of tyrosine phosphoylation of IRS2
2009). 
1.1.4.2. Irs
The crucial role of IRS proteins in insulin action has been 
demonstrated using transgenic knockout mouse models. A compelling 
molecular link to diabetes emerged from the finding that loss of the 
IRS2 branch of the insulin/IGF signaling system in mice impai
ne-tune the biologic signals 
IRS protein family
-2 binding site; SHP
pink) domain which serves as a negative regulatory element 
2-deficient mouse model
 the interaction of the insulin 
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capacity of the pancreatic β-cells to compensate for insulin resistance 
(Burks and White, 2001). Targeted disruption of the Irs2 gene was first 
reported by the laboratory of Morris White (Withers et al., 1998). Irs2 
deficiency causes peripheral insulin resistance due to defective insulin 
action but it also prevents β cell compensation. Histological analysis 
revealed that, as early as 4 weeks, β cell mass is reduced by 17% 
compared with wild-type, in marked contrast to the 85% increase in β 
cell mass in Irs1-/- islets (Withers et al., 1998, Burks and White, 2001). 
Irs2-/- mice develop hyperinsulinemia as young adults, and males 
usually die by 12 weeks of age whereas diabetes in females 
progresses less rapidly and many live until around 24 weeks of age 
(Burks et al., 2000). As the disease progresses, pancreatic islet size 
invariably decreases and β cell function fails.  
Irs2-/- mice also display profound peripheral insulin resistance, 
particularly at the hepatic level (White, 1997, Withers et al., 1998, 
Previs et al., 2000). More recent studies with conditional knockout 
models have confirmed the importance of IRS2 signals for maintaining 
hepatic insulin sensitivity (Dong et al., 2006). Irs2-/- mice also display 
dysregulated lipolysis characteristic of insulin resistance (Garcia-
Barrado et al., 2011). Thus, the Irs2-deficient model provides proof-of-
concept that a single gene mutation can induce both peripheral insulin 
resistance and the β cell deficiency typical of T2D (Brady, 2004). In 
contrast, Irs1-/- mice never develop diabetes because they display 
lifelong, compensatory hyperinsulinemia (White, 2002, White, 2006). 
The progression of Irs2-/- mice toward diabetes is retarded or 
prevented by modifying elements of the insulin/IGF-signaling cascade 
that promote compensatory β cell function, including downregulation 
of protein tyrosine phosphatase PTP1b or the transcription factor 
Foxo1; or upregulation of AKT or pancreatic duodenal homeobox 1 
(PDX1). Transgenic upregulation of Irs2 in pancreatic β cell also 
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prevents diabetes in Irs2-/- mice, obese mice, and streptozotocin-
induced diabetic mice by promoting sufficient and sustained 
compensatory insulin secretion (Lin et al., 2004).  
Irs2 null mice also display a dysregulation of appetite at the 
hypothalamic level (Bruning et al., 2000, Lin et al., 2004). 
Furthermore, increased food intake is further complicated by 
abnormalities in fuel storage; Irs2-/- mice weigh 20% more and store 
twice as much body fat as age-matched controls (Burks et al., 2000). 
Interestingly, the development of peripheral insulin resistance could 
be uncoupled from increased fat mass, suggesting that the reduction 
in hypothalamic IRS2 mediated signalling affected insulin sensitivity in 
other tissues (Kubota et al., 2004, Taguchi et al., 2007). Irs2-
deficiency also causes elevated leptin levels and central nervous 
system (CNS) resistance to leptin (Burks et al., 2000), suggesting 
crosstalk between leptin and insulin signaling in regulating 
hypothalamic neuronal energy sensing and appetite. Irs2-deficient 
females are infertile due to reduced pituitary size and gonadotroph 
numbers, a decrease in concentrations of luteinizing hormone (LH) in 
plasma, a reduction in ovary size, reduced numbers of follicles, and 
consequent anovulation (Burks et al., 2000). Although IRS2 signaling 
in the CNS plays crucial roles in energy homeostasis (Choudhury et 
al., 2005), signaling events downstream of IRS2 in the ovary play 
critical roles in follicular development and ovulation by regulating key 
components of the cell-cycle (Neganova et al., 2007). However, the 
mechanisms by which reduced Irs2 expression in the brain diminishes 
both central leptin sensitivity and peripheral insulin sensitivity are 
unclear (Brady, 2004).  
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1.2. Type 2 Diabetes Mellitus 
1.2.1. Definition and epidemiology 
Type 1 diabetes (T1D) is due primarily to autoimmune-mediated 
destruction of pancreatic β cell islets, resulting in absolute insulin 
deficiency. Its frequency is low relative to type 2 diabetes, which 
accounts for over 90% of cases globally (Amos et al., 1997). Type 2 
diabetes (T2D) is characterized by insulin resistance and/or abnormal 
insulin secretion, either of which may predominate. Patients with T2D 
are not dependent on exogenous insulin, but may be required if 
control of blood glucose levels if this is not achieved with diet alone or 
with oral hypoglycaemic agents (Campbell, 2000). The “diabetes 
epidemic” particularly describes T2D, and is occuring both in 
developed and developing nations.  
Prevalence of diabetes in adults worldwide was estimated to be 4.0% 
in 1995 and to rise to 5.4% by the year 2025 (King et al., 1998). It is 
higher in developed than in developing countries. The world 
prevalence of diabetes among adults (20-79 years) will be 6.4%, 
affecting 285 million adults, in 2010, and will increase to 7.7%, and 
439 million adults by 2030 (Shaw et al., 2010). Between 2010 and 
2030, there will be a 69% increase in numbers of adults with diabetes 
in developing countries and a 20% increase in developed countries. 
The countries with the largest number of people with diabetes are, 
and will be in the year 2025, India, China, and the U.S. In developing 
countries, the majority of people with diabetes are in the age range of 
45-64 years. In the developed countries, the majority of people with 
diabetes are aged 65 years. 
The Di@bet.es Study is the first national study to examine the 
prevalence of diabetes and impaired glucose regulation in Spain. The 
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results of this study indicate an increase in the prevalence of diabetes 
mellitus: 13.8% of the Spanish population over 18 years of age suffers 
from diabetes, whereas 30% present with either impaired fasting 
glucose or impaired glucose tolerance (Soriguer et al., 2012). 
Diabetes mellitus and impaired glucose regulation (IGR) were 
significantly associated with a greater frequency of obesity, high blood 
pressure, hypertriacylglycerolaemia and low HDL cholesterol 
(Soriguer et al., 2012, Marcuello et al., 2012).  
The current criteria for the diagnosis of T2D established by the 
American Diabetes Association Expert Committee on Diagnosis and 
Classification of Diabetes Mellitus are: a random plasma glucose of 
≥200mg/dl (11,1 mmol/l); or a fasting plasma glucose (FPG) of 
≥126mg/dl (7,0 mmol/l); or a two-hour oral glucose tolerance test with 
plasma glucose ≥200 mg/dl. Abnormal FPG is ≤110mg/dl (6,1 mmol/l) 
and a FPG 110–126mg/dl is defined as impaired glucose tolerance, 
impaired fasting glucose, or prediabetes (Lieberman, 2003).   
1.2.2. Inflammation and potential molecular mechanisms of 
insulin resistance 
The ability of insulin to stimulate glucose disposal varies at least six-
fold in healthy individuals, and approximately one-third of the 
population is resistant to insulin action. When insulin-resistant 
individuals cannot maintain the hyperinsulinemia needed to overcome 
the defect in insulin action, T2D develops, and this was the first 
clinical syndrome identified as insulin resistance. The combination of 
insulin resistance and hyperinsulinemia increases the risk of 
developing other diseases involved in other tissues (Reaven, 2004b, 
Reaven, 2004a). 
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Defects in insulin-receptor function are associated with insulin-
resistant states such as obesity and T2D. Mutations in the IR gene 
have been identified in patients with genetic syndromes of extreme 
insulin resistance (Taylor, 1992). In other patients, insulin resistance 
results from a decrease in the number of insulin receptors on the cell 
surface (Gavin et al., 1974, Epstein et al., 1991) However, defects in 
downstream signalling cascades may account for insulin resistance in 
most T2D patients. Most if not all insulin signals are produced or 
modulated through tyrosine phosphorylation of IRS 1, 2, its homologs, 
or other scaffold proteins. Dysregulation of these IRS proteins by 
proinflammatory cytokines impairs glucose tolerance as a result of 
peripheral insulin resistance (Starr et al., 1997, Yasukawa et al., 2000, 
Rui et al., 2001, Yuan et al., 2001). The idea that inflammation is 
associated with insulin resistance has been known for a long time and 
is consistent with the finding that stress-induced cytokines tumor 
necrosis factor α (TNF-α) and interleukin 6 (IL6) cause insulin 
resistance, suggesting that diet, physiological stress, and obesity 
promote insulin resistance (Derek LeRoith  MD, 2003).  
TNF α via activation of their transduction pathways, are able to alter 
insulin signaling by inactivating IRS through serine/threonine 
phosphorylation (Hotamisligil et al., 1996). There are many 
serine/threonine kinases are involved in the inhibition of 
phosphorylation of insulin signaling: I-kappa-β kinase (IKKβ), c-Jun 
NH2-terminal kinase (JNK) and protein kinase C θ (PKC θ). JNK 
phosphorylates numerous cellular proteins, including IRS 1 and IRS 2, 
SHC, and GAB1 (Rui et al., 2001, Lee et al., 2003, Taniguchi et al., 
2006, Boura-Halfon and Zick, 2009) A role for JNK during insulin 
action is compelling, as both IRS 1 and IRS 2 contain JNK binding 
motifs. Both factor pathways are activated in obesity, not only in 
response to adipokines, but also by increased free fatty acid 
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concentrations and oxidative stress. As well as its link with insulin 
resistance, JNK activity regulates insulin production, while selective 
inhibition of JNK improves insulin production in the pancreatic islets of 
obese mice in response to glucose (Hirosumi et al., 2002). 
Ubiquitin-mediated degradation of IRS1 and IRS2 also promotes 
insulin resistance (Rui et al., 2002). IL6 secreted from leukocytes and 
adipocytes increases expression of suppressor of cytokine signaling 
proteins (SOCS), which are known for their ability to inhibit cytokine 
receptor signaling. However, SOCS1 and SOCS3 also recruit an 
elongin BC-based ubiquitin ligase into the IRS protein complexes to 
mediate ubiquitinylation. Protein or lipid phosphatases, including 
protein-tyrosine phosphatase 1B (PTP1B), SH2-containing inositol 
phosphatase 2 (SHIP2) or phosphatase and tensin homologue 
deleted on chromosome ten (PTEN) inhibit insulin signaling. 
Disruption of each gene in mice increases insulin sensitivity (White, 
2003, White, 2002).  
1.3. Obesity 
1.3.1. Definition and epidemiology 
Obesity has been classified as a ‘global epidemic’ by the WHO. At 
least 2.8 million adults die each year as a result of being overweight or 
obese. The WHO estimates that globally there are more than 1 billion 
overweight adults [Body Mass Index in kg/m2 (BMI) > 27], 300 million 
of whom are obese (BMI > 30). Overweight and obesity are linked to 
more deaths worldwide than underweight pathologies (Wang et al., 
2002, Popkin and Gordon-Larsen, 2004, Mendez et al., 2005). In 
adults, obesity is associated with an increased risk of diseases that 
 are a major cause of morbidity and mortality, 
23% of the 
of certain cancer burdens are attributa
(Organization, 2010
et al., 2012
weight, composition, and the storage of energy as triglyceride (TG) in 
adipose tissue are determined by the interaction between genetic, 
environmental, and psychosocial factors 
 
Figure 5: Population 
Under conditions of normal energy intake and expenditure, subpopulations with a 
normal genetic background or with a genetic susceptibility to obesity have comparable 
body mass indices (BMI, expressed as mass in kg divided by squared he
When energy intake is high, the BMI distribution curve shifts to the right. This shift is 
more pronounced in a subpopulation with genetic susceptibility for obesity. An additional 
reduction in energy expenditure results in a further rise in BMI
the subpopulations. Patients with rare monogenic forms of obesity show a marked 
increase in BMI irrespectively of the environmental conditions 
 
BMI is a simple index of weight
to classify overweight and obesity in adults. It is defined as a person's 
weight in kilograms divided by the square of his height in meters 
(kg/m2). The WHO define overweight as a BMI greater than or equal 
ischemic heart disease burden and between 7% and 41% 
, Organization, 2011
). Obesity is a complex disease 
distribution of BMI. 
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to 25 and obesity with a  BM
distribution plays an important role in metabolic risk
Jensen, 2008)
shaped obesity) promotes a high risk of metabolic disease, whereas 
increased subcutaneous fat in the thighs and hips (peripheral or pear
shaped obesity) exerts little or no risk (
distribution can be measured by body mass index (BMI) and waist
ratio (WHR) or waist circumference
Figure 6: Fat Distribution 
Obesity is the consequence of an excess in fat accumulation and is defined by a 
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secreting hormones, cytokines, and proteins that affect the function of 
cells and tissues throughout the body (Gesta et al., 2007). 
The CNS influences energy balance and body weight through three 
mechanisms (Spiegelman and Flier, 2001): (1) effects on behaviour, 
including feeding and physical activity; (2) effects on autonomic 
nervous system activity, which regulates energy expenditure and 
other aspects of metabolism; and (3) effects on the neuroendocrine 
system, including secretion of hormones such as growth hormone, 
thyroid, cortisol, insulin, and sex steroids. 
1.3.2. Adipose Tissue  
All animal species, from C. elegans to Homo sapiens have developed 
a mechanism for storing excess energy in the form of fat for future 
needs. In most species, fat storage occurs in a mesodermal tissue 
(Gesta et al., 2007). Adipose tissue (AT) has been historically 
considered as an inert tissue, providing a site for passive fat 
accumulation, insulation against heat loss and mechanical and/or 
structural support. However, newly recognized endocrine, paracrine 
and autocrine activities of AT have forced a re-evaluation of this static 
view of AT biology. Research of the last two decades has 
demonstrated the importance of white adipose tissue (WAT) 
metabolism and WAT-derived factors in the development of obesity 
and systemic insulin resistance. WAT secretes bioactive molecules, 
generally termed  adipokines ,that modulate fat storage, adipogenesis, 
energy metabolism, and food intake (Zulet et al., 2012). 
When the intake of energy chronically exceeds energy expenditure, 
the excess energy is stored in the form of triglycerides (TG) in 
adipocytes. Increased AT mass may be produced by an increase in 
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cell size, cell number, or both since adipose cells are variable in size, 
reflecting principally the amount of stored TG (Björntorp, 1974, 
Johnson et al., 1978, Björntorp et al., 1982). Mild obesity mainly 
reflects an increased adipose cell size (hypertrophic obesity) while 
more severe obesity also involves an increased fat cell number 
(hyperplastic obesity). The reversible response to obesity treatment 
may be related to the plasticity of AT. Studies in humans and other 
models of obesity indicate that an increase in cell size (adipocyte 
hypertrophy) often precedes increases in cell number (adipocyte 
hyperplasia). The development of hyperplastic adipose tissue is 
associated with the most severe forms of obesity and has the poorest 
prognosis for treatment (Hausman et al., 2001). 
1.3.2.1. Types of adipose tissue 
The AT of mammals is classified into 2 types: white and brown 
adipose tissue. Both share many metabolic characteristics but WAT 
mainly stores excess energy for subsequent metabolic demand 
whereas BAT functions as an energy-dissipating organ (Cannon et al., 
1982, Cinti, 2001b, Cannon and Nedergaard, 2004, Cinti, 2005). WAT 
is found as subcutaneous (SC) and visceral (V) depots. Classically, 
the V depot was considered to be more metabolically active as it 
released factors can be delivered to the portal venous system and, 
thus, can directly impact liver metabolism (Björntorp, 1990). In 
humans, WAT is dispersed throughout the body with major intra-
abdominal depots around the omentum, intestines, and perirenal 
areas, as well as in SC depots in the buttocks, thighs, and abdomen 
(Figure 7). WAT can be found in many other areas, including in the 
retro-orbital space, on the face and extremities, and within the bone 
marrow. Some AT is responsive to sex hormones, such as adipose 
tissue in the breasts and thighs (Cinti, 2001a).  
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The developmental patterns of BAT and WAT are distinct. BAT 
emerges earlier than WAT during fetal development. Morphologically, 
BAT can be distinguished from WAT by multilocular lipid inclusions, 
rich vascularization, and abundant mitochondrial density (Cinti, 
2001b). BAT responds to cold-induced energy loss through the 
expression of uncoupling protein 1 (UCP 1) found in the mitochondria 
membrane that allows dissipation of the proton electrochemical 
gradient generated by respiration in the form of heat (Nicholls and 
Locke, 1984). With the exception of UCP 1, which is generally 
accepted as the defining marker of brown fat, most other differentially 
expressed genes show only relative differences between the two 
types of adipose cells. These include among others the fatty acid 
activated transcription factor PPARα and the peroxisome proliferator-
activated receptor gamma coactivator 1 alpha (PGC 1α) as well as 
factors involved in mitochondrial biogenesis and function (Gesta et al., 
2006). Leptin, the nuclear corepressor RIP140, and the matrix protein 
fibrillin-1 are more enriched in WAT than BAT. At the cellular level, 
both BAT and WAT appear to originate from MSC (Gesta et al., 2007, 
Powelka et al., 2006).  
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Figure 7: Types of AT and distribution in the human body. 
In humans, depots of WAT are found all over the body, with SC and V depots 
representing the main compartments for fat storage. BAT is abundant at birth and still 
present in adulthood but to a lesser extent (Gesta et al., 2007). 
 
The distribution of WAT not only varies considerably between species 
but also between individuals of the same species. In humans, 
variations of WAT distribution have gained considerable interest due 
to their association with metabolic disorders. There are two major 
theories about why these different fat distributions are differentially 
linked to metabolic complications. The first is based on anatomy and 
the fact that V fat drains its products (FFA and various adipokines) 
into the portal circulation where they can act preferentially on the liver 
to affect metabolism (Björntorp, 1990). The second reflects cell 
biology and is based on the concept that fat cells in different depots 
have different properties causing them to be linked to a greater or 
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lesser development of metabolic disorders (Lafontan and Berlan, 
2003). Depot-specific variations in gene expression and adipose 
tissue function appear to be intrinsic. Thus, isolated cloned human 
preadipocytes from SC adipose tissue exhibit a greater ability to 
differentiate in culture than those from V depots (Hauner and 
Entenmann, 1991, van Harmelen et al., 2004). These differences are 
conserved over multiple cell generations and are associated with 
different patterns of gene expression, suggesting that these adipose 
depots could result in part from different precursor cells (Tchkonia et 
al., 2002, Tchkonia et al., 2005, Tchkonia et al., 2006, Tchkonia et al., 
2007). 
Sensitivity of AT to insulin is also depot-dependent. Lipogenesis is the 
pathway of TG synthesis and is promoted by insulin via activation of 
lipoprotein lipase (LPL) and by adenosine, the autocrine regulator 
(Mauriege et al., 1990, Bouchard and Perusse, 1993, Bouchard, 
1997). Insulin acts as a potent lipogenic agent, both by promoting lipid 
synthesis (LPL activity, glucose transport and TG synthesis) and by 
reducing catecholamine sensitivity via down regulation of β adrenergic 
receptors (Engfeldt et al., 1988). Adipocytes isolated from V fat depots 
have reduced (via decreased β 1 and β 2 receptor expression) lipolytic 
response to catecholamines when compared to SC abdominal 
adipocytes (increased β 1 and β 2 and decreased α 2 receptor 
expression). SC abdominal fat cells have a higher affinity for insulin 
and are more sensitive than V fat cells (Bouchard et al., 1993). There 
are marked differences between AT origen, particularly in women, in 
LPL expression (SC < V) and in the sensitivity of AT to insulin 
stimulated increases in LPL activity (Fried et al., 1993). There are also 
important depot-specific differences exist in replication, adipogenesis 
and apoptosis. Adipose depots appear to possess differing 
proportions of preadipocyte populations with differing capacities for 
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replication and apoptosis. Human preadipocytes and adipocytes from 
the V depot display greater rates of apoptosis than cells from SC 
depots of the same subject. Human V adipocytes are also more 
susceptible to apoptosis induced by TNF α (Henry et al., 2006).  
1.3.2.2. Developmental Origen of Adipose Tissue 
The prevailing developmental model suggests that mesoderm/ 
mesenchymal stem cells (MSC) give rise to bone, muscle, WAT, and 
BAT in response to appropriate developmental cues (Wassermann, 
1965). The formation of the mesoderm begins with the migration of a 
layer of cells between the primitive endoderm and ectoderm. This 
layer spreads along the anteroposterior and dorsoventral axes of the 
developing embryo giving rise to the axial, intermediate, lateral plate, 
and paraxial mesoderm. MSC were initially identified in postnatal 
human bone marrow and are capable of differentiating into 
adipocytes, osteoblasts, chondrocytes, myoblasts, and connective 
tissue (Grigoriadis et al., 1988, Pittenger et al., 1999, Zuk et al., 2001). 
Although the exact number of intermediate stages between a MSC 
and a mature adipocyte is uncertain, it is believed that the MSC gives 
rise to a common early precursor (preadipocyte), which in turn 
develops into committed white and brown preadipocytes that under 
appropriate stimulatory conditions differentiate into mature adipocytes 
of different types (Figure 8). However, as none of these precursor 
cells possesses any unique morphological characteristics or definitive 
gene expression markers, it is not clear if separate preadipocytes for 
BAT and WAT exist or if there are different white preadipocytes for 
different white adipose depots (Gesta et al., 2007). Recent studies 
suggest that WAT and BAT may actually derive from distinct precursor 
populations. Skeletal muscle progenitor cells can give rise to either 
muscle cells or brown fat cells, but not white fat cells and the decision 
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of this precursor to become muscle or BAT is controlled by the 
transcription factor PRDM16 (Seale et al., 2007, Seale et al., 2008). 
Expression of PRDM16 causes Myf5 expressing muscle precursors to 
commit to becoming brown fat cells, whereas reduction of PRDM16 
expression by shRNA targeting induces the myogenic differentiation 
program  (Seale et al., 2008). The discovery that muscle and BAT 
share common progenitor cells may also help to explain the functional 
dimorphism of adipose tissues, with WAT acting primarily to storage 
lipid and BAT serving to metabolize lipids to produce heat. Although 
the WAT and BAT are superficially similar in that they both contain 
lipid droplets, they appear to arise from divergent developmental 
programs (Won Park et al., 2008)  
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Figure 8: Development of AT from Mesoderm Lineage.  
Mesenchymal stem cells are precursors of bone, muscle, and fat cells. WAT 
differentiation is driven by the transcription factors PPARγ and C/EBPs, giving rise to 
TG storing WAT. Brown fat cells share precursors (Myf5+) with muscle cells but not with 
white adipocytes. Adapted figure from American College of Cardiology and (Won Park 
et al., 2008). 
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1.3.2.3. Function and metabolism of adipose tissue 
The main role of WAT is the storage of TG during energy consumption 
and release of fatty acids (FA) when energy expenditure exceeds 
energy intake (Figure 9). As de novo lipogenesis from glucose or 
other precursors is reduced in human AT, most of the substrate for 
storage is obtained from circulating lipids, either in the form of 
lipoprotein particles or complexed with albumin (Henry et al., 2006). 
This regulation is achieved through endocrine, paracrine and 
autocrine signals that allow the adipocyte to regulate the metabolism 
of other fat cells or cells located in brain, liver, muscle or pancreas. 
Adipocytes and AT are actively involved in metabolic processes such 
as angiogenesis, adipogenesis, extracellular matrix dissolution and 
reformation, steroid metabolism, immune response and hemostasis 
(Vázquez-Vela et al., 2008).  
The adipocyte has developed a system for the control of the storage 
and release of FA. The following proteins involved in lipogenesis 
program have an impact on insulin sensitivity and circulating lipid 
levels:  
 Lipoprotein lipase (LPL) catalyzes the release of FA from 
circulating lipoproteins. LPL activity is greater in SC WAT 
compared to V WAT (Fried et al., 1993).  
 Fatty acid transporters: The uptake of long chain FA (LCFA) into 
adipocytes is a saturable process and at least a portion of FFA 
diffusion is protein mediated (Stahl, 2004). Several proteins are 
involved including plasma membrane fatty acid-binding protein 
(FABP), fatty acid transport protein (FATP) and fatty acid 
translocase (FAT).  
 Fatty acid-binding proteins (FABP): Subsequent to diffusion and 
transport, cytosolic FFA bind to FABPs. FABPs increase the 
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solubility of FFAs, augment FFA uptake by increasing the FFA 
concentration gradient and serve to direct intracellular FFAs to 
specific fates (Haunerland and Spener, 2004). Nine members of 
the FABP subfamily of lipid-binding proteins have been identified 
(Glatz and Storch, 2001).  
 Phosphoenolpyruvate carboxykinase (PEPCK): Efficient storage 
of FA requires esterification to TG. The backbone for TG 
formation is provided by glycerol-3-phosphate (G3P), arising from 
glucose uptake into the cell during the fed state. The key enzyme 
in the glyceroneogenesis pathway is the cytosolic PEPCK 
(Reshef et al., 2003, Beale et al., 2003). 
 Perilipin: properly stored TG does not exist as lipid micelles. 
Rather, the lipid droplet is coated by members of the family of 
lipid droplet-associated proteins (Londos et al., 1999, Tansey et 
al., 2004). In adipocytes, this role is filled by the perilipin family of 
lipid-binding proteins, including perilipin, adipophilyn and TIP47. 
Alternative splicing of the perilipin gene results in two products, 
perilipin A and B; perilipin A is the hormone sensitive form 
(Greenberg et al., 1993).  
 Hormone-sensitive lipase (HSL): Stoed TG are hydrolyzed by 
HSL to generate FFA when needed. Three isoforms of HSL have 
been identified (Holm, 2003, Yeaman, 2004). 
 Glucose transporters (GLUT): WAT represents a secondary site 
for glucose utilization. Glucose transport into adipocytes is 
mediated by two members of the family: GLUT1 and GLUT4. 
GLUT1 is constitutively expressed and predominately localized to 
the plasma membrane and is primarily responsible for basal 
transport. Meanwhile, GLUT4 is responsible for insulin-stimulated 
increases in cellular transport in cardiac and skeletal muscle and 
adipocytes, rapidly translocating from intracellular pools to the 
cell surface (Yokomori et al., 1999, Uldry and Thorens, 2004) 
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Figure 9: Regulation of lipogenesis and lipolysis in adipocytes.  
Under lipogenic conditions, insulin stimulates translocation of GLUT4 to the plasma 
membrane. Intracellular glucose is converted to G3P. Insulin also activates LPL located 
on the cell surface of the vascular endothelium. Activated LPL removes fatty acids from 
intestine-derived chylomicron (CM) and liver-derived very low density lipoprotein 
(VLDL), and then fatty acids are incorporated into adipocytes. Under lipolytic conditions, 
catecholamines stimulate adrenergic receptors to translocate HSL, a key enzyme 
hydrolyzing TG to FFA and glycerol, to the lipid droplets. FFA and glycerol are released 
into the bloodstream and utilized for thermogenesis and gluconeogenesis, respectively 
(Hibuse et al., 2006). 
 
1.3.2.4. Control of Adipose tissue: cell size vs number 
Hyperplasia (increase of cell number) and hypertrophy (cell size 
increase) are two possible mechanisms for increasing AT mass 
(Hirsch and Batchelor, 1976). Radio-tracing studies of human AT 
suggest that adipocyte number may be determined early in life 
(Spalding et al., 2008), providing a possible basis for the concept of a 
fixed individual body weight. AT adipocytes are remarkably variable in 
size, reflecting principally the amount of stored TG. Fat cell size 
reflects the integrated effect of a number of factors affecting cellular 
lipid metabolism. Adipocyte volume has been correlated with lipolytic 
activity in human WAT (Björntorp, 1974, Mauriege et al., 1990). 
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Adipocyte size correlates positively with insulin resistance and 
IL6/TNFα secretion. In addition, severely obese individuals with a 
healthy metabolic profile have smaller adipocytes than obese 
individuals with altered metabolism (O'Connell et al., 2010). The 
mechanism underlying this phenomenon is poorly understood but the 
hypothesis suggests that as an adipocyte increases in size it 
eventually reaches a state where it can no longer store lipids. This 
causes an ‘overflow’ of FA into ectopic sites such as the liver and 
muscle, promoting insulin resistance. Individuals with a low adipocyte 
endowment or impaired lipid storage may be more susceptible to 
obesity related diseases than individuals with superior lipid storage 
potential (Henry et al., 2012).  
1.3.2.5. The role of inflammation and adipokines in metabolic 
diseases 
Obesity is associated with a state of chronic low-grade inflammation 
such as elevated serum concentrations of C reactive protein (CRP) 
and inflammatory cytokines produced by immune cells located within 
the AT (Rajala and Scherer, 2003, Pickup et al., 1997). The number of 
macrophages present in WAT strongly correlates with obesity and 
adipose tissue macrophages (ATM) are considered as a critical factor 
for the development of obesity-induced insulin resistance and the 
progression to T2D (Falcão-Pires et al., 2012, Rupnick et al., 2002, 
Maury and Brichard, 2010, Trayhurn and Wood, 2004). Moreover, AT 
itself is a source of inflammation: increased TNFα and IL6 expression 
are implicated in both whole-body and local insulin resistance (Pittas 
et al., 2004, Ofei et al., 1996, Bastard et al., 2002). 
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Figure 10: Relationship between obesity, inflammation and insulin resistance. 
Different pathways through which adipokines generated by an expanding adipose tissue 
can contribute to the development of the metabolic complications associated with 
abdominal obesity such as insulin resistance and atherogenic dyslipidemia. Figure 
adapted from the International Chair on Cardiometabolic Risk. 
 
Adipokines are factors that are produced and secreted by AT and 
induce responses in various tissues through binding to specific 
receptors (Calle and Fernandez, 2012). Some adipokines such as 
adiponectin or lepitn are exclusively produced by the adipose tissue 
whereas others like TNF α or IL6 can be secreted by diverse cell 
types in different organs (Antuna-Puente et al., 2008, Kiefer et al., 
2010, Zeyda et al., 2011). Obesity is associated with altered 
expression of the following adipokines:  
 LEPTIN is the product of the the ob gene (Zhang et al., 1994). 
Leptin is secreted mainly by SC fat (Montague et al., 1997). 
Plasma leptin and mRNA expression in AT are directly related to 
obesity severity, as an increase of fat mass is associated with an 
increase of leptin (Considine and Caro, 1997). Leptin activates its 
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receptors (gen db) in hypothalamus, inhibiting food intake and 
promoting energy expenditure (Vaisse et al., 1996, Friedman and 
Halaas, 1998). Additionally, leptin is associated with inflammation 
since it can modulate TNFα production and macrophage 
activation (Kiguchi et al., 2009). Insulin resistance characterizes 
states of severe leptin deficiency or resistance, such as ob/ob or 
db/db mice, or genetic models of lipoatrophic diabetes. (Kahn, 
2001, Adilson Guilherme, 2008). 
 ADIPONECTIN, also called Acrp30 or adipoQ (gen Adipoq), is a 
fat cell derived peptide that, in contrast to other adipokines, is 
downregulated in obese patients with insulin resistance or T2D 
(Hu et al., 1996). Acute treatment of mice with this adipokines 
decreases insulin resistance, decreases plasma FFAs and the 
TG content of muscle and liver, and increases expression of 
genes involved in FA oxidation and energy expenditure (Kahn, 
2001). A genome-wide scan in humans mapped a susceptibility 
locus for type 2 DM and metabolic syndrome to chromosome 
3q27 in a region near the adiponectin gene (Kahn, 2001, Adilson 
Guilherme, 2008). 
 RESISTIN: Initial studies suggested that resistin might cause 
insulin resistance, as levels were increased in obese mice and 
reduced by anti-diabetic drugs of the TZD class (Steppan et al., 
2001). However, studies of resistin in humans have failed to 
reveal a clear relationship with obesity and T2D and more recent 
studies suggest a role for this factor in inflammation. Resistin can 
directly injure endothelium not only by inducing synthesis and 
secretion of endothelin 1 by endothelial cells, but also by altering 
vascular cell adhesion molecule (VCAM1) and monocyte 
chemoattractant protein 1 (MCP 1) expression (Calabro et al., 
2004).. 
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 RETINOL BINDING PROTEIN (RBP) 4: RBP4 levels are 
elevated in insulin-resistant mice and humans with obesity and 
type 2 DM. Transgenic overexpression of human RBP4 or 
injection of recombinant RBP4 in normal mice causes insulin 
resistance. Conversely, genetic deletion of Rbp4 enhances 
insulin sensitivity (Qin Yang, 2005). 
 Tumor Necrosis Factor (TNFα) is a proinflammatory cytokine 
produced by numerous cells, but mainly macrophages and 
lymphocytes. Adipocytes also produce TNFα in rodents, and to a 
lesser extent in humans (Hotamisligil et al., 1993). TNFα is 
increased in fat of obese rodents and humans, and has been 
shown to produce serine phosphorylation of IRS, resulting in 
reduced insulin receptor kinase activity and insulin resistance 
(Hotamisligil et al., 1996). 
 Interleukin 6 (IL6) is a cytokine produced by several cells 
(fibroblasts, endothelial cells, monocytes) and by AT, which is 
increased in obesity. Capacity to secrete IL6 is six times higher in 
V than in SC adipose tissue (Fried et al., 1998, Fain et al., 2004). 
Several studies suggest that IL6 could be implicated in insulin 
resistance and its complications (Bastard et al., 2000, Bastard et 
al., 2002) . One of its major actions is control of the hepatic 
production of inflammatory proteins such as CRP. There is a 
positive relationship between IL6 levels in AT and circulating 
CRP levels which is an important cardiovascular risk factor.  
 MONOCYTE CHEMOATTRACTANT PROTEIN 1 (MCP1) is 
secreted in large amounts by hypertrophied adipocytes where it 
functions as a chemoattractant that enhances macrophage 
infiltration into adipose tissue in obese mice and humans (Sartipy 
and Loskutoff, 2003, Weisberg et al., 2003, Cancello et al., 
2005). Consistent with this role of MCP1, AT of lean subjects 
usually consists of approximately 5–10% macrophages, whereas 
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in obese patients, macrophage content in adipose tissue can be 
as high as 50% of the total number of cells. Thus, the increased 
production of MCP1 by larger adipocytes might contribute to a 
pro-inflammatory st
Figure 11: Contribution of adipokines to obesity and metabolic syndrome
The schematic overview 
central metabolic processes. Macrophage
the inflammatory response modulation, but their interaction with endothelial cells and 
adipocytes is also fundamental. ROS: reactive oxygen species
(Falcão-Pires et al., 2012
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the result of an increase in size and number of adipocytes. As the 
proliferation of mature adipocytes in vivo is very limited, this pool of 
APC is responsible for the renewal of adipocytes and the potential of 
this tissue to expand in response to chronic energy overload (Dani 
and Billon, 2012). 
1.4.1. Identification and phenotype of APC 
Considerable controversy exists regarding the specific makers  
expressed by preadipocyte  and thus, the only definitive criteria that 
identifies preadipocytes is their subsequent ability to differentiate to 
cells that express adipocyte markers and accumulate lipid. It is also 
important to realize that even cell lines considered good models of 
WAT do not express all WAT markers. For example, mouse 
preadipocytes line 3T3L1 produce little, if any, leptin compared to 
normal white adipocytes (Gesta et al., 2007). 
APC have been detected in the proximity of WAT vasculature. Using 
FACS to analyze the expression of cell surface and stem cell markers, 
two cell populations were isolated: one CD24+ (lin-
:CD29+:CD34+:Sca-1+:CD24+) and one CD24-. Transplantation of 
this CD24+ population into the fat depots of A-Zip lipodystrophic mice 
(lipoatrophic diabetic phenotype) led to the development of fat depots 
with normal adipocyte morphology (Rodeheffer et al., 2008). However, 
the CD24- and CD34- populations failed to reconstitute WAT after 
transplantation into A-ZIP mice, suggesting that CD24+ populations 
are the true source of white APC in vivo (Won Park et al., 2008).  
APC isolated from different depots display different characteristics in 
terms of proliferation, differentiation, and gene expression profiles. 
The cellular and molecular mechanisms underlying these fat depot 
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dependent differences are currently unknown. However, several 
observations suggest that developmental mechanisms contribute to 
regional variation in function. Consequently, studies on the origins of 
APC could verify that adipocytes derived from different developmental 
origins or cellular sources are functionally different (Gesta et al., 2006, 
Tchkonia et al., 2007, Dani and Billon, 2012). 
1.4.2. Molecular regulation of adipogenesis 
Adipogenesis is the process by which preadipocytes mature into 
adipocytes. The transition from preadipocyte to adipocyte involves 
four stages: growth arrest, clonal expansion, early differentiation, and 
terminal differentiation (Gregoire et al., 1998). These stages are 
orchestrated by a cascade of transcription factors (Spiegelman and 
Flier, 1996). Initial growth arrest coincides with the expression of the 
transcription factors peroxisome proliferator activated receptor γ 
(PPARγ) and CCAAT/ enhancer binding protein α (C/EBPα). The 
induction of these two proteins is characterized by a second, 
permanent period of growth arrest followed by expression of the fully 
differentiated phenotype (Figure 12). 
PPARγ is a member of the nuclear-receptor superfamily, and is both 
necessary and sufficient for adipogenesis (Tontonoz et al., 1994b, 
Tontonoz et al., 1994a). Thus, it has been called the master regulator 
of adipogenesis. Most pro-adipogenic factors active PPARγ 
expression or activity. Indeed, the pro-adipogenic C/EBPs and 
Kruppel-like factors (KLFs) have all been shown to induce at least one 
of the two Pparγ promoters. By contrast, anti-adipogenic GATA 
factors function in part by repressing PPARγ expression (Rosen and 
MacDougald, 2006). PPARγ exists as two isoforms (γ1 and γ2) 
formed by alternative splicing and differing in their N-termini. PPARγ2 
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is expressed at high levels in adipose tissue, while levels of PPARγ1 
can be found in many other tissues. This receptor is induced very 
early in adipose cell differentiation, and is present at higher levels in 
preadipocytes than other fibroblastic cells (Zhu et al., 1995, Fajas et 
al., 1997). The adipogenic activity of PPARγ, like the well established 
3T3-L1 and 3T3-F442A preadipocyte cell lines, is markedly enhanced 
by presence of insulin (Spiegelman and Flier, 1996). Roles for PPARγ 
in energy homeostasis have been extensible studied following the 
discovery that PPARγ ligands decrease blood glucose of patients with 
T2D (Yki-Järvinen, 2004, Rangwala and Lazar, 2004) (Figure 12).  
PPARγ is not the only transcription factor that is significantly elevated 
in adipocyte differentiation. C/EBP α, β and δ are all markedly induced 
during differentiation in culture (Cao et al., 1991). C/EBPβ and 
C/EBPδ are induced early during the differentiation upon hormonal 
stimulation and this is followed by the induction of PPARγ and 
C/EBPα, since both C/EBPβ and C/EBPδ play a role in the initiation of 
the adipogenic program (Wu et al., 1996). Ectopic expression of 
C/EBPβ promotes adipogenesis in both pre-adipocytes and fibroblasts 
by inducing the expression of PPARγ. C/EBPα, like PPARγ, directly 
binds to many fat cell–specific genes and it is increased late in the 
process of adipogenesis. Precocious expression of C/EBPα can 
accelerate the endogenous differentiation program of preadipocytes, 
while antisense mRNA blocks the differentiation markedly. The 
genetic disruption of C/EBPα causes a major reduction in the lipid 
content of the fat tissue; however, fat cell differentiation apparently still 
occurs (Spiegelman and Flier, 1996, Wu et al., 1999). C/EBPα may 
also play a role in glucose homeostasis and appears to regulate 
insulin sensitivity during adipogenesis (Rosen and Spiegelman, 2000, 
Gerin et al., 2006). 
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1.4.3. Insulin and IGF1 in adipogenesis 
Efficient differentiation of APC to adipocytes requires insulin (Hauner 
et al., 1989, Litthauer and Serrero, 1992). In the early stages of 
adipogenesis, insulin functions predominantly through IGF1 receptor 
signalling. Fibroblasts and brown pre-adipocytes from mice that lack 
insulin receptors are deficient in adipogenesis (Blüher et al., 2002). 
The loss of individual IRS proteins inhibits adipogenesis in brown 
adipocytes, with an order of importance of IRS1>IRS3>IRS2>IRS4 
(Tseng et al., 2004). Combined deletion of Irs1 and Irs3 induce 
significant lipoatrophy, although brown-adipose tissue is relatively 
unaffected (Laustsen et al., 2002).  
 
1.5. Osteopontin 
Osteopontin (OPN, gene Spp1), also called secreted phosphoprotein-
1 and sialoprotein-1, is a multifunctional protein expressed in activated 
macrophages and T cells, osteoclasts, hepatocytes, smooth muscle, 
endothelial, and epithelial cells. OPN was originally classified as a T 
helper type 1 (Th1) cytokine that is involved in physiological and 
pathological mineralization in bone and kidney, cell survival, 
inflammation, and tumor biology (Mazzali et al., 2002, Kiefer, 2010, 
Kiefer et al., 2010). OPN can exist as a soluble cytokine or a 
mineralized matrix-associated molecule. The OPN gene consists of 7 
exons, of which exon 1 is non-coding (Craig and Denhardt, 1991, 
Hijiya et al., 1994).  Similarities in gene location and exon structure, 
but not amino acid sequence have led to the proposal that OPN is a 
member of a family of proteins termed the small integrin binding 
ligand, N-linked glycosylation (SIBLING) family.  Other members of 
this family include bone sialoprotein (BSP), dentin matrix protein 1 
74 
 
(DMP1), dentin sialophosphoprotein (DSPP), and matrix extracellular 
phosphoglycoprotein (MEPE) (Fisher et al., 2001, Kazanecki, 2007). 
1.5.1. Structure and functions 
OPN is a negatively‐charged acidic hydrophilic protein of 
approximately 300 amino acid residues, and is secreted into all body 
fluids (Mazzali et al., 2002). The OPN cDNA from various mammalian 
species exhibits a high degree of sequence homology. The molecule 
undergoes post‐translational modification, and is phosphorylated and 
glycosylated (Sørensen et al., 1995, Jono et al., 2000). OPN has an 
arginine‐glycine‐aspartic acid (RGD) cell binding sequence, a calcium 
binding site and two heparin binding domains.  Alternate splice forms, 
different alleles, and polymorphisms of OPN have been reported, 
however the significance of these changes with regard to OPN’s 
function have not been elucidated.  
Cells may bind OPN via multiple integrin receptors including the 
vitronectin receptor (αvβ3) as well as various β1 and β5 integrins. 
OPN does not bind the standard form of CD44 (hyaluronic acid 
receptor) but does bind various isoforms of CD44. The interaction of 
CD44 and OPN has been implicated in migration of macrophages and 
tumor cell lines. A feedback loop may also exist as many researchers 
have shown that OPN increased expression of CD44, primarily using 
cancer cell lines such as the breast cancer cell line 21NT (Khan et al., 
2005), liver carcinoma cell line HepG2 (Gao et al., 2003), melanoma 
cells (Samanna et al., 2006) or macrophages. OPN may be cleaved 
by thrombin, resulting in the exposure of additional cryptic binding 
sites as well as the production of functional chemotactic fragments 
(Kazanecki et al., 2007). Osteopontin’s function in many tissues is to 
promote adhesion and facilitate migration of a variety of cell types 
INTRODUCTION 
75 
 
through interaction with the integrin and CD44 variants; it is also a 
cytokine that activates many signaling pathways and supports cell 
survival. 
In bone, OPN is one of the more abundant non-collagenous proteins 
in bone and is localized to cell-matrix and matrix-matrix interfaces. 
OPN is expressed by all the major bone-specific cell types: 
osteoblasts, osteoclasts and osteocytes (Merry et al., 1993). The 
major role for OPN is in stress-induced bone remodeling, with most 
studies focusing on stresses that induce bone resorption by 
osteoclasts. In addition to its effects on the cells in bone, OPN is also 
a regulator of crystal growth, including hydroxyapatite (HA) the crystal 
of bone (Shapses et al., 2003).  
In kidney and urine, OPN protein has been shown to be a component 
of kidney stones and its expression is upregulated in the diseased 
state (Xie et al., 2001). OPN promotes accumulation of macrophages, 
and may play a role in macrophage-mediated renal injury. However, 
OPN has some renoprotective actions in renal injury, such as 
increasing tolerance to acute ischemia, inhibiting inducible nitric oxide 
synthase and suppressing nitric oxide synthesis, reducing cell 
peroxide levels and promoting the survival of cells exposed to 
hypoxia, decreasing cell apoptosis and participating in the 
regeneration of cells. In addition, OPN is associated with renal stones, 
but whether it acts as a promoter or inhibitor of stone formation is 
controversial (Xie et al., 2001). 
In immune response and inflammation, OPN induces the expression 
of a variety of proinflammatory cytokines and chemokines in 
peripheral blood mononuclear cells (O’Regan et al., 2000). Moreover, 
it functions in cell migration, particularly of monocytes/macrophages, 
and stimulates expression of matrix metalloproteases to induce matrix 
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degradation and facilitate cell motility. In a mouse model of systemic 
lupus, OPN produced by T cells stimulated IgM and IgG production by 
B cells. OPN expression is increased in response to cellular injury, 
attracting and supporting the infiltration of macrophages and T 
lymphocytes into sites of injury and inflammation (Wang et al., 2005, 
Wang and Denhardt, 2008). OPN is chemotactic for many cell types 
including macrophages, dendritic cells, and T cells; it enhances B 
lymphocyte immunoglobulin production and proliferation. In 
inflammatory situations it stimulates both pro- and anti-inflammatory 
processes, which on balance can be either beneficial or injurious 
depending on what the cell is receiving. OPN influences cell-mediated 
immunity and has been shown to have Th1 cytokine functions. OPN 
deficiency is linked to a reduced Th1 immune response in infectious 
diseases, autoimmunity and delayed type hypersensitivity. OPN’s role 
in the central nervous system and in stress responses has also 
emerged as an important aspect related to its cytoprotective and 
immune functions (Wang and Denhardt, 2008). OPN plays a role in 
various inflammatory disorders, such as rheumatoid arthritis and 
atherosclerosis, in diabetic macro- and microvascular diseases and 
hepatic inflammation. Hepatic OPN expression is upregulated in 
obesity and in various models of liver injury where OPN is localized to 
macrophages and Kupffer cells. Furthermore, OPN is involved in the 
pathogenesis of non-alcoholic fatty liver disease (NAFLD), which is 
strongly associated with visceral obesity (Gómez-Ambrosi et al., 2007, 
Kiefer et al., 2011, Zeyda et al., 2011).  
1.5.2. Role of OPN in Diabetes and Obesity 
OPN plasma concentrations are elevated in morbidly obese patients 
but data are conflicting in murine models of obesity (Zeyda et al., 
2011, Kiefer et al., 2011). Adipose tissue macrophages (ATM) 
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infiltrating into obese adipose tissue from the circulation are a key 
source of inflammation in obesity and provide a causal link between 
obesity and the development of adipose tissue insulin resistance. 
Macrophage recruitment during inflammatory processes is dependent 
on the expression of OPN (Ashkar et al., 2000). Consistent with this 
notion, OPN expression in obese adipose tissue colocalized with 
macrophages and that OPN mRNA is highly expressed in 
macrophages isolated from the SVF (Nomiyama et al., 2007). 
Although OPN is expressed in proliferating fibroblasts, earlier reports 
documenting decreased OPN mRNA levels in differentiated 
adipocytes as compared with preadipocytes (Senger et al., 1983, 
Dorheim et al., 1993). Interestingly, OPN has previously been 
characterized as a PPARγ target gene in macrophages, and 
overexpression of PPARγ or ligand treatment with a thiazolidinedione 
suppresses OPN transcription (Wang et al., 2005, Wang and 
Denhardt, 2008). 
OPN is rapidly expressed after cellular activation, and it is abundantly 
secreted by activated macrophages but not resting macrophages or 
monocytes. The MAPK kinase kinase 1/c-Jun N-terminal kinase 
(JNK)1/activator protein, which is also strongly activated upon obesity, 
is activated by OPN in a myeloma cell line (Philip and Kundu, 2003, 
Rangaswami et al., 2006). Importantly, JNK is readily phosphorylated 
by OPN treatment in adipocytes. OPN inhibits adipocyte insulin 
sensitivity of differentiating or fully mature adipocytes (Hotamisligil, 
2006, Weisberg et al., 2003, Nomiyama et al., 2007). Moreover, 
inflammatory signaling can be induced in adipocytes by OPN. Hence, 
adipocytes express functional receptors for OPN. Therefore, OPN 
could contribute to adipose tissue insulin resistance in obesity by a 
direct action on adipocytes in addition to its role in macrophage 
migration (Zeyda et al., 2011)..  
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Hepatic levels of OPN are upregulated in obesity, and hepatic OPN 
levels correlate with liver TG content (Sahai et al., 2004b, Sahai et al., 
2004a, Kiefer et al., 2008, Bertola et al., 2009). Within the liver, OPN 
is predominantly produced in inflammatory cells but also hepatocytes. 
Antibody-mediated OPN neutralisation was shown to protect against 
high-fat diet-induced hepatic macrophage infiltration and D-
galactosamine- induced inflammatory liver injury. However, a 
functional role of OPN in obesity-associated hepatic steatosis and 
liver insulin sensitivity still remains unclear (Nomiyama et al., 2007, 
Kiefer et al., 2011) . 
1.5.3. OPN knockout model 
Loss of osteopontin (Spp1-/-) prevents high-fat diet-induced hepatic 
steatosis and inflammation in mice, and markedly improves insulin 
signalling and insulin sensitivity in the liver, thereby improving hepatic 
glucose and lipid homeostasis (Nomiyama et al., 2007, Kiefer et al., 
2010, Kiefer et al., 2011). Spp1-/- mice are protected from obesity 
induced hepatic steatosis. Reduced hepatic TG synthesis underlies 
this absence of steatosis. Indeed, V WAT weight is increased in obese 
Spp1−/− mice indicating that OPN deficiency facilitates fat storage in 
adipose tissue, thereby preventing its ectopic accumulation in the 
liver. Decreased inflammatory alterations in V WAT of obese Spp1-/-
mice could contribute to the improvement of metabolic parameters. 
Moreover, decreased steatosis in obese Spp1-/- mice was paralleled 
by improved whole-body insulin sensitivity due to reduction in hepatic 
insulin resistance and glucose production. Phosphorylation of IRS2 
and AKT is enhanced in liver of OPN deficient mice (Kiefer et al., 
2011).  
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Macrophages are the major source of obesity associated inflammatory 
cytokine production in liver and adipose tissue. Loss of OPN is also 
associated with downregulated hepatic gene expression of MCP1, a 
chemokine that promotes hepatic macrophage infiltration and 
steatosis (Kanda et al., 2006, Obstfeld et al., 2010, Kiefer et al., 
2011). Since OPN and MCP1 cooperate in monocyte chemotaxis, 
abrogation of inflammatory cell migration is likely to account for 
reduced abundance of macrophages in livers from obese Spp1−/− mice 
(Kiefer et al., 2011). 
The observation that OPN is primarily expressed by macrophages in 
obese adipose tissue combined with the important autocrine role of 
OPN in macrophage function suggest a model in which endogenous 
OPN amplifies macrophage recruitment in the early stages of obesity 
(Giachelli et al., 1998). Ex vivo experiments demonstrate increased 
macrophage chemotaxis toward the SVF isolated from obese mice, 
indicating that the continued recruitment of macrophages within the 
SVF may further exacerbate macrophage infiltration. In contrast, 
migration toward the SVF was substantially decreased in obese Spp1-
/- mice (Nomiyama et al., 2007). Decreased ATM accumulation in 
OPN-deficient mice is associated with increased insulin sensitivity: 
Spp1-/- mice developed less obesity-associated hyperinsulinemia, 
cleared glucose more rapidly following an intraperitoneal glucose 
challenge, and exhibited an enhanced insulin response after an 
intraperitoneal injection of insulin. Increased insulin sensitivity 
associated with OPN deficiency was unlikely a result of altered 
adipokine secretion, since plasma levels of 3 adipokines implicated in 
insulin resistance (adiponectin, resistin, and leptin) were not 
significantly different in Spp1-/- mice. Macrophages present in adipose 
tissue directly interfere with insulin signaling and insulin-stimulated 
glucose uptake in adipocytes by decreasing GLUT4 and IRS 1 
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expression, leading to a decrease in Akt phosphorylation and impaired 
insulin-stimulated GLUT4 translocation to the plasma membrane 
(Nomiyama et al., 2007). 
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2. MATERIALS AND METHODS 
2.1. Animals 
Mice were maintained in an enclosed, pathogen-free facility with a 
controlled photoperiod of 12h light and 12h dark per day at 23ºC with 
free access to food and water. All studies involving rodents were 
approved by animal welfare committee of the Principe Felipe 
Research Center (CV-46007, CIPF, Valencia). Animal 
experimentation was conducted according to the regulations of the 
Spanish and European law (RD 1201/2005, B.O.E. 252, 10th October 
2005 and European Convention 1-2-3 18th March 1986). For this 
study, only female mice were used. Irs2-deficient (Irs2-/-) mice were 
produced and maintained on a C57BL/6 background as described 
(Withers et al., 1998). Wild-type (WT) mice of the same genetic 
background were employed as controls. Irs2-/- were identified by 
genotyping using a published PCR strategy (Withers et al., 1998)  
The mice used during the collaboration in Vienna were produced and 
maintained on a C57BL/6J WT. B6.Cg-Spp1tm1Blh/J (referred to as 
OPN knockouts or Spp1-/-) mice were purchased from Charles River 
Laboratories (Sulzfeld, Germany). All mice were housed in a specific 
pathogen-free facility with a 12 h light/ dark cycle. Mice had free 
access to food and water. The protocol was approved by the local 
ethics committee for animal studies and the Austrian Federal Ministry 
for Science and Research and complied fully with the guidelines on 
accommodation and care of animals formulated by the European 
Convention for the Protection of Vertebrate Animals Used for 
Experimental and Other Scientific Purposes. Animals were fasted for 
12-16 h.  
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Females of 12-16 weeks were used in all experiments. Animals were 
sacrificed by decapitation and blood was collected to measure 
glucose and hormones. 
2.2. Tissue collection  
Upon sacrifice, visceral (V) WAT was excised from the abdominal 
cavity and subcutaneous (SC) WAT was excised from the inguinal 
skin-folds. Tissue samples were weighed and were frozen in liquid 
nitrogen for protein and gene expression studies. For histological 
analysis, WAT was fixed in 4% paraformaldehyde.  
2.3. Glucose and hormones measurements 
Blood glucose was determined upon decapitation of mice using a 
glucometer (Ascensia ELITE®, Bayer HealthCare). Collected blood 
was centrifuged (13200rpm 20 minutes 4ºC) and serum was frozen for 
hormone analysis. Insulin levels were determined by Ultrasensitive 
Mouse Insulin ELISA (Mercodia®). Leptin, Adiponectin and Resistin 
were estimated by Luminex® technology using the Millipore 
commercial kit MILLIPLEX™ Multi-Analyte Profiling (MAP). MAP 
technology performs a variety of immunoassays on the surface of 
fluorescent-coded beads known as microspheres, which are then read 
in a compact analyzer. Using flow cytometry-based bead isolation, two 
lasers and high-speed digital-signal processors, the analyzer reads 
signals on each individual microsphere particle. The multiple 
conjugated beads permit the measurement of various hormones from 
a sample of 10µL of serum.  
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Figure 13: Scheme of the Luminex® technology.  
The method is based on the use of 2 different wavelengths for detection of antigen-
antibody reactions. The 633nm laser distinguishes the color of the bead and the type of 
analyte detected. The second laser at 522nm permits quantification by indirect 
measuring of the Streptavidin-Phycoerythrin conjugate. 
2.4. Histological analysis of WAT depots 
Fat tissue was fixed overnight by immersion in 4% paraformaldehyde, 
washed, dehydrated in ethanol and embedded in paraffin as 
described (Cinti, 2001b) using the Spin Tissue Processor (Myr; STP 
120-2, El Vendrell, Spain). The processor consists of a metal wire 
chamber and 12 buckets which are set up in a circle.  The plastic 
cassettes which contain the fat are placed into the chamber and 
covered with a lid. 3µm sections were cut using a microtome 
(Microm/Thermo Scientific; HM 340E, Walldorf, Germany) and placed 
on 25 x 75 x 1mm polylysine slides (VWR International, Leuven, 
Belgium).  For assessment of V and SC WAT architecture and 
structure, sections were stained with hematoxylin and eosin. Tissue 
sections were first placed in xylene for 15 min to remove the paraffin, 
then hydrated in decreasing concentrations of ethanol (96% and 70%) 
for 5 min each, then rinsed in distilled H2O for 5 min.  Slides were then 
immersed in Harris Hematoxylin solution (Sigma) for 1 min and 
washed with water for 5 min before being rinsed 10 times in 1% 
hydrochloric acid/70% ethanol. Tissue sections were rinsed in water 
for 5 min and subsequently stained in Eosin Y Solution (Sigma) for 10 
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min. After a 5 min rinse in water, tissue sections were dehydrated in 
increasing concentrations of ethanol (70% and 96%) for 5 min each 
and finally cleared in xylene for 10 min.  Samples were allowed to dry 
and then were mounted using Entellan (Merck #107961, Darmstadt, 
Germany) and covered with a 24 x 60mm coverslip (Menzel-Glaser, 
Braunschweig, Germany). Images of stained WAT sections were 
captured using a Leica DM microscope and the Leica Application 
Suite (v 2.4.0 RI) imaging software. The diameter of the adipocyte 
was measured with ImageJ (v 1.43u, NIH, USA), a public domain 
Java image processing and analysis program. At least 40 cells were 
measured from each image. V and SC depots were analyzed from 12 
mice of each genotype. 
2.5. Analysis of mRNA expression by Real Time Polymerase 
Chain Reaction (RT-PCR) 
To isolate RNA, frozen tissue or cell samples were homogenized in 
TRIzol® reagent (Invitrogen/Life Technologies, Carlsbad, CA, USA) 
and processed based on manufacturer’s instructions. RNA quality was 
assessed using the 280/260 nm absorbance ratio which provides an 
assessment of RNA integrity and 280/230 nm absorbance ratio which 
indicates the contamination of the sample with salts or organic 
compounds. RNA concentrations were quantified using a ND-1000 
Nanodrop Spectrophotometer (v3.7, Thermo Scientific, Wilmington, 
DE, USA) and RNA was stored at -80ºC until used for cDNA 
synthesis. 
Total RNA (1µg) was treated with DNase I and transcribed into cDNA 
using Superscript II and random hexamer primers (Invitrogen). The 
samples were incubated for 50min at 42ºC, 15min at 70ºC to 
inactivate the enzyme. Quantitative PCR was performed using Step 
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One Plus Real Time PCR System (Applied Biosystems) with the 
TaqMan probes (Applied Biosystems) summarized in Table 3. The 
RT-PCR reaction contained: 12.5µL TaqMan® Universal PCR Master 
Mix 2x (Applied Biosystems), 1.25µL primer mix (Applied Biosystem) 
1µL cDNA (sample) and 10.25µL MilliQ water. The comparative 
threshold cycle (CT) method was used to calculate the relative 
expression (Livak and Schmittgen, 2001) and Stem One ™ Software v 
2.1. was used to analyze the data. The cycling conditions were as 
followed: an initial step called Holding stage for the reaction initiation 
(50ºC for 2 min and 95ºC for 10 min) followed by 40 cycles of the 
Cycling Stage (95ºC for 15 sec and 60ºC for 1 min). Each reaction 
was performed in duplicate and the value of the gene of interest was 
normalized to the expression of Ubiquitin C.  A negative control (MilliQ 
water) was included for each gene and data were analyzed by the 
comparative Ct method (2-ΔΔCt).  
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Gene Name Assay ID 
Ubc Ubiquitin C Mm01201237_m1 
Spp1 OPN, secreted phosphoprotein 1 Mm00436767_m1 
Irs1 Insulin receptor substrate 1 Mm01278327_m1 
Irs2 Insulin receptor substrate 2 Mm03038438_m1 
Irs3 Insulin receptor substrate 3 Mm01207023_m1 
Insr Insulin receptor Mm01211875_m1 
Gsk3β Glycogen synthase kinase 3 beta Mm00444911_m1 
Slc2a4 Glucose transporter member 4 (GLUT4) Mm00436615_m1 
Pparg Peroxisome proliferator activated receptor gamma Mm01184322_m1 
Fabp4 Fatty acid binding protein 4 Mm00445878_m1 
Adn Complement factor D, adipsin (ADN) Mm01143935_g1 
Fasn Fatty acid synthase Mm00662319_m1 
Ppargc1a Peroxisome proliferative activated receptor gamma coactivator 1 alpha (PGC1) Mm00447183_m1 
Srebf1 Sterol regulatory element binding transcription factor 1 Mm01138344_m1 
Dgat1 Diacylglycerol O-acyltransferase 1 Mm00515643_m1 
Dgat2 Diacylglycerol O-acyltransferase 2 Mm01273905_m1 
Adipoq Adiponectin Mm00456425_m1 
Rbp4 Retinol binding protein 4 Mm00803266_m1 
Retn Resistin Mm00445641_m1 
Hif1a Hypoxia inducible factor 1 Mm00468869_m1 
Vegfa vascular endothelial growth factor A Mm01281447_m1 
Ccl2 Chemokine (C-C motif) ligand 2, monocyte chemotactic protein-1 (MCP1) Mm00441242_m1 
Emr1 EGF-like module-containing mucin-like hormone receptor-like 1, F4/80 Mm00802530_m1 
Tnf Tumor necrosis factor alpha Mm00443258_m1 
Il6 Interleukin 6 Mm00446190_m1 
Ptprc Protein tyrosine phosphatase receptor type C (CD45) Mm01293575_m1 
Cd3e CD3 antigen epsilon polypeptide Mm01179194_m1 
Cd8a CD8 antigen alpha chain Mm01182108_m1 
Table 3: Summary of primers used in mRNA expression studies.  
The complete name of the gene and the Applied Biosystem reference number are 
provided.  
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2.6.  Preparation of Stromal-Vascular Fraction (SVF) from 
mouse WAT 
SC-WAT tissue was obtained from inguinal skin-fold and V-WAT was 
obtained from the abdomen of female mice. Tissue was minced with 
scissors and then digested in adipocyte isolation buffer Krebs Ringer 
containing: NaHCO3 24mM, HEPES 10mM, Bovine Serum Albumin 
(BSA) 2.5% (Sigma 7906), Collagenase 1mg/mL (GIBCO CAT Nº 
17104-019 1.362 PZU/mg), Dispase 1mg/mL (GIBCO Cat No. 17105-
041 1.7 units /mg), Desoxirribonuclease 1 0,25mg/mL (Sigma DN25), 
1% v/v of Penicillin /Streptomycin (Gibco Cat.Nº 15140-122) and 
0,005mg/mL Amphotericin B (Sigma 9528). Subsequently, samples 
were incubated in 3 mL of buffer Krebs Ringer/g WAT for 40-60 min at 
37 ºC in a shaker bath. The digested tissue was passed through a 
nylon screen and rinsed several times with PBS/2,5% BSA/antibiotics 
to remove the collagenase. The suspension was centrifuged at 300xg 
for 10 minutes and the pellet was resuspended in complete 
Dulbecco’s Modified Eagle high glucose Medium (DMEM, Gibco 
41966) supplemented with 10% (v/v) of Fetal Clone III Bovine Serum 
(FcBS) (HyClone SH30109.03) and Penicillin/ Streptomycin 1% 
(Gibco Cat.Nº 15140-122). This suspension was filtered through a 
100 cell-strainer and centrifuged again at 300xg for 10 minutes. The 
pellet was resuspended and filtered first through a 70 cell strainer 
and subsequently through a 40 cell strainer. The resulting cells were 
counted and 1x105 cells were seeded in 60cm2 plates or sorted by 
Fluorescent Activated Cell Sorting Analysis (FACS) to obtain the 
specific APC population.  
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2.7. Fluorescent Activated Cells Sorting (FACS) Isolation of 
APC 
To isolate the APC population from the stroma vascular fraction (SVF) 
of WAT, a FACS enrichment strategy was developed based on 
published methods (Rodeheffer et al., 2008). The High Speed Cell 
Sorter MoFlo (Beckman Coulter, CA, USA) is equipped with 3 lasers 
(488nm, 351nm y 635nm), two detectors for the light forward (FS) and 
side (SS) scatter and eight photomultipliers for fluorescence detection. 
This optical configuration allows a selection procedure based on 
staining of five antibodies specific to certain cell populations (Table 4). 
Each antibody was tittered and the corresponding isotype was 
analyzed to minimize possible false positive.  
Conjugated 
Primary 
Antibody 
Manufacturer 
Cell 
population 
Quantity 
(µg/106 cells) 
λem (nm) 
Sca1 
FITC 
eBioscience  
11-5981 
Stem cell 0.25 530 ± 40 
CD31 
PE 
eBioscience  
12-0311 
Endothelial 
cells 
0.4 580 ± 40 
Ter119 
PE Cy5 
eBioscience  
15-5921 
Erythroid 
cells 
0.25 670 ± 30 
CD34 
Alexa 647 
eBioscience  
51-0341 
Stroma cells 1.5 670 ± 20 
CD45 
PE Cy7 
eBioscience  
25-0451 
Hematopoietic  
cells 
0.125 > 740 
DAPI 
Sigma  
D8417 
dead cells 1µg/µL 405 
Table 4: Fluorescent-conjugated primary antibodies utilized for APC isolation.  
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Cells isolated from SVF were incubated with the antibodies for 1h at 
4ºC. Just prior to FACS, DAPI was added to each sample in order to 
identify and eliminate dead cells. First, the endothelial, erythroid and 
hematopoietic cells were depleted from the SVF by staining for CD31, 
Ter119 and CD45 antigens, thereby generating a lineage-negative 
(Lin-) population. Subsequently, the Lin- population was further sorted 
based on CD34 and stem cell antigen 1 (Sca1), two cell-surface 
proteins expressed on stem cell populations from different tissues 
(Spangrude et al., 1988, Zuk et al., 2002, Rodeheffer et al., 2008). 
The sorting criterion was based on the double staining for CD34 
antigen and Sca1. From the live cell population (DAPI-), two 
populations were recovered: CD34-/Sca1- and CD34+/Sca1+. Double 
negative population was frozen and double positive population was 
seeded in 60mm2 cell culture plates and fresh medium with βFGF was 
added as described above. All the data were processed by Summit 
V4.3 software (Beckman Coulter, CA, USA). 
2.8.  Magnetic Cell Sorting Analysis (MACS®) 
To isolate the APC from Spp1-/- and WT mice, indirect Magnetic Cell 
Sorting (MACS®) technology was used since these experiments were 
performed at the University of Vienna with different tools. This two-
step procedure is summarized in Figure 14.  
Cells from the SVF were first labeled with a similar set of antibodies as 
employed for FACS analysis. CD45, CD31 and Ter119 were 
incubated for 1h at 4ºC. Subsequently, the cells were incubated with a 
primary rat IgG antibody coupled to magnetic beads (Goat Anti-Rat 
IgG Microbeads, Miltenyi Biotec 130-048-502). The cell suspension 
was passed through a MACS® column, which is placed in the 
magnetic field of MACS Separator. The magnetic labeled (CD45, 
CD31 and Ter119) positive cells were retained within the first column. 
92 
 
The unlabelled cells which flowed through the column were then 
labeled with the second set of primary rat IgG antibodies (CD34 and 
Sca1) for 1h at 4ºC. After removing the column from the magnetic 
field, the magnetically retained cells were eluted to obtain the 
positively-selected cell fraction (CD45- CD31- Ter119- CD34+ and 
Sca1+).  
 
Figure 14: MACS® strategy used for APC isolation from V and SC-WAT from WT 
and Spp1-/-.   
Cells were first incubated with CD45, CD31 and Ter119 antibodies and the negative 
population was collected for further incubation with Sca1 and CD34. Then, the positive 
population was retained in the magnetic field to isolate and establish the APC culture. 
2.9. Routine culture of primary APC 
Mouse APCs were cultured at 37ºC and 5% CO2. The cell culture 
medium was Dulbecco’s Modified Eagle high glucose Medium 
(DMEM, Gibco 41966) supplemented with 10% (v/v) of Fetal Clone III 
Bovine Serum (FcBS) (HyClone SH30109.03), Penicillin / 
Streptomycin 1% (Gibco Cat.Nº 15140-122). To passage the cells, the 
medium was removed and the cells were washed with PBS without 
calcium and magnesium (Gibco). The cells were incubated with 
incubation with 0.25% trypsin / 0.02% EDTA (Gibco 25200) for 5 min 
at 37ºC and gently shaken to detach the cells. The trypsin/EDTA was 
neutralized by complete medium (DMEM/10% FBS). The suspension 
was then centrifuged at 200xg for 4 min. The supernatant was 
removed and the pellet containing the cells was resuspended in the 
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growth medium and seeded at 2x104 cells/cm2. For normal condition 
growth, the medium was supplemented with 10 ng/ml recombinant 
basic Human Fibroblast Growth Factor (FGFβ or FGF-2, Gibco, 
PHG0026) to maintain their self renewal capacity and inhibit 
differentiation (Rodeheffer et al., 2008, Dani and Billon, 2012).  
2.10. Proliferation studies: cell growth curves and 
doubling time determination 
5x104 of the isolated APCs were seeded in 100 mm culture plates. 
Every day during 5 days one plate was trypsinized and counted to 
establish the growth kinetics of each experimental group. The 
doubling time was calculated with the online tool (http://www.doubling-
time.com/compute.php).  
2.11. Differentiation of APC cultures 
To assess the adipogenic potential of APC, cells were seeded so as 
to reach confluence in 3 days, based on their growth properties. On 
day 0 of the differentiation protocol, cells were switched from growth 
to adipogenic medium: advanced DMEM/F12 (Gibco 12634) with 5% 
heat-inactivated (56ºC for 30min) FBS (Sigma F7524) with different 
factors: insulin (INS, Roche), dexamethasone (DXM, Sigma) and 
Isobutilmethylxantine (IBMX, Sigma). The concentrations and duration 
of treatment are summarized in Figure 15. Samples were taken during 
the time-course of differentiation to analyse differentiation markers by 
immunostaining, Western blotting, or RT-PCR. 
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Figure 15: Adipocyte differentiation scheme.  
Cells were plated to reach confluence after 3 days and then the adipocyte differentiation 
medium was used for 10 days until lipids droplets were detected inside the cells. 
2.12. Flow Cytometry analysis of APC 
The flow cytometry experiments were performed with a Cytomics 
FC500 MCL flow cytometer (Beckman Coulter, CA, USA) equipped 
with two lasers (488nm and 635nm), two detectors for the light 
forward (FS) and side (SS) scatter and five photomultipliers for 
fluorescence detection.  
To detect the fluorescence emission from BODIPY, anti-Sca1 FITC, 
and annexin V FITC, the FL1 (525±20nm) channel in logarithmic 
amplification was used. For BODIPY measures FL1 was also used in 
linear amplification. For propidium iodide measure, FL3 (620±20nm) 
was used in logarithmic amplification for apoptotic assays and to 
exclude the dead cells and in linear amplification for cell cycle and cell 
proliferation studies.  
2.12.1. Cell-cycle analysis by Hypotonic Propidium Iodide 
staining 
To assess the cell cycle, APC cells were stained with propidium iodide 
(PI), a nucleic acid probe which identifies DNA and RNA. Upon 
binding to nucleic acids, the PI fluorescence emission can be detected 
by flow cytometry. Since the binding is proportional to the amount of 
nucleic acid in the sample, different amounts of DNA can be 
 distinguished at distinct cell cycle phases (
staining, cells were suspended in a hypotonic solution of PI (trisodium 
citrate 1mg/mL, Triton X
ribonuclease A (RNase A) 100μg/mL) and incubated at 4 
dark. At least 1x10
cytometer. The PI emission was detected in the FL3 
channel and the cellular aggregates were excluded from analysis. The 
histograms were generated with the WimMDI® program and the FL3 
histogram gated for single cells was analyzed wi
obtaining the percentage of cells in each phase of the cell cycle. 
Figure 16
cycle progression. 
DNA replication during cell cycle is 
As a result, the post
compared to the G1 cell (B). 
2.12.2.
Highly fluorescent Annexin V conjugates provide quick and 
detection methods for studying the externalization of 
phosphatidylserine, an indicator of intermediate stages of apoptosis
(Koopman et al., 1994
suspended in 100µL of binding buffer containing 10mM HEPES, 
140mM NaCl and 2,5mM CaCl2 adjusted at pH
5µL of Annexin V
4 cells from each sample were asses
: Schematic representation of cellular DNA content changes during cell 
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incubated for 15 minutes at room temperature in the dark. 1µL of PI 
solution (1mg/mL) was added for 5 min. The cells were analyzed with 
the 525nm channel to detect the emission of Annexin V-FITC and the 
620nm channel for the PI emission. All the data were processed by 
Summit V4.3 software (Beckman Coulter, USA). For the analysis, 
three different groups were identified: (i) live cells (double negative for 
Annexin V-FITC and PI, (ii) early apoptotic cells (positive for Annexin 
V-FITC and negative for PI), and (iii) dead/necrotic cells (positive for 
PI).  
2.12.3. Sca1-FITC Staining  
Fresh APC cells were gently trypsinized and transferred to flow 
cytometry tubes. The cells were carefully centrifuged at 100xg for 5 
min and resuspended into 100µL of PBS containing 0.25g/106 cells 
Sca1 antibody for 1 hour at room temperature in the dark. Then were 
washed with PBS and resuspended in 500µL of PBS containing 
2.5µg/mL of PI 5 min before flow cytometry analysis. All data were 
processed by Summit V4.3 Build 2445 software (Dako Colorado, Inc.).  
2.12.4. BODIPY™ 493/503 Staining  
Detection of cellular lipid droplets with BODIPY 493/503 dye 
(Molecular Probes, D3922) is more specific for than staining with other 
dyes such as nile red (Gocze and Freeman, 1994, Listenberger and 
Brown, 2007). Due to its low molecular weight (262 daltons), the 
diffusion of BODIPY 493/503 dye across membranes is relatively fast 
diffusion. A stock solution of The BODIPY 493/503 was prepared at 
1mg/ml in DMSO. The working solution was freshly prepared and 
incubated (1ng/ml) in suspension of APC cells for 30min at 37ºC. 
Then, 5µg/mL of PI was added to each tube for 5 min before flow 
cytometry analysis. The side scatter (SS) parameter was used to 
 detect changes in the cell granularity and the green fluorescence 
(525nm) of BODIPY to measure the intracellular lipid droplets 
formation (see 
2.13.
After cell sorting, the isolated population was plated using a 
4 Cytocentrifuge (
directly from the sorter were resuspended in 100µL of DMEM + 10% 
FcBS and processed with CytoSpin to attach the cells into polylysine 
slides. The cells were centrifuged and fixed with 10% formalin solution 
(Sigma) for 15 min in the dark. Af
times with PBS/Ca
incubated in blocking solution containing PBS/Ca
Horse Serum (HS) (Sigma) for 1h at RT. Primary antibody was 
incubated as detailed
PBS/Ca
phenylindole dihydrochloride (DAPI) at a concentratio
5 min at RT
and washed twice for 5 min in distilled H
with a coverslip with one drop of Dako Fluorescent Mounting Medium 
(Barcelona
Figure 17
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Alternatively, APC were grown in 24-well plate with glass coverslips. 
Before the cells were stained, the culture medium was aspirated from 
the wells and the cells were washed in PBS/Ca+2/Mg+2 pH 7.4, 
incubated in 10% formalin solution (Sigma) for 15 min in the dark, 
washed 3 times with PBS/Ca+2/Mg+2 pH 7.4 and then cells were 
incubated in 500μL of blocking solution containing PBS/Ca+2/Mg+2 pH 
7.4, 10% Horse Serum (HS) (Sigma) and 0.05% Tween-20 (Sigma) 
for 1h at RT. The blocking solution was aspired and cells were 
incubated in each antibody, diluted in the blocking solution, for 2h at 
room temperature (Table 5). Afterwards, the cells were washed three 
times with PBS/Ca+2/Mg+2, and incubated with the secondary antibody 
diluted in the blocking solution for 1h at RT (Invitrogen). Then, cells 
were washed 3 times with PBS/Ca+2/Mg+2, the nuclei was 
counterstained with DAPI (1µg/ml of DAPI in MilliQ H2O) and 
incubated for 5 min at RT (Table 5). The DAPI solution was removed 
by aspiration and stained cells were washed twice for 5 min in distilled 
H2O.  
For BODIPY staining, APC were grown in 24-well plate with glass 
coverslips. Before the cells were stained, the culture medium was 
aspirated from the wells and the cells were washed in PBS/Ca+2/Mg+2 
pH 7.4, incubated in 10% formalin solution (Sigma) for 15 min in the 
dark, washed 3 times with PBS/Ca+2/Mg+2 pH 7.4 and then cells were 
incubated in 500μl of BODIPY staining  containing PBS/Ca+2/Mg+2 pH 
7.4, and 0.5 μg/ml BODIPY 493/503 (Molecular Probes)  for 1h at RT. 
Then, cells were washed 3 times with PBS/Ca+2/Mg+2, the nuclei was 
counterstained with DAPI (1µg/ml of DAPI in MilliQ H2O) and 
incubated for 5 min at RT (Table 5). The DAPI solution was removed 
by aspiration and stained cells were washed twice for 5 min in distilled 
H2O (Table 5). 
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Each coverslip was placed on the top of a glass slide with Dako 
Fluorescent Mounting Medium (Barcelona, Spain). Images were 
captured using a Leica DM 6000B fluorescent microscope attached to 
Leica Application Suite (v 2.8.1) imaging software. Three different cell 
cultures were used for each immunostaining and representative 
pictures are show for each antibody. 
For In-Cell analysis, APC were cultured and processed for 
immunostaining in 24 well plates (Costar 3524. Corning Incorporated 
NY 14831) as described above (Table 5). The images were acquired 
and quantified with the In Cell Analyzer 1000 system (GE Healthcare). 
This system is a high content image analysis instrument with ability to 
capture cell images and quantify different cell parameters. 30 images 
per well were acquired and nuclei staining of both Ki67 and pH3 were 
analyzed.  
Primary  
Antibody Dilution 
Commercial 
source 
Incubation 
conditions 
Ki67 1/500 Abcam  5580 2h RT 
Phospho Histone H3 
Serine 10-Alexa 647 1/200 
Cell Signaling  
9716S 2h RT 
BODIPY 0.5μg/mL in PBS 
Molecular Probes 
D3922 1h RT 
Sencondary Antibody Dilution Commercial source 
Incubation  
conditions 
Goat Anti Rabbit Alexa 
488 
1/500 
 
Invitrogen 
A11070 1h RT 
Table 5: Primary antibodies used for immunofluorescence.   
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2.14. Western blotting  
Samples were lysed in a buffer containing: 50mM HEPES, 150mM 
NaCl , 10% glycerol, 1% triton-X-100, pH 7.5. The appropriate 
protease/phosphatase inhibitors were added to the lysis buffer 
immediately before use: 1mM sodium orthovanadate (Na3VO4), 50mM 
sodium fluoride (NaF) and 1x Complete protease cocktail inhibitor 
(Roche Diagnostics, Mannheim, Germany). Tissue samples were 
homogenized (PT-MR 1600E, Kinematica Inc., Littau, Switzerland) in 
ice-cold lysis buffer at a concentration of 50mg tissue per 1ml of lysis 
buffer. The homogenate was cleared by centrifugation at 13200xg for 
20 min. The lipid layer was removed from the top and the supernatant 
transfered to a clean eppendorf tube to discard pellet of debris and 
insoluble material. The protein concentration was estimated using the 
BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). 
Standards were prepared from 2mg/ml Bovine serum albumin (BSA) 
with serial dilutions until 0.125mg/mL.  Colorimetric analysis was 
performed in a 96-well plate using a Multiskan FC Microplate 
Photometer (Thermo Scientific, Finland).  
Laemmli 6x loading buffer, containing 9% sodium dodecyl sulphate 
(SDS, Sigma-Aldrich), 60% Glycerol (Sigma-Aldrich), 10% β-
Mercaptoethanol (Sigma-Aldrich), 0.03% bromophenol blue(Biorad) 
and 0.375M Tris-HCl pH 6.8 was added to extracts at a 1:1 volume. 
Samples were denatured by heating for 2 min at 100oC. 50µg of 
protein were loaded per lane and resolved under reducing and 
denaturing conditions by SDS-polyacrylamide gel electrophoresis 
(Sambrook and Russell, 1989, Schägger, 2006) 
Polyvinylidene fluoride (PVDF) membranes were pre-activated by 
incubating in 100% methanol for 5 min, and then thoroughly rinsed in 
the transfer buffer before beginning the transference. Resolved 
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proteins were transferred from SDS-PAGE gels to PVDF membranes 
at 350mA for 1h30min-2h at 4ºC.  Following transfer, non-specific 
binding of proteins to the PVDF membranes was blocked by 
incubating in blocking solution containing 5% BSA in 1xTBST (Tris-
Buffered Saline-Tween 20) composed for 50mM Tris-HCl pH7.5, 
150mM NaCl and 0.05% Tween-20, for 1h at room temperature on a 
see-saw rocker plate. Primary antibodies (Table 6 for technical 
details) were diluted in 3% BSA solution and incubated on a see-saw 
rocker. After the incubation, the primary antibody was removed and 
the PVDF membrane was washed 3 times for 10 min in 1x TBST on a 
see-saw rocker plate. The appropriate horseradish peroxidase-
conjugated (HRP) secondary antibody (Thermo-Scientific) was diluted 
in blocking solution and incubated with the PVDF membrane for 1h at 
room temperature. The secondary antibody was then removed and 
the PVDF membrane was washed in 1xTBST 3 times for 10 min per 
wash on a see-saw rocker plate. Reactive bands were revealed on X-
ray film CURIX RP2 Plus (AGFA), using Pierce Enhanced 
Chemiluminescent (ECL) Western Blotting Substrate reagents 
(Thermo Scientific #32106).  
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Primary Antibody Dilution Manufacturer Incubation Conditions 
C/EBPα 1/200 Santa Cruz 61 14h-4ºC 
GLUT4 1/1000 Millipore 07-1404 14h-4ºC 
HSL 1/500 Santa Cruz 74489 14h-4ºC 
IGF1R 1/500 Santa Cruz 713 14h-4ºC 
IRβ 1/1000 Santa Cruz 711 14h-4ºC 
IRS1 1/1000 Cell Signaling 23825 14h-4ºC 
IRS1 1/1000 Lab. Made PH 14h-4ºC 
IRS2 1/1000 Millipore MAB515 14h-4ºC 
IRS2 1/500 Santa Cruz 8299 14h-4ºC 
IRS3 1/500 Lab. Made 299 14h-4ºC 
ObR 1/200 Santa Cruz 8391 14h-4ºC 
PDGFRβ 1/500 Santa Cruz 432 14h-4ºC 
PPARγ 1/2000 Santa Cruz 7273 14h-4ºC 
β ACTIN 1/10000 Sigma A1978 1h- RT 
Table 6: Primary antibodies used in western blot analysis.  
 
2.15. Statistical Analysis  
All data presented were obtained from at least three independent 
experiments and are expressed as the mean ± SEM.  Paired 
Student’s t test was performed to compare genotypes.  
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3. HYPOTHESIS AND OBJECTIVES 
Defects in insulin signaling are implicated in obesity and T2D. Deletion 
of Irs2 in mice causes insulin resistance and progressive beta cell 
failure, culminating in diabetes. Reduced expression of Irs2 has been 
observed in islets of patients with T2D, suggesting a direct link 
between failed insulin signalling and human metabolic disease. 
Female Irs2-/- animals develop moderate obesity and display 
resistance to catecholamines and leptin. However, the precise role of 
IRS2 in adipose tissue and obesity-related inflammation has not yet 
been defined. Thus, the Irs2 knockout model was used to address the 
following objectives: 
 
1. Characterize WAT of female Irs2-/- mice by assessing markers 
of inflammation, adipocyte function, and insulin signal 
transduction. 
2. Isolate and characterize APCs of WAT to determine whether 
IRS2 plays a role in the development, proliferation and 
differentiation of adipocyte progenitors. 
3. Assess the potential physiological relationship between IRS2 
signaling and the cytokine OPN though the study WAT from 
female Irs2-/- and Spp1-/- mice. 
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4. RESULTS 
4.1. Irs2-/- females mice display increased adiposity 
4.1.1. Analysis of glucose and insulin levels 
Consistent with published results, Irs2-/- females displayed slightly 
elevated blood glucose levels and pronounced hyperinsulinemia 
(Figure 18). Male Irs2-deficient mice develop hyperglycemia earlier 
than females and progress rapidly to severe diabetes (Garcia-Barrado 
et al., 2011). All females used in this study were 8-12 weeks of age 
and although the fasting glucose levels in Irs2-/- were higher than in 
WT (WT 85.6±2.69 mg/dl vs Irs2-/- 95.6±2.34), none presented 
hyperglycemia (fasting glucose > 120 mg/dl) which facilitated the 
study of Irs2-deficiency in the absence of diabetic complications. The 
presence of hyperinsulinemia in these mice is due to insulin 
resistance in peripheral tissues, mainly liver and muscle (Withers et 
al., 1998). 
A B 
Serum glucose 
 
Insulin 
 
Figure 18: Glucose and insulin levels of female WT and Irs2-/- mice. 
Female mice (8-12 weeks of age) were fasted for 14-16 hours. A). Glucose was 
measured by Ascensia ELITE® glucometer. B) Insulin was estimated by ELISA. Results 
are expressed as mean ± SEM. * p<0.05, ** p<0.01, and *** p<0.001. For glucose 
measurements, n= 20 mice per genotype. For serum insulin levels, N=10 mice per 
genotype.  
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4.1.2. Characterization of body weight and WAT depts 
As reported, female Irs2-deficient mice weighed more than controls 
(Figure 19). Increased body weight was associated with increased 
accumulation of WAT in both visceral (V) and subcutaneous (SC) 
depots (% of total body weight).  
                                    A   
Body weight 
 
B C 
% V-WAT 
 
% SC-WAT 
 
Figure 19: Analysis of adipose depots. 
A) Total body weight. B) Visceral white adipose depots (V-WAT) were weighed and 
compared to total body weight. C) Sub-cutaneous white adipose (SC-WAT) depots were 
weighed and compared to total body weight. Results are expressed as mean ± SEM. * 
p<0.05, ** p<0.01, and *** p<0.001. N=20 mice of each genotype. 
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 4.1.3.
The increase of WAT present in the 
an increase in the size of adipocytes (hypertrophy) as a result of more 
stored triglycerides or to an increase in the number of adipocytes 
(hyperplasia). To distinguish between these possibilities, histological 
sections of V
eosin and examined
WAT revealed no apparent differences in the average diameter of 
adipocytes between 
suggesting that enhanced adipocyte size does not account for the 
increased fat mass in this model.
A 
B 
Figure 20
Hematoxylin and eosin staining 
adipocyte
expressed as mean ± SEM and paired 
WT and Irs2
Representative images were captured using a 20x objective. The scale bar represents 
50µm.  
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4.2. Irs2-deficiency is associated with enhanced expression of 
cytokines and markers of inflammation 
Obesity is associated with low-grade chronic inflammation attributed 
to the dysregulated production and release of cytokines and 
adipokines (Barbosa-da-Silva et al., 2012). Consistent with published 
results (Burks et al., 2000), leptin levels of Irs2-deficient females were 
elevated (Figure 21). Serum adiponectin levels were enhanced 
approximately 2-fold as compared with WT control females. However, 
a reduction in serum resistin was observed in Irs2-/- females. The role 
of resistin in obesity remains controversial (Schwartz and Lazar, 2011) 
but some studies suggest that this cytokine activates the anti-
inflammatory mediator SOCS3 in rodent WAT (Steppan et al., 2001, 
Steppan et al., 2005). SOCS3 is known to decrease insulin signaling 
in adipose and other tissues.  
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B C 
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Figure 21: Adipokines serum levels in WT and Irs2-/- mice. 
A, B, C) Serum was obtained from blood samples and adipokines were measure with 
Luminex® technology. Results were expressed as mean ± SEM. * p<0.05, ** p<0.01 
and *** p<0.001. N=8 mice of each genotype.  
To confirm the results obtained by measuring hormones in serum with 
Luminex®, RT-PCR was used to assess the mRNA expression of 
various adipokines in V and SC WAT. All results were normalized to 
the expression in V-WAT of WT mice (100% of expression). As 
observed in serum, adiponectin expression (Adipoq) was up-regulated 
in V and SC WAT of Irs2-/- when the expression is compared with WT 
V-WAT (Figure 22). Resistin was decreased in Irs2-/-, confirming the 
results obtained from serum samples. It was not possible to measure 
some obesity-associated molecules with Luminex® technology 
because the serum values were near the lower limits of detection. 
Thus, Retinol Binding Protein 4 (Rbp4), Interleukin 6 (IL6), Tumor 
necrosis factor α (Tnfα), and Monocyte Chemotactic Protein 1 (Mcp1) 
were assessed by RT-PCR. RBP4, expressed mainly by adipocytes, 
was increased in Irs2-/- V-WAT but reduced in Irs2-/- SC-WAT (Figure 
22).  
Adipocytes express low levels of MCP1 but the adipose tissue of 
obese humans contains increased numbers of macrophages, and 
once activated, these macrophages are responsible for the expression 
of cytokines such as TNFα, IL6, and MCP1 (Vykoukal and Davies, 
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2011). The expression of IL6 was greater in V-WAT and SC-WAT of 
Irs2-deficient mice than in WT controls (Figure 22). IL6 impairs insulin 
signaling in the liver and adipocytes by inducing ubiquitin-mediated 
degradation of insulin receptor substrate through SOCS 1 and 3 
(Kristiansen and Mandrup-Poulsen, 2005). The expression of TNFα is 
also up-regulated in V-WAT but not SC-WAT of Irs2-deficient females. 
However, it should be noted that the expression of TNFα is drastically 
higher in SC-WAT than V-WAT in animals of both genotypes (Figure 
22). This may reflect contamination with lymph nodes in the SC 
samples. In adipose tissue, TNFα is mostly secreted by macrophages 
in the stroma vascular fraction (SVF) and circulating TNFα and 
adipose tissue TNFα gene expression are increased in insulin 
resistance (Kern et al., 2001). MCP1 is a chemoattractant that plays 
an important role in the recruitment of macrophages to the adipose 
tissue (Sartipy and Loskutoff, 2003, Kanda et al., 2006). Obesity is 
associated with increased plasma levels of MCP1 and overexpression 
in adipose tissue (Di Gregorio et al., 2005). MCP1 was increased in V-
WAT of Irs2-/- mice but the expression was equivalent between 
genotypes in SC-VAT. Mice lacking MCP1 receptor (CCR2) have 
decreased adipose tissue macrophage infiltration and improved 
metabolic function (Weisberg et al., 2003, Kanda et al., 2006).  
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Figure 22: Gene expression studies of adipokines in WAT from WT and Irs2-/-.  
Total RNA was extracted from V and SC-WAT with Trizol®. RT-PCR was performed 
using TaqMan probes for the indicated genes. Each reaction was performed in duplicate 
and the value of the gene of interest was normalized to the expression of Ubiquitin C. 
Data was analyzed by the comparative Ct method (2-ΔΔCt) (Livak and Schmittgen, 2001). 
Results are expressed as mean ± SEM.   * p<0.05, ** p<0.01 and *** p<0.001. For data 
presentation, V-WAT of WT mice was considered as 100%. N= 5 mice of each 
genotype. Relative gene expression of Adiponectin (A), Resistin (B), Retinol Binding 
Protein 4 (C), Interluekin 6 (D), Tumor necrosis factor α (E) and Monocyte Chemotactic 
Protein 1 (F) are shown in the graphs.  
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Osteopontin (Spp1, OPN) is a multifunctional protein expressed in 
activated macrophages and T cells that may also  play an important 
role in the inflammatory process in WAT (Mazzali et al., 2002, Standal 
et al., 2004). OPN is a T helper type 1 (Th1) cytokine and has been 
shown to be involved in monocyte/macrophage migration and 
activation (Zeyda et al., 2011). In the Irs2 knockout model, no 
differences were detected in the expression of OPN in either source of 
WAT (Figure 23). Another macrophage marker implicated in obesity-
related adipose inflammation is the glycoprotein F4/80 (Emr1). This 
marker was up-regulated in V-WAT of Irs2-deficient females but not in 
SC-WAT (Figure 23), perhaps reflecting the fact that macrophage 
infiltration occurs to a larger extent in visceral fat.  
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Figure 23: Gene expression studies of osteopontin and F4/80 in WAT from WT 
and Irs2-/-.  
Total RNA was extracted from V and SC-WAT with Trizol®. RT-PCR was performed 
using TaqMan probes for the indicated genes. Each reaction was performed in duplicate 
and the value of the gene of interest was normalized to the expression of Ubiquitin C. 
Data were analyzed by the comparative Ct method (2-ΔΔCt) (Livak and Schmittgen, 
2001). Results are expressed as mean ± SEM.   * p<0.05, ** p<0.01 and *** p<0.001. 
For data presentation, V-WAT of WT mice was considered as 100%. N= 5 mice of each 
genotype. Relative gene expression of osteopontin (A) and F4/80 (B) are shown in the 
graphs.  
 
Another mechanism involved in obesity-induced inflammation is the 
presence of lymphocytes and leukocytes in WAT, chiefly cytotoxic T 
lymphocytes. CD45 (Ptprc), also called leukocyte common antigen, 
was increased in V-WAT of Irs2-deficient mice but no differences were 
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observed between genotypes with respect to SC-WAT (Figure 24). 
CD3 together with the T-cell receptor alpha/beta and gamma/delta 
heterodimers forms the T-cell receptor-CD3 complex (Alarcon et al., 
1988, Blumberg et al., 1990). The expression of CD3 was similar 
between WAT of WT and Irs2-/-. CD8 is a transmembrane glycoprotein 
that serves as a co-receptor for the T cell receptor (Gao and 
Jakobsen, 2000). The expression of this marker was enhanced in V-
WAT, but not SC-WAT, from Irs2-/- when compared to control mice. 
                               A 
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Figure 24: Gene expression studies of lymphocytes markers in WAT of WT and 
Irs2-/-. 
Total RNA was extracted from V and SC-WAT with Trizol®. RT-PCR was performed 
using TaqMan probes for the indicated genes. Each reaction was performed in duplicate 
and the value of the gene of interest was normalized to the expression of Ubiquitin C. 
Data was analyzed by the comparative Ct method (2-ΔΔCt) (Livak and Schmittgen, 2001). 
Results are expressed as mean ± SEM.   * p<0.05, ** p<0.01 and *** p<0.001. For data 
presentation, V-WAT of WT mice was considered as 100%. N=5 mice of each 
genotype. Relative gene expression of leukocyte marker CD45 (A), CD3 (B), and CD8 
(C) are shown in the graphs.  
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4.3. Markers of hypoxia are up-regulated in WAT of Irs2-/- 
females 
Hypoxia is a pathogenic state whereby the surrounding tissue is 
devoid of an adequate supply of oxygen (Semenza, 2000, Hosogai et 
al., 2007). Local hypoxia is observed in WAT of obese mice and 
human subjects. It has been proposed (Kabon et al., 2004, Pasarica 
et al., 2009, Wood et al., 2009) that hypoxia may occur as a result of 
adipocyte hypertrophy which reduces the O2 supply from the 
vasculature, thereby triggering an inflammatory response associated 
with expression of the transcription factor hypoxic inducible factor-1 
(Hif1α) and Vascular endothelial growth factor A (Vegfa). Thus, 
hypoxia-induced inflammation represents a potential underlying cause 
of ATM infiltration in WAT (Finucane et al., 2012). Consistent with this, 
the expression of Hif1a was significantly up-regulated in V-WAT of 
Irs2-deficient mice. Vegfa expression was augmented in both V-WAT 
and SC-WAT when compared to WT control samples (Figure 25).  
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Figure 25: Gene expression studies of hypoxia markers in WT and Irs2-/- WAT. 
Total RNA was extracted from V and SC-WAT with Trizol®. RT-PCR was performed 
using TaqMan probes for the indicated genes. Each reaction was performed in duplicate 
and the value of the gene of interest was normalized to the expression of Ubiquitin C. 
Data was analyzed by the comparative Ct method (2-ΔΔCt) (Livak and Schmittgen, 2001). 
Results are expressed as mean ± SEM.   * p<0.05, ** p<0.01 and *** p<0.001. For data 
presentation, V-WAT of WT mice was considered as 100%. N=5 mice of each 
genotype. Relative gene expression of Hypoxic inducible factor α (A) and vascular 
endothelial growth factor A (B) are presented in the graphs.  
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4.4. Expression of insulin signaling genes 
Inflammatory events decrease the sensitivity to insulin in obese 
patients (Zeyda et al., 2011, Kiefer et al., 2010, Hotamisligil, 2003, 
Hotamisligil, 2006). Elevated serum concentrations of proinflammatory 
impairs insulin-signaling and thus, decreases insulin sensitivity in 
many tissues, including WAT (Belkina and Denis, 2010). Given the 
presence of moderate obesity and insulin resistance in the Irs2 model, 
RT-PCR analysis of some components of the insulin pathway was 
performed from both WAT sources. Irs1 and Irs3 were increased in V-
WAT but not SC-WAT of Irs2-/- mice as compared to WT controls 
(Figure 26). However, the expression of Insr (IRβ) was equivalent 
between V and SC-WAT of both experimental groups. The expression 
of glycogen synthase kinase 3 (GSK3β), a negative regulator of 
insulin signaling (Cross et al., 1995, Sharfi and Eldar-Finkelman, 
2008, Boura-Halfon and Zick, 2009), was enhanced in both WAT 
depots of Irs2-deficient mice (Figure 26). 
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Figure 26: Gene expression analysis of insulin signalling components of WAT 
from WT and Irs2-/- . 
Total RNA was extracted from V and SC-WAT with Trizol®. RT-PCR was performed 
using TaqMan probes for the indicated genes. Each reaction was performed in duplicate 
and the value of the gene of interest was normalized to the expression of Ubiquitin C. 
Data was analyzed by the comparative Ct method (2-ΔΔCt) (Livak and Schmittgen, 2001). 
Results are expressed as mean ± SEM. * p<0.05, ** p<0.01 and *** p<0.001. For data 
presentation, V-WAT of WT mice was considered as 100%. N= 5 mice of each 
genotype. Insulin receptor substrate 1 (A), Insulin receptor substrate 3 (B), Insulin 
receptor (C) and glycogen synthase kinase 3 (D).  
 
4.5. Adipogenesis-related genes are altered in WAT from Irs2-
deficient mice 
Nuclear receptors are key regulators of adipogenesis as they form 
platforms for co-activator proteins and regulate the assembly of these 
cofactors into protein complexes on specific DNA sequences (Glass et 
al., 1997, Spiegelman, 1998, Moras and Gronemeyer, 1998, Wu et al., 
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1999, Glass and Rosenfeld, 2000). Peroxisome proliferator activated 
receptor-γ (Pparg) is a nuclear hormone receptor that promotes the 
conversion of preadipocytes into fully differentiated adipocytes, 
including cell growth arrest, triglyceride accumulation, and improved 
insulin sensitivity (Walkey and Spiegelman, 2008). Pparγ expression 
was increased in both V-WAT and SC-WAT of Irs2-deficient mice as 
compared with control mice (Figure 27). Some co-activators have 
histone acetyltransferase activity that functions to ‘open’ the 
configuration of chromatin, allowing more efficient transcription 
(Puigserver and Spiegelman, 2003). Several co-activators, such as 
PPARγ co-activator‑1α (PGC-1α, gen Ppargc1a) enhance the activity 
of PPARγ. Consistent with attenuated expression of Pparg, the gene 
for PGC-1α was also down-regulated in WAT of Irs2-/- (Figure 27). 
PGC1α is crucial for liver gluconeogenesis and the altered expression 
of this co-activator has been implicated in hepatic insulin resistance of 
Irs2-deficient mice (Dong et al., 2006, Dong et al., 2008, Guo et al., 
2009). Sterol Regulatory Element Binding Protein (SREBP) 1c  
(Srebf1) has emerged as a major protein involved not only in the 
regulation of genes related with carbohydrate and lipid metabolism in 
the liver, but also in adipose tissue, muscle and pancreatic beta cells 
(Tontonoz et al., 1993, Brown and Goldstein, 1997). Srebf1 mediates 
the effects of insulin on gene expression and thus, favours glucose 
utilization and glycogen synthesis, as well as lipid synthesis from 
glucose and triglyceride storage into adipocytes (Kim et al., 1998, 
Fajas et al., 1999). This expression of this gene was increased 
significantly in V-WAT of Irs2-/- (Figure 27). Up-regulation of Srebf1 
may reflect an effort to increase lipid storage or alternatively, may 
represent the effects of chronic hyperinsulinemia in Irs2-deficient 
mice.  
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Figure 27: Gene expression of adipogenesis markers in WT and Irs2-/- WAT.  
Total RNA was extracted from V and SC-WAT with Trizol®. RT-PCR was performed 
using TaqMan probes for the indicated genes. Each reaction was performed in duplicate 
and the value of the gene of interest was normalized to the expression of Ubiquitin C. 
Data was analyzed by the comparative Ct method (2-ΔΔCt) (Livak and Schmittgen, 2001). 
Results are expressed as mean ± SEM.   * p<0.05, ** p<0.01  and ***  p<0.001. For 
data presentation, V-WAT of WT mice was considered as 100%. N= 5 mice of each 
genotype. Relative gene expression of Peroxisome proliferator activated receptor-γ (A), 
PPARγ co-activator‑1α (B) and Sterol Regulatory Element Binding Protein 1c (C) are 
presented in the graphs.  
 
One of the targets of PPARγ, the Fabp4 gene encoding fatty acid 
binding protein (FABP4 or aP2), was increased in the Irs2-/- model, 
perhaps reflecting some compensation mechanism. Adipsin (Adn) and 
Fatty Acid Synthase (Fasn) are acquired during differentiation to 
mature adipocytes (Choy et al., 1992, Spiegelman et al., 1993) and 
both were down-regulated in both types of WAT from Irs2-deficient 
mice (Figure 28). A decrease of Adn and Fasn has been described in 
0%
25%
50%
75%
100%
125%
WT V Irs2-/- V WT SC Irs2-/- SC
R
el
at
iv
e 
ex
pr
es
si
on
*
*
0%
40%
80%
120%
160%
200%
WT V Irs2-/- V WT SC Irs2-/- SC
R
el
at
iv
e 
ex
pr
es
si
on
****
0%
50%
100%
150%
200%
250%
300%
WT V Irs2-/- V WT SC Irs2-/- SC
R
el
at
iv
e 
ex
pr
es
si
on
**
 RESULTS 
123 
 
other obesity models (Lowell et al., 1990). GLUT4 (Slc2a4), the main 
glucose transporter present in WAT, was increased in V-WAT but not 
SC-WAT of Irs2-/- females. 
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Figure 28: Gene expression of PPARγ targets in WT and Irs2-/- WAT.  
Total RNA was extracted from V and SC-WAT with Trizol®. Real Time PCR was 
performed using TaqMan probes for the indicated genes. Each reaction was performed 
in duplicate and the value of the gene of interest was normalized to the expression of 
Ubiquitin C. Data was analyzed by the comparative Ct method (2-ΔΔCt) (Livak and 
Schmittgen, 2001). Results are expressed as mean ± SEM.   * p<0.05, ** p<0.01 and ***  
p<0.001. For data presentation, V-WAT of WT mice was considered as 100%. N= 5 
mice of each genotype. Relative gene expression of Glucose transporter 4 (A), Fatty 
Acid Binding Protein 4 (B), Fatty acid synthase (C) and Adipsin (D) are shown in the 
graphs.  
 
Synthesis of triacylglycerol (TG) involves acyl CoA diacylglycerol 
acyltransferase (Dgat) enzymes, which catalyze a reaction with 
diacylglycerol and fatty acid (FA) acyl CoA substrates (Bell and 
Coleman, 1980, Cases et al., 1998). Cellular TG storage is directly 
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correlated with levels of DGAT activity. Interestingly, DGAT1 
expression in adipocytes and WAT is regulated by PPARγ activation 
(Sugii et al., 2009). However, although PPARγ expression is reduced 
in Irs2-/- mice, only Dgat1 expression from SC-WAT was reduced in 
Irs2-deficient mice and it was equivalent between V-WAT samples of 
both genotypes (Figure 29). In sharp contrast, Dgat2 was enhanced in 
both V and SC WAT of Irs2-/- females as compared to WT controls. 
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Figure 29: Gene expression of TG synthesis in WT and Irs2-/- WAT.  
Total RNA was extracted from V and SC-WAT with Trizol®. Real Time PCR was 
performed using TaqMan probes for the indicated genes. Each reaction was performed 
in duplicate and the value of the gene of interest was normalized to the expression of 
Ubiquitin C. Data was analyzed by the comparative Ct method (2-ΔΔCt) (Livak and 
Schmittgen, 2001). Results are expressed as mean ± SEM.   * p<0.05, ** p<0.01 and ***  
p<0.001. For data presentation, V-WAT of WT mice was considered as 100%. N= 5 
mice of each genotype. Relative gene expression of acyl CoA diacylglycerol 
acyltransferase 1 (A) and acyl CoA diacylglycerol acyltransferase 2 (B) are presented.  
 
4.6. Adipocyte progenitor cells (APCs) are increased in V-
WAT of Irs2-/- mice 
The development of insulin resistance and its complications are 
related with abdominal adipose tissue accumulation and adipocyte 
enlargement rather than peripheral obesity, which is usually 
associated with a recruitment of new preadipocytes (hyperplasia) 
(Isakson et al., 2009). Since mature adipocytes are postmitotic 
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(Simon, 1965), adipocyte hyperplasia in adults requires that new 
adipocytes be produced from the differentiation of precursor cells. 
Previous reports have shown that cells derived from the stroma-
vascular fraction (SVF) of WAT from mice and humans can 
differentiate into several lineages, including adipocytes (Zuk et al., 
2002). Based on results presented above, the increased adiposity 
observed in Irs2-/- females is not due to cell hypertrophy since 
adipocyte size was similar to control mice. Alternatively, the moderate 
obesity of this model might be due to increased production of new 
adipocytes from APC.  
4.6.1. Establishment of FACS method for isolation of APC 
To assess the effects of Irs2-deficiency on APCs, a FACS-based 
strategy was developed to isolate this population of cells from SVF 
preparations of V-WAT and SC-WAT (Figure 30). WAT was digested 
enzymatically to obtain the SVF fraction which was then sorted based 
on lack of expression of CD45 (hematopoietic marker), CD31 
(endothelial marker) and Ter119 (erythroid marker) to obtain a 
negative lineage (Lin-). The Lin- subpopulation was further separated 
based on expression of stem cell antigen 1 (Sca1) and CD34 
(preadipocyte/stroma marker), markers that are associated with the 
population of primary preadipocytes (Rodeheffer et al., 2008, Tang et 
al., 2008, Joe et al., 2009). 
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Figure 30: Strategy for APCs isolation by FACS.  
After the selection of live cells (DAPI-), the sequential  isolation of CD45-, CD31- and 
Ter119- cells guarantees that all the haematopoietic cells (CD45+), endothelial cells 
(CD31+) and erythroid cells (Ter119+) are discarded from the selected fraction. The 
population was then selected positively for CD34 and Sca1.   
 
The population resulting from the FACS strategy displayed the 
following characteristics: CD45- CD31- Ter119- CD34+ Sca-1+. These 
cells were recovered from the Cell Sorting MoFlo and corrected to the 
weight of the starting material (grams of WAT). The APC population 
obtained from Irs2-/- V-WAT was 2.5-fold higher than WT but there 
were no significant differences between genotypes in the APC 
isolated from SC-WAT (Figure 31). After cell sorting the cells were 
plated and the primary culture was established as show the pictures 
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Figure 31
Quantification of APC 
Results were corrected for weight of original WAT sample and then compared to WT V
WAT which was assigned the value of 1. 
images of APC after FACS isolation from V
expressed as 
genotype were used to generate the SVF and five independent isolation experiments 
were analyzed
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hematopoietic lineage) CD34- (stroma/preadipocyte cell marker) and 
Sca1- (stem cell marker) (Figure 32) were isolated from the SVF 
fractions of both V and SC WAT. 
A 
 
 
Figure 32: Scheme for FACS isolation of inflamation-related cells.  
After the selection of the live cells (DAPI-), the isolation of CD45+ cells enriches for 
haematopoietic cells in the selected fraction. Negative selection for CD34 - and Sca1 - 
cells eliminates adult stem cells.  
 
The population CD45+CD34-Sca1- was normalized to cells per gram 
of WAT and was 3-fold higher in V-WAT from Irs2-/-, whereas this 
population isolated from SC-WAT was equivalent between genotypes 
(Figure 33).  
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Figure 33: Quantification of inflammatory-related cells in WT and Irs2-/- WAT. 
The CD45+ CD34- Sca1- population was isolated from the SVF fraction of V-WAT (A) 
and SC-WAT (B) as outlined in Figure 32. Results are expressed as mean ± SEM. * 
p<0.05, ** p<0.01 and *** p<0.001. N=3 mice of each genotype were used to generate 
the SVF and five independent isolation experiments were analyzed. 
 
4.6.3. Validation of FACS strategy and long-term 
maintenance of APC phenotype 
To confirm that the population obtained by the FACS strategy indeed 
represented APCs, Western blotting was performed to assess 
expression of an independent marker of adult adipose stem cells, the 
platelet-derived growth factor (PDGF) receptor. PDGFRβ is 
considered one of the main markers in adult stem cells from WAT 
since it is involved in the angiogenesis when new cells are 
differentiated from the precursors (Carmeliet, 2003, Armulik et al., 
2005, Tang et al., 2008). After APC differentiate to a mature 
adipocyte, expression of PDGFRβ is drastically reduced. Consistent 
with this, PDGFRβ was expressed in only the APC population (CD45- 
CD31- Ter119- CD34+ Sca1+) isolated from both genotypes (Figure 
34).  
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    + CELLS: CD45- CD31- Ter119- CD34+ Sca1+ 
    - CELLS: CD45+ CD34- Sca1- 
Figure 34 : Western blot analysis of APC obtained by FACS from WAT of WT and 
Irs2-/- mice.  
Sorted cells were lysed and protein was extracted for Western blot analysis of APC 
marker PDGFRβ. βActin was used as a loading control. PDGFR: platelet-derived 
growth factor receptor.  
 
To ensure that when cultured in vitro the APC population maintained a 
stem cell phenotype, FACS was repeated after culturing the SVF 
preparation for five days and compared to cells freshly isolated from 
SVF. The percentage of non-stem cell populations was higher in fresh 
preparations than when the SVF was cultured one week (DMEM + 
10% FcBS + 10ng/mL βFGF). The CD45+ CD31+ Ter119+ cells 
basically disappeared when the cells were cultured (Figure 35B). 
Thus, the CD34+ Sca1+ population represented almost 90% of the 
cells in culture. 
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Figure 35
in culture
(A) FACS analysis of SVF directly isolated from the WAT. 
APC after one week of culture. Enrichment of CD34+ Sca1+ population was 
approximately 90%.
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detected from 4 to 8 weeks but expression of IRS3 as well as IRβ 
remained constant in both genotypes. Consistent with RT-PCR 
results, Glut4 was up-regulated V-WAT of Irs2-deficient mice (see 
Figure 28 and Figure 36). The expression of various proteins involved 
in the adipocyte metabolism was reduced in WAT from Irs2-/- mice 
including hormone sensitive lipase (HSL) and the leptin receptor 
(ObR). Concerning proteins with a clear role in the adipogenesis, 
PPARγ expression was increased in WAT of WT mice at 8-weeks of 
age compared to 4-week old mice. However, the expression of 
PPARγ was greatly reduced in Irs2-deficient WAT at both time points, 
consistent with qPCR data (see Figure 27 and Figure 36).  
A 
 
 
Figure 36: Western blot from WAT of 4 and 8 weeks old WT and Irs2-/- mice.  
WAT from 4 and 8-week old mice was lysed and Western blot analysis was performed 
for IRS proteins and the main regulators markers of adipogenesis. -actin was used as 
a loading control. IRS2, insulin receptor substrate 2; IRS1, Insulin receptor substrate 1; 
IRS3, insulin receptor substrate 3; IRβ, Insulin receptor; IGF1R, insulin growth factor 
receptor; ObR, leptin receptor, HSL, hormone sensitive lipase; PPARγ peroxisome 
proliferator-activated receptor gamma; GLUT4, glucose transporter 4. 
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4.7.2. Differentiation in vitro of Irs2-/- APC to adipocytes is 
impaired 
Adipocytes are postulated to derive from multipotent mesenchymal 
stem cells (Pittenger et al., 1999). During the first phase of 
adipogenesis adult stem cells commit to the adipocyte lineage. In the 
second phase, which is known as terminal differentiation, the pre-
adipocyte acquires the characteristics of mature adipocyte: transport 
and synthesis of lipids, insulin sensitivity and the secretion of 
adipocyte-specific proteins (Rosen and Spiegelman, 2000, Rosen and 
MacDougald, 2006). To examine the role of IRS2 in adipocyte 
differentiation, APC isolated from SVF were plated (day -3) and 
cultured until confluent (day 0). Adipocyte differentiation was induced 
by a standard protocol that employs a cocktail of insulin, 
glucocorticoids, and isobutylmethylxanthine (see Figure 15 page 93 ).  
At the onset and conclusion of the 10-day differentiation protocol, 
images were captured to assess the morphology of APC cultures. As 
expected, all cultures were fully confluent on Day 0 of the protocol. 
Lipid droplets were observed in cultures of both V and SC APCs 
isolated from WAT of WT mice (Figure 37 B and F). However, few if 
any lipid droplets were noted in 10-day cultures of Irs2-/- APC, 
suggesting that adipogenesis might be impaired in WAT of this model 
(Figure 37 D and H). It is also noteworthy that under the experimental 
conditions used for this study, the adipogenic differentiation of APC 
from SC-WAT was higher than V-WAT in control samples.  
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Figure 37: Phase contrast images of APC cultures from WT and Irs2-/- WAT 
subjected to adipocyte differentiation protocol. 
Phase contrast images of APC at day 0 and day 10 of adipocyte differentiation. A,B) 
WT V-WAT; C,D) Irs2 V-WAT; E,F) WT SC-WAT; G,H) Irs2 SC-WAT. Images were 
captured with 20x objective and 40x objectives (right of the picture). Representative 
images from 3 different experiments are shown. 
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Mature adipocytes are highly specialized for the storage of excess 
lipid and contain triacylglycerol-rich lipid droplets (Björntorp, 1991a, 
Henry et al., 2006). Fluorescent lipophilic dyes, which partition into the 
nonpolar lipid droplet core, are useful lipid droplet markers. Thus, 
BODIPY 493/503 was used to more precisely quantify the 
differentiation of APC to adipocytes. Cells were fixed with 4% 
paraformaldehyde and incubated with BODIPY 493/503 to reveal lipid 
droplets. At day 0, all cultures were devoid of lipid droplets but after 4 
days in adipogenic medium, WT APC display lipid droplets inside the 
cells as detected by BODIPY staining (Figure 38). Consistent with the 
results observed using light microscopy, cultures of Irs2-/- APC were 
negative for BODIPY staining, suggestive of impaired adipocyte 
differentiation. APC isolated from SC-WAT differentiated more 
efficiently than V-WAT in WT control cultures. It is interesting that the 
DAPI staining revealed differences in cell and nuclei size between WT 
and Irs2-/- APC. 
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Figure 38: BODIPY staining at day 0 and day 4 of differentiation of APC to 
adipocytes.  
The presence of lipids droplets was detected with BODIPY 493/503 (green). DAPI 
(blue) was used to reveal cell nuclei. A) APC from V-WAT; B) APC from SC-WAT. 
Scale bars represent 100μm.  
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Flow cytometry analysis was employed to quantify the differentiation 
of APC to adipocytes. Cells at different points of differentiation 
program (day 0, 4 and 10) were stained first with BODIPY to preserve 
lipid droplets. Subsequently, these cells were incubated with anti-Sca-
1 antibody to assess loss of this stem cell marker during the 
differentiation to adipocyte. BODIPY staining was analyzed in linear 
amplification to estimate the time when the cells started to accumulate 
lipids. The fluorescence intensity of BODIPY detected in cultures of V-
WAT APC from WT was higher at both day 4 and day 10 than Irs2-/- 
cultures (Figure 39). WT acquired lipids faster than Irs2-/- since by day 
4 the curve is completely shifted to right.  
A 
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Figure 39: Quantification of BODIPY staining during the time-course of APC 
differentiation.  
Lineal fluorescent intensity in X axis reflects BODIPY staining. (A) Differentiation of WT 
APC from V-WAT at days 0, 4 and 10. (B) Differentiation of Irs2-/- APC from V-WAT at 
days 0, 4 and 10. Results were expressed as mean ± SEM. N=3 different primary cell 
cultures were analyzed. 
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The profile BODIPY staining during the differentiation time-course was 
inversely related to Sca1 staining in WT cultures of APC: BODIPY 
increased steadily with adipocyte differentiation whereas the stem 
marker Sca1 decreased (Figure 40). However, in cultures of Irs2-/- V-
APC Sca1 expression was not down-regulated along the course of 
differentiation and BODIPY staining was significantly lower as 
compared to V-APC (Figure 40). 
A 
 
Figure 40: Comparison of BODIPY and Sca1 staining in ADP of APC from V-WAT.  
The % of total cells positive for BODIPY or Sca-1 was estimated by FACS. Results are 
expressed as mean ± */# p<0.05, **/## p<0.01, and ***/### p<0.001. N=3 different primary 
cell cultures were analyzed. 
 
Similar results were obtained with cultures of APC from SC-WAT, 
although the differences were more pronounced between WT and null 
samples since the differentiation to adipocytes was generally more 
efficient in these cultures. Between day 4 and 10, the majority of WT 
APC were positive for BODIPY, in contrast to Irs2-/- SC-WAT where 
only a limited number of cells contained lipid (Figure 41).  
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Figure 41: Quantification of BODIPY staining during the time-course of APC 
differentiation from SC-WAT.  
Lineal fluorescent intensity in X axis reflects BODIPY staining. (A) Differentiation of WT 
APC from SC-WAT at days 0, 4 and 10. (B) Differentiation of Irs2-/- APC from SC-WAT 
at days 0, 4 and 10. Results were expressed as mean ± SEM. N=3 different primary cell 
cultures were analyzed. 
 
Sca1 expression declined only slight from day 0 to day 10 in cultures 
of to Irs2-/- SC-WAT, whereas the adipogenic protocol caused a 
dramatic reduction of this stem marker in WT cultures (Figure 42). 
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Figure 42: Comparison of BODIPY and Sca-1 staining in ADP of APC from SC-
WAT.  
The % of total cells positive for BODIPY or Sca-1 was estimated by FACS. Results are 
expressed as mean ± */# p<0.05, **/## p<0.01, and ***/### p<0.001. N=3 different primary 
cell cultures were analyzed. 
 
4.7.3. Western blot analysis of APC differentiation 
To identify potential molecular mechanisms underlying the differential 
capacity of WT versus Irs2-/- APC to differentiate, Western blot 
analysis was performed at various time points during the adipogenic 
protocol. Interestingly, the expression of IRS2 increased significantly 
from day 0 to day 4 during the differentiation of both V and SC APC 
isolated from WT mice (Figure 43). Conversely, IRS1 levels 
decreased from day 0 to day 4, consistent with a role for IRS1 in 
regulating proliferation. PPARγ and C/EBPα were up-regulated as 
expected in cultures of WT APC. However, similar to RT-PCR results 
(see Figure 27), the basal expression of PPARγ was reduced in Irs2-/- 
APC and did not increase during with culture in adipogenic medium. 
These observations suggest that IRS2 may exert a specific role in 
promoting the adipogenic program and may explain, in part, the 
observed failure of Irs2-/- APC to differentiate to adipocytes.  
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Figure 43: Western blot analysis of Adipocyte differentiation of APC.  
APC cultures were harvested at the indicated days during adipocyte differentiation. (A) 
Western blot from differentiation of APC from V-WAT. (B) Western blot from 
differentiation of APC from SC-WAT. Shown is a representative image for 3 
differentiation experiments. Anti- Actin was used to assess protein loading.  
 
4.8. Irs2-deficient APCs display altered proliferation in vitro 
Proliferation of cells within adipose tissue is influenced both by 
circulating factors and neuronal inputs as well as by internal controls 
such as paracrine/autocrine factors secreted from the various cells 
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within adipose tissue (Hausman et al., 1993, Lau et al., 1996, Serrero 
and Lepak, 1996, Mohamed-Ali et al., 1998). Studies have shown that 
conditioned media from adipose tissue of obese subjects stimulates 
the proliferation of preadipocytes better than do those from lean 
individuals (Considine et al., 1996). Adipose tissue is a source of 
growth factors, such as IGF-I, IGF binding proteins, TNFα, angiotensin 
II, and Macrophage colony-stimulating factor (MCSF).  
4.8.1. Characterization of cell growth and estimation of 
doubling time 
Various wells of each culture were plated at the same density and 
proliferation was assessed by counting the cell number at 24-hour 
intervals during 5 days. After day 6, most of the cultures were 
confluent and contact inhibition occurred. Proliferation curves were 
generated by graphing the number of cells during consecutive days. In 
both genotypes, the proliferation rate was higher in SC-APC than V-
APC (Figure 44). However, starting at day 3 of the analysis cell 
number was greater in Irs2-/- cultures as compared to WT controls. It 
should be noted that the curves in Figure 44 are not exponential 
growth curves since primary cultures and need to recover after the 
isolation procedure before their proliferation starts. 
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Figure 44: Growth curves estimated from cultures of APC. 
APC cultures were harvested and counted on the indicated days from V (A) and SC (B) 
WAT. Results were expressed as mean *p<0.05, ** p<0.01 and *** p<0.001. N=3 
different primary cell cultures were analyzed. 
 
 
The doubling time of the various cultures was calculated using the 
daily cell counts and the online software (http://www.doubling-
time.com/compute.php). Irs2-/- APC displayed a lower doubling time 
than WT APC, suggesting that they need less time to complete the 
cell-cycle (Figure 45).  
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Figure 45: Estimated doubling time of APC cultures from WT and Irs2-/- mice. 
APC cultures were harvested and counted as indicated for Figure 45 and the doubling 
time was calculated by the online software (http://www.doubling-
time.com/compute.php). Results are expressed as mean ± SEM.* p<0.05, ** p<0.01 
and *** p<0.001. N=3 different primary cell cultures were analyzed. 
 
4.8.2. Expression of proliferation markers Ki67 and 
phospho-Histone 3 are increased in Irs2-/- APC 
The Ki67 protein (also known as MKI67) is a nuclear antigen 
specifically associated with cell proliferation (Gerdes et al., 1984). 
Expression of Ki67 occurs preferentially during late G1, S, G2 and M 
phases of the cell cycle but cannot be detected in G0 phase 
(Scholzen and Gerdes, 2000). Immunostaining for Ki67 was 
performed 24 hours after initial plating of APCs isolated from both 
genotypes. A greater proportion of Irs2-/- APC (both V and SC WAT) 
were positive for KI67 protein as compared to WT (Figure 46). 
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Figure 46: Quantification of Ki67 staining with In Cell® technology.  
(A) InCell® quantification of Ki67 immunostaining. APCs were isolated from the 
indicated genotypes and plated. 24 hours later, cultures were fixed and stained for Ki67. 
(B) Representative images of APC stained with anti-Ki67 (green). DAPI was used to 
identify cell nuclei (blue). Results were expressed as mean ± SEM * p<0.05, ** p<0.01 
and *** p<0.001. N=3 different primary cell cultures. 
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Anti-pH3 Alexa 647 conjugated (red) and positive cells were quantified 
with In Cell® technology (see Figure 47). Irs2-/- APC from V-WAT 
showed an increase of pH3 staining whereas no differences were 
observed in APC from SC-WAT. 
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Figure 47: Quantification of anti-p-H3 in APC cultures.  
(A) InCell® quantification of anti-phospho-Histone 3 immunostaining. APCs were 
isolated from the indicated genotypes and plated. 24 hours later, cultures were fixed 
and stained for p-H3. (B) InCell® quantification of p-H3 immunostaining (red). DAPI 
(blue) was used to reveal cell nuclei. Results are expressed as mean ± SEM. * p<0.05, 
** p<0.01 and ***  p<0.001. Three different primary cell cultures were analyzed. 
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4.8.3. Cell cycle analysis by Flow Cytometry reveals 
abnormalities in APC from Irs2-deficient mice 
To gain further insight into the enhanced proliferation observed in Irs2-
/- APC cultures, the cell-cycle was assessed with propidium iodide 
(PI). PI is a DNA fluorochrome used for cell-cycle analysis of single-
cell suspensions. Flow cytometry analysis revealed enrichment of 
cells with double-quantity of DNA (4n) in Irs2-/-APC, suggesting a 
population which is compounded by polyploidy cells as a result of 
DNA replication in the absence of mitosis. However, no differences in 
cells in S phase were observed. These results might suggest a 
increase in cells undergoing mitosis and/or a failure in cell-cycle 
control in Irs2-/- APC (Figure 48). 
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Figure 48: Analysis of DNA content by PI staining of APC from WT and Irs2-/- 
mice. 
Cells adhering to the dish and detached cells (mitotic) were collected and subjected to 
PI nuclei staining and flow cytometry analysis. A and C, % of cells with different DNA 
content: 2n (normal cells G0-G1), S (synthesis phases of diploidy cells) and 4n (diploidy 
cells in mitosis and G0-G1 tetraploidy cells). B and D, DNA content on a logarithmic 
scale, determined by PI staining. Cells with 2n and 4n DNA are detected at 150 and 
300, respectively, whereas cells between these two populations are cell in S phase. 
Results were expressed as mean ± SEM. * p<0.05, ** p<0.01 and *** p<0.001. N=5 
primary cell cultures. 
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4.8.4. Apoptosis is not increased in APC cultures of Irs2-
deficient mice 
To determine whether Irs2 deficiency might also alter apoptosis in 
APC, flow cytometry analysis was performed with Annexin V 
conjugated to FITC. Apoptotic cells were identified as cells positive for 
both Annexin V and PI. For this study, cells were maintained in normal 
growth medium (DMEM + 10% Serum), apoptotic conditions (DMEM 
without serum) or with supplemented βFGF (DMEM + 10ng/mL βFGF) 
during 24h. All samples were assayed in duplicate. Basal rates of 
apoptosis in APC cultures were similar between Irs2-/- APC and WT 
cultures. Serum withdrawal induced apoptosis in cultures of both V 
and SC APC and no differences were observed between genotypes 
(Figure 49). SC-APCs were more sensitive to serum withdrawal than 
V-APC, since the % of cell death was higher in these cultures. βFGF 
alone in the medium prevented apoptosis in response to serum 
withdrawal. 
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Figure 49: Detection of apoptosis by flow cytometry analysis of Annexin V. 
Apoptotic cells of APC from V-WAT (A) or SC-WAT (B). Results are expressed as 
mean ± SEM.* p<0.05, ** p<0.01 and *** p<0.001. N=3 different primary cell cultures 
were analyzed. 
 
 
0,0
0,5
1,0
1,5
2,0
2,5
3,0
3,5
4,0
DMEN +10% S DMEN DMEN+βFGF 10ng/mL
R
el
at
iv
e 
ap
op
to
si
s:
 +
 A
ne
xi
n 
V 
ce
lls
WT.V
Irs2 -/-.V
*
**
0,0
0,5
1,0
1,5
2,0
2,5
3,0
3,5
4,0
DMEN +10% S DMEN DMEN+βFGF 10ng/mL
R
el
at
iv
e 
ap
op
to
si
s:
 +
 A
ne
xi
n 
V 
ce
lls
WT.SC
Irs2 -/-.SC* *
 RESULTS 
151 
 
4.9. Osteopontin deficiency (Spp1-/-) reduces inflammatory 
markers in WAT 
Chronic inflammation appears to underlie obesity-induced metabolic 
deterioration including insulin resistance and DT2 (Dandona et al., 
2004, Dandona et al., 2005, Hotamisligil, 2006). Osteopontin (OPN) is 
up-regulated in adipose tissue of obese humans and murine models 
of obesity. OPN acts as a chemokine and an inflammatory cytokine 
that is expressed in many cell types including adipose tissue 
macrophages (M Zeyda, 2007, Kiefer et al., 2010, Zeyda et al., 2011). 
Moreover, OPN added to the medium of primary adipocyte impairs 
differentiation as determined by PPAR γ and adiponectin gene 
expression (Zeyda et al., 2011). Given the impaired differentiation of 
Irs2-deficient APC, the relationship between insulin and OPN 
signalling in WAT was investigated. The results of this section were 
obtained in the laboratory of Dr. Thomas Stulnig of the University of 
Vienna. 
 
4.9.1. Characterization of metabolic parameters in Spp1-
deficient females 
To assess the role of Spp1 in adipose tissue inflammation and insulin 
resistance, female Spp1-/- and WT mice were maintained on a normal 
diet. Most of the previous studies with these mice were performed 
using high-fat diet but components of high-fat chow can themselves 
induce inflammation. Body weight was similar between WT and Spp1 
as were levels of fasting glucose (Figure 50). Adiposity was expressed 
as the quantity of WAT (g) divided by total body weight (g). Although 
there was a tendency for the WAT depots of Spp1-/- mice to weigh 
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less than WT, these differences were not statistically significant 
(Figure 50).  
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Figure 50: Metabolic parameters of WT and Spp1-/-.  
WT and Spp1-/- mice were fed a normal diet for 12 weeks. Mice were weighed (A) 
fasted overnight and blood glucose was measured using a glucometer (B). V and SC-
WAT were excised and weighed (C,D). Results are expressed as mean ± SEM. N=10 
mice of each genotype. Results are expressed as mean ± SEM. * p<0.05, ** p<0.01 and 
*** p<0.001.  
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4.9.2. Spp1-deficiency in mice alters the expression of 
adipokines and inflammatory markers 
Based on the results presented in Figure 18 and Figure 21, Irs2 
knockout mice display increased circulating levels of insulin, leptin, 
TNFand inflammation markers, suggestive of a state of obesity-
induced inflammation and pre-diabetes. To assess the role of OPN in 
WAT and adipose tissue inflammation, gene expression studies were 
performed with V and SC-WAT of Spp1-/- and WT mice. All results 
were compared to expression in V-WAT that was considered as 
100%. Similar to Irs2-deficient animals, adiponectin and Rbp4 were 
up-regulated in both types of WAT from Spp1 knockout mice (Figure 
51). Resistin and IL6 were reduced in Spp1-/- mice as compared to 
control samples, which is the opposite of what was observed in Irs2-/- 
females. Other markers related with inflammation were measured in 
WAT. The genes for IL6, TNFα and MCP1 were all down-regulated in 
V and SC-WAT of Spp1-/- mice (Figure 51), suggesting that loss of 
Spp1 reduces inflammatory cytokines in WAT. 
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Figure 51: Gene expression of adipokines in WAT from WT and Spp1-/-. 
Total RNA was extracted from V and SC-WAT with Trizol®. RT-PCR was performed 
using TaqMan probes for the indicated genes. Each reaction was performed in duplicate 
and the value of the gene of interest was normalized to the expression of Ubiquitin C. 
Data was analyzed by the comparative Ct method (2-ΔΔCt) (Livak and Schmittgen, 2001). 
Results are expressed as mean ± SEM. * p<0.05, ** p<0.01  and ***  p<0.001. For data 
presentation, V-WAT of WT mice was considered as 100%. N= 5 mice of each 
genotype. Relative gene expression of Adiponectin (A), Resistin (B), Retinol Binding 
Protein 4 (C), Interluekine 6 (D), Tumor necrosis factor α (E) and Monocyte 
Chemotactic Protein 1 (F) are shown in the graphs.  
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Markers of inflammatory cells were studied next. To determine 
whether macrophage infiltration was altered in WAT of Spp1- 
deficienct mice, F4/80 (Emr1) was analyzed by RT-PCR and the 
expression of this marker was diminished in both WAT sources 
(Figure 51), indicative of a reduced macrophage infiltration. 
Expression of the mRNA for Leukocyte marker CD45 was also lower 
in Spp1-/- mice as compared with WT WAT. Taken together with the 
reduction of the T-cell infiltration markers CD3 (Cd3e) and CD8 
(Cd8a), these results indicate reduced inflammation in WAT of Spp1-/-. 
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Figure 52: Gene expression of inflammatory-related markers in WAT from WT and 
Spp1-/-. 
Total RNA was extracted from V and SC-WAT with Trizol®. RT-PCR was performed 
using TaqMan probes for the indicated genes. Each reaction was performed in duplicate 
and the value of the gene of interest was normalized to the expression of Ubiquitin C. 
Data was analyzed by the comparative Ct method (2-ΔΔCt) (Livak and Schmittgen, 2001). 
Results are expressed as mean ± SEM.   * p<0.05, ** p<0.01 and ***  p<0.001. For data 
presentation, V-WAT of WT mice was considered as 100%. N= 5 mice of each 
genotype. Relative gene expression of macrophage infiltration marker F4/80 (A), 
leukocyte marker CD45 (B) and T lymphocyte marker CD3 (C) and CD8 (D) are showed 
in the graphs.  
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4.10. Hypoxia markers are down-regulated in Spp1-/- 
WAT 
In the Irs2-deficient model, enhanced expression of inflammatory-
related markers was also associated with up-regulation of the principal 
markers of hypoxia, HIFα and VEGF (see Figure 25), suggesting low 
oxygen availability in WAT. HIFα was down-regulated in both types of 
WAT in Spp1-/- as compared to WT controls (Figure 53). However no 
differences were founded in VEGF. 
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Figure 53: Gene expression studies of hypoxia markers in WAT from WT and 
Spp1-/-.  
Total RNA was extracted from V and SC-WAT with Trizol®. RT-PCR was performed 
using TaqMan probes for the indicated genes. Each reaction was performed in duplicate 
and the value of the gene of interest was normalized to the expression of Ubiquitin C. 
Data was analyzed by the comparative Ct method (2-ΔΔCt) (Livak and Schmittgen, 2001). 
Results are expressed as mean ± SEM.   * p<0.05, ** p<0.01 and *** p<0.001. For data 
presentation, V-WAT of WT mice was considered as 100%. N= 5 mice of each 
genotype. Relative gene expression of Hypoxic inducible factor α (A) and Vascular 
endothelial growth factor A (B) are shown in the graphs. 
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4.11. Expression of Irs2 mRNA is increased in WAT of 
Spp1-/- 
To explore the relation between the reduced inflammation mediated 
by Spp1-deficiency and insulin action in WAT, various genes of the 
insulin signaling were studied by RT-PCR. Interestingly, Irs2 mRNA 
was up-regulated in both depots of Spp1-/- WAT (Figure 54), 
suggesting that a general reduction of the inflammatory milieu might 
positively regulate IRS2 expression and thereby increase insulin 
sensitivity. The expression of Irs1 and Irs3 were decreased in Spp1-/- 
WAT whereas they were up-regulated in WAT of Irs2-deficient mice 
(Figure 54). The Insr was also reduced in V-WAT or SC-WAT from 
Spp1-/- mice. The expression of GLUT4 (Slc2a4) was increased in V-
WAT of Spp1-deficient mice suggesting an increased glucose uptake 
but there were no differences in the expression of Gsk3β between 
genotypes.  
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Figure 54: Analysis of genes of the insulin signalling pathway in WAT from WT 
and Spp1-/-. 
Total RNA was extracted from V and SC-WAT with Trizol®. RT-PCR was performed 
using TaqMan probes for the indicated genes. Each reaction was performed in duplicate 
and the value of the gene of interest was normalized to the expression of Ubiquitin C. 
Data was analyzed by the comparative Ct method (2-ΔΔCt) (Livak and Schmittgen, 2001). 
Results are expressed as mean ± SEM.   * p<0.05, ** p<0.01 and *** p<0.001. For data 
presentation, V-WAT of WT mice was considered as 100%. N= 5 mice of each 
genotype.  Relative gene expression of Insulin receptor substrate 2 (A), Insulin receptor 
substrate 2 (B), Insulin receptor substrate 3 (C), Insulin receptor (D), Glucose 
transporter 4 (E) and glycogen synthase kinase 3 (F) are presented in the graphs.  
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4.12. The major genes associated with adipogenesis 
are up-regulated in WAT from Spp1-/- mice 
To further assess potential differences in Spp1 versus Irs2 deficiency 
for WAT physiology, adipogenic-related genes were measured by RT-
PCR. Pparγ was increased in V-WAT in Spp1-/- mice (Figure 55), 
contrasting the decrease observed in Irs2-deficient females (see 
Figure 27). Fabp4, Fasn, and Adn were also increased in WAT from 
OPN deficient mice (Figure 55). 
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Figure 55: Gene expression of adipogenesis markers in WAT from WT and Spp1-/-. 
RT-PCR was performed using TaqMan probes for the indicated genes. Data was 
analyzed by the comparative Ct method (2-ΔΔCt) (Livak and Schmittgen, 2001). Results 
are expressed as mean ± SEM. * p<0.05, ** p<0.01 and *** p<0.001. For data 
presentation, V-WAT of WT mice was considered as 100%. N= 5 mice of each 
genotype. Relative gene expression of Peroxisome proliferator activated receptor-γ (A), 
Fatty acid binding protein 4 (B), Fatty acid synthase (C) and Adipsin (D) are shown in 
the graphs. 
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The expression of adipogenesis co-regulators Pgc1α and Srebf1 was 
similar between WT and Spp1-/- except that Srebf1 was reduced in 
SC-WAT from Spp1-/- mice (Figure 56). Expression of the two 
enzymes implicated in the synthesis of triacylglycerol, Dgat1 and 
Dgat2, were enhanced in WAT from Spp1-/- mice, suggesting that 
adipocytes lacking OPN may display an increased energy storage 
capacity. Consistent with these results, addition of OPN to culture 
medium has been shown to inhibit the differentiation of progenitors to 
adipocytes (Zeyda et al., 2011). 
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Figure 56: Gene expression of adipogenic coactivators in WAT from WT and 
Spp1-/-. 
RT-PCR was performed using TaqMan probes for the indicated genes. Each reaction 
was performed in duplicate and the value of the gene of interest was normalized to the 
expression of Ubiquitin C. Data was analyzed by the comparative Ct method (2-ΔΔCt) 
(Livak and Schmittgen, 2001). Results are expressed as mean ± SEM.   * p<0.05, ** 
p<0.01 and ***  p<0.001. For data presentation, V-WAT of WT mice was considered as 
100%. N= 5 mice of each genotype. Relative gene expression of PPARγ co-
activator‑1α (A), Sterol Regulatory Element Binding Protein 1c (B), Acyl CoA 
diacylglyceron acyltransferase 1 (C) and Acyl CoA diacylglyceron acyltransferase 2 (D) 
are shown in the graphs.  
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4.13. Flow cytometry analysis reveals a decrease of 
APC isolated from SC-WAT from Spp1-/- mice 
Mice lacking the osteopontin gene are resistant to diet-induced 
obesity (Kiefer et al., 2011), perhaps owing to reduced inflammation. 
Adipose mass is determined by many factors which ultimately regulate 
adipocyte cell size and/or adipocyte cell number. To gain further 
insight into the role of OPN in WAT regulation, APC were isolated 
from the SVF Spp1-/- WAT, as described previously for Irs2-deficient 
mice. The cells were analyzed by Flow cytometry to identify the APC 
population of CD45- CD31- Ter119- CD34+ Sca1+ cells. The % of 
APC obtained from V-WAT was similar between Spp1-/-.and WT 
controls (Figure 57). Surprisingly, the population of APC from SC-
WAT of Spp1-/- mice was reduced, suggesting that an anti-
inflammatory niche may reduce adult stems cells in WAT.  
A  B  
Figure 57: Analysis of APC population in WAT from WT and Spp1-/-.  
Flow cytometry analysis was used to quantify the APC population (CD45-CD31-Ter119-
CD34+Sca1+ cells) in V-WAT (A) and SC-WAT (B). Results are expressed as mean ± 
SEM. * p<0.05, ** p<0.01 and *** p<0.001. The SVF was isolated from 3 mice of each 
genotype in 3 independent experiments for a total n of 9 mice of each genotype.  
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4.14. Spp1-/- APCs differentiate more efficiently to 
adipocytes in vitro 
Previous studies have demonstrated that addition of OPN to cultures 
of human preadipocytes did not grossly alter adipogenesis as 
assessed by lipid droplet formation but analysis of gene expression 
revealed a concentration-dependent inhibition of PPARγ and 
adiponectin expression (Zeyda et al., 2011). Spp1 gene expression is 
up-regulated in obese humans (Gómez-Ambrosi et al., 2007, 
Nomiyama et al., 2007, Bertola et al., 2009). A recent publication 
suggests that OPN deficiency improves diet-induced insulin resistance 
(Kiefer et al., 2011). Therefore, the capacity of Spp1-/-.APC to 
differentiate to adipocytes was tested in vitro. APC were isolated from 
SVF with MACS® technology (see Figure 14 page 91) to obtain cells 
of the following immunophenotype: CD45- CD31- Ter119- CD34+ and 
Sca1+. The differentiation method was the same as used for APC 
from the Irs2-deficient model. APC were grown to confluence (day 0) 
and then exposed to the differentiation medium. After 10 days, the 
presence of lipid accumulation was assessed by phase contrast 
microscopy. The differentiation of SC-APC was more robust than V-
APC in both genotypes. However, Spp1-/-.APC differentiated more 
efficiently to adipocytes than WT controls based on the enhanced 
accumulation of lipid droplets in these cultures (Figure 58). These 
results contrast those obtained with Irs2-/-APC where differentiation 
was impaired compared to control cultures (see Figure 37).  
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Figure 58: Phase contrast images of APC cultures from WT and Spp1-/- WAT 
subjected to adipocyte differentiation protocol.  
Phase contrast images of APC at day 0 and day 10 of adipocyte differentiation. A,B) 
WT V-WAT; C,D) Spp1-/- V-WAT; E,F) WT SC-WAT; G,H) Spp1-/- SC-WAT. Images 
were captured with 20x objective and 40x objectives (right of the picture). 
Representative images from 2 different experiments are shown. 
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To characterize the molecular changes during the differentiation of 
Spp1-/- APC into adipocytes, RT-PCR analysis was performed at 
various time points (day -3, 0, 3, 7 and 10) during the adipogenic 
program. In both V-APC and SC-APC, Irs2 expression increased at 
day 3 but then was down-regulated between day 7 and 10, depending 
on WAT source (Figure 59). Consistent with RT-PCR analysis 
observations in WAT (see Figure 54), Irs2 expression was greater in 
Spp1-/- cultures of V-APC at day 10 and SC-APC at day -3. The 
expression profile of IRβ (Insr) was also distinct different between WT 
and Spp1-/- cultures (Figure 59); in V-APC the expression peaked at 
day 3 whereas in SC-APC, this peak occurred at the end of 
differentiation at day 10. GLUT4 (Slc2a4) expression was significantly 
higher in Spp1-/- SC-APC at day 10.  
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Figure 59: Gene expression analysis of insulin signaling related genes in APC 
from WT and Spp1-/- during differentiation of APC to adipocytes in vitro. 
APC cultures were collected at the indicated days and used to prepare total RNA with 
Trizol®. RT-PCR was performed using TaqMan probes for the indicated genes.  Each 
reaction was performed in duplicate and the value of the gene of interest was 
normalized to the expression of Ubiquitin C. Data was analyzed by the comparative Ct 
method (2-ΔΔCt) (Livak and Schmittgen, 2001). Results are expressed as mean ± SEM.   
* p<0.05 , ** p<0.01  and ***  p<0.001. For data presentation, APC from V-WAT of WT 
mice collected at day -3 was considered as 100%. N= 2 independent experiments. 
Insulin receptor substrate 2 (A), Insulin receptor β (B) and Glucose transporter 4 (C) are 
shown in the graphs. 
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V-APC cultures from day 0 to 10 but peaked sharply at day 3 in SC-
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day 7 in both V and SC cultures as compared to WT controls. Fsn 
expression was similar between WT and Spp1-/- with respect to V-
WAT but in APC from SC-WAT, Spp1-/- APC had higher levels than 
WT APC. The peaks of Adn expression were significantly higher in 
Spp1-/- APC (see Figure 60).   
A 
PPARγ 
  
B 
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C 
ADN (Adn) 
  
Figure 60: Gene expression analysis of adipogenesis related genes in APC from 
WT and Spp1-/- during differentiation of APC to adipocytes in vitro. 
APCs were collected at the indicated days and used to prepare total RNA with Trizol®. 
RT-PCR was performed using TaqMan probes for the indicated genes.  Each reaction 
was performed in duplicate and the value of the gene of interest was normalized to the 
expression of Ubiquitin C. Data was analyzed by the comparative Ct method (2-ΔΔCt) 
(Livak and Schmittgen, 2001). Results are expressed as mean ± SEM.   * p<0.05, ** 
p<0.01  and ***  p<0.001. For data presentation, APC from WT V-WAT collected by day 
-3 was considered as 100%. N= 2 independent experiments. Peroxisome-proliferating 
receptor γ (A), Fatty acid synthase (B) and Adipsin (C). 
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5. DISCUSSION 
Lipids stored in adipose tissue represent the largest reserve of energy 
in the human body. In normal-weight adult humans, white adipose 
tissue represents 10 to 29% of body weight but this mass increases in 
obesity (Wang et al., 2008). Western dietary habits and a sedentary 
lifestyle have produced a worldwide epidemic of obesity. Indeed, at 
least one in 13 annual deaths in the European Union are likely to be 
related to excess weight (Banegas et al., 2003). Obesity predisposes 
patients to the development of cardiovascular disease and T2D, most 
likely due to the state of low-grade chronic inflammation which 
characterizes increased adipose mass. In recent years, various lines 
of evidence have demonstrated that activation of pro-inflammatory 
pathways can modulate insulin action via a number of mechanisms 
including down-regulation of insulin signalling pathway proteins (Starr 
et al., 1997, Hotamisligil, 2003). IRS proteins are the principal targets 
of the insulin receptor tyrosine kinase. Tissues from insulin-resistant 
and diabetic humans exhibit defects in IRS-dependent signalling 
(Copps et al., 2010, Copps and White, 2012), implicating their 
dysregulation in the initiation and progression of metabolic disease. 
Loss of Irs2 expression is associated with beta cell insufficiency in 
both mice and humans with T2D (Withers et al., 1998, Gunton et al., 
2005). The Irs2-deficient mouse model has demonstrated a crucial 
role for this signalling molecule in hepatic insulin sensitivity, brain and 
photoreceptor development, and hypothalamic regulation of appetite 
(Withers et al., 1998, Kubota et al., 2000, Burks et al., 2000, Withers, 
2001, Burks and White, 2001, Schubert et al., 2003, Valverde et al., 
2004, Choudhury et al., 2005, Taguchi et al., 2007). However, the role 
of IRS2 in adipose tissue has not been characterized. The results of 
the present project reveal that deletion of Irs2 causes an increase in 
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stores of both V and SC WAT which is accompanied by a pro-
inflammatory profile of cytokines and immune markers.   
The role of IRS2 in WAT was examined initially by comparing V and 
SC fat between Irs2-/- and control mice. The increased body weight of 
female Irs2-deficient mice was associated with larger stores of both V 
and SC WAT. The % of total body weight reflected by V and SC-WAT 
was almost doubled in Irs2-/- females as compared with control mice. It 
is important to note that only female mice were used in the study since 
male Irs2-/- develop severe diabetes and die by 16 weeks of age 
(Garcia-Barrado et al., 2011). Thus, the study of female mice 
permitted the analysis of Irs2 deficiency without the complications of 
hyperglycemia. Circulating levels of leptin were increased in Irs2-/- 
females but adiponectin was also increased which is surprising since 
adiponectin levels are reduced in obese subjects (Hu et al., 1996). 
However, this may be explained by recent studies which suggest that 
adiponectin levels reflect adipose tissue triglyceride storage capacity 
(Vega and Grundy, 2013). RT-PCR analysis of WAT depots revealed 
that expression of the genes for TNFα, IL6, and MCP1 are also 
increased in Irs2-deficient females. This is consistent with the 
observation that adipose tissue of obese humans contains increased 
numbers of macrophages, and once activated, these macrophages 
are responsible for the expression of various cytokines including 
TNFα, IL6, and MCP1 (Weisberg et al., 2003). TNFα is an important 
mediator of insulin resistance in obesity and diabetes through its 
ability to decrease the tyrosine kinase activity of the insulin receptor 
and inactivate IRS proteins. The present results suggest that reduced 
IRS2 signaling could contribute to obesity in at least two ways, first 
through the simple impairment of insulin signaling pathways and 
second, by increasing the expression of cytokines such as TNFα in 
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WAT which would compound insulin resistance by inhibiting the 
activity of the insulin receptor.  
Increased WAT mass can arise through an increase in cell size, cell 
number, or both. Adipose cells are quite variable in size which 
depends principally on the amount of stored triglycerides. Mild obesity 
mainly reflects an increased adipose cell size (hypertrophic obesity) 
while more severe obesity or obesity arising in childhood derives from 
an increased fat cell number (hyperplastic obesity) (Spiegelman and 
Flier, 1996). Recent studies indicate that the adipocyte population is 
more dynamic than previously believed. In humans, adipocyte number 
increases dramatically throughout the first two decades of life and 
continues to turn over at the rate of about 10% per year throughout 
adulthood (Spalding et al., 2008, Jo et al., 2009). Individuals with 
early-onset obesity develop increased numbers of adipocytes, 
suggesting the concept of a “fixed body weight” since even after 
significant weight loss the number of adipocytes remains constant in 
these individuals. In the Irs2-deficient model, the increase in adipose 
mass was not due to an increase in cell size as a consequence of 
hypertrophy, suggesting that enhanced WAT mass might be 
attributable to increased adipocyte number. This notion was 
corroborated by the upregulation of the main markers of hypoxia HIF 
and VEGFa in WAT of Irs2-/- females. Several laboratories have 
proposed that hypoxia in WAT occurs as a result of adipocyte 
hyperplasia which reduces the O2 supply from the vasculature (Kabon 
et al., 2004, Pasarica et al., 2009). 
Although how pre-adipocytes differentiate into adipocytes has been 
defined through extensive study of in vitro models such as 3T3-L1, 
very little is known about the development and regulation of 
preadipocytes in vivo. As key parts of a homeostatic system that 
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modulates energy balance, the identification of the signaling 
mechanisms that regulate preadipocyte cell growth and differentiation 
are of extreme interest since they represent potential targets for 
controlling obesity. Embryonic mesoderm is thought to give rise to 
mesenchymal stem cells, which in turn give rise to common early 
precursors or adipoblasts (Gesta et al., 2007). Under appropriate 
conditions, adipoblasts develop into committed white and brown 
preadipocytes and, ultimately mature adipocytes. Due to absence of 
specific markers, the specific steps in lineage commitment and 
differentiation, and the factors controlling these pathways have not 
been defined. During the last several years, various laboratories have 
identified APC in the SVF using lineage tracing studies in mouse 
models (Tang et al., 2008). These specialized cells express PPARγ, 
Sca1, and CD34. Although advances have been made towards the 
identification of the APC in vivo, no studies have yet addressed the 
role of insulin signaling in regulating this population in WAT. Based on 
the results of the present study, insulin sensitivity may play a key role 
in establishing the number of APC in vivo. The number of APCs 
isolated from V-WAT of Irs2-/- females was increased more than 2-
fold. However, it remains to be determined whether the increase of V-
WAT progenitors observed in this model is due directly to the loss of 
Irs2 expression or whether it more accurately reflects systemic 
inflammation resulting from Irs2-deficiency.  
WAT depots in different parts of the body have different 
developmental timing and different physiological effects. Although an 
increase of both V and SC fat was observed in Irs2-/- females, the 
population of APC was increased in V but not SC-WAT when 
compared to control mice. This observation is consistent with the fact 
that visceral adiposity, but not subcutaneous adiposity, is associated 
with diabetes and other metabolic diseases (Gesta et al., 2007). 
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Increasing evidence suggest that subcutaneous fat is not related to 
many of the classic obesity-induced pathologies but rather might play 
a protective role. The typically female, pear-shape of body fat 
distribution is subcutaneous fat, and appears to pose less of a health 
risk compared to visceral fat (Kissebah and Krakower, 1994). 
Under the experimental conditions employed, the differentiation of SC-
APC to adipocytes was more robust than V-APC in both genotypes. 
An interesting observation from this study is the fact that IRS2 
expression increased greatly during the early phases of the 
differentiation of WT APC in vitro. In contrast, IRS1 and IRS3 were 
slightly down-regulated, suggesting that IRS2 signals may be 
important for initiating the transcriptional program that directs 
adipogenesis. Consistent with this hypothesis, cultures of Irs2-/- APC 
from both V and SC-WAT differentiated poorly to adipocytes in vitro as 
determined by the accumulation of lipid by BODIPY. The impaired 
differentiation of Irs2-/- APC correlated with decreased expression of 
the principal adipogenic transcription factors PPARγ and C-EBPα and 
markers of adipocyte function. Moreover, cultures of both V and SC 
Irs2-/- APC proliferated more rapidly than control cells, suggesting that 
enhanced doubling time might explain, in part, the failure of Irs2-
deficient precursors to differentiate (Figure 61). The mitotic index of 
mature adipocytes is quite low since these cells exit the cell cycle in 
order to differentiate and mature functionally. The increased 
proliferation might be explained by the observation that IRS1 
signaling, unopposed by IRS2, is mitogenic as evidenced by the 
hyperplasia of beta cells in Irs1-deficient mice (Withers et al., 1998). 
How is possible that Irs2-/- APC display impaired differentiation to 
adipocytes in vitro yet Irs2-deficiency causes moderate obesity in 
vivo? Interestingly, it has been recently reported that the differentiation 
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potential of human preadipocytes is inversely correlated with obesity, 
whereas the pool of precursors cells was positively correlated to BMI, 
suggesting that the obese microenvironment is capable of inducing 
proliferation of human preadipocytes while inhibiting their 
differentiation (Permana et al., 2004, Isakson et al., 2009). Medium 
conditioned by macrophages stimulates proliferation of human 
preadipocytes in vitro (Lacasa et al., 2007, Keophiphath et al., 2009). 
The expression of MCP1 was increased in V-WAT but not SC-WAT of 
Irs2-/- females, providing yet an additional explanation for the 
enhanced proliferation and impaired proliferation of the APC 
population. Therefore, it seems quite likely that pro-inflammatory 
signals or cells that accumulate within adipose tissue with obesity 
might contribute to fat mass enlargement through paracrine effects on 
progenitor cells. In addition to increased expression of cytokines and 
adipokines, the population of immune cells was increased in V-WAT. 
Moreover, the expression of enzymes involved in synthesis and 
storage of lipids was altered in WAT of Irs2-deficienct mice, 
suggesting the possibility that although there are more adipocytes 
present in the WAT of these animals, these cells are not fully mature 
at a functional level. Indeed, WAT of Irs2-/- females regulation of 
lipolyis is resistant to catecholamines due to increased expression of 
HSL (Garcia-Barrado et al., 2011).   
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IL6 and MCP1 were greatly reduced in WAT of Spp1-/- mice as were 
makers of hypoxia such as HIF1α and VEGFa. Interestingly, the 
expression of Irs2 was up-regulated in WAT of Spp1-/- mice, whereas 
the expression of Irs1 and Irs3 were moderately down-regulated, an 
opposite pattern to that observed in Irs2-/- WAT. Additionally, the 
expression of the insulin receptor gene was also decreased in WAT of 
these mice, perhaps reflecting the presence of general insulin 
sensitivity. These observations suggest a relationship between 
inflammation, Irs2 expression, and insulin sensitivity whereby Irs2 is 
increased in an anti-inflammatory setting and diminished in a pro-
inflammatory environment.  
OPN inhibits expression of PPARγ and adiponectin in cultures of 
human preadipocytes (Zeyda et al., 2011) However, the precise role 
of OPN in regulating APC development and differentiation has not 
been characterized. The results of the present study reveal that the 
expression of genes required for efficient adipogenesis such as 
PPAR are increased in WAT of Spp1-/- mice. Quantification of APC 
progenitors revealed a decrease in this population isolated from SC-
WAT, whereas the population from V-SC was similar to WT controls. 
However, these Spp1-/- APC from SC-WAT differentiated more 
efficiently to adipocytes than WT controls based on the enhanced 
accumulation of lipid droplets in these cultures (Figure 62). These 
results contrast those obtained with Irs2-/-APC where differentiation 
was impaired. The genetic approach used for this study suggest that 
that adipogenesis and adipocyte physiology are improved in Opn-
deficiency but impaired in the absence of IRS2 signals. The key to 
these observations may be the presence of a pro-inflammatory 
environment in WAT of Irs2-/- females in contrast to the anti-
inflammatory detected in Spp1-/- mice. 
 Figure 62
 
Reversing or controlling the worldwide epidemic of obesity requires a 
more precise knowledge of adipogenesis and WAT function. 
Collectively, the observations of this study suggest that inflammation 
and loss of insulin sensitivity negatively modulate the po
adipocyte precursors which reside in WAT in vivo. Reduced IRS2 
function causes insulin resistance and is associated with inflammation 
and impaired differentiation of APC to adipocytes. In contrast, loss of 
the cytokine OPN increase insulin sens
and enhances adipogenesis. These findings reveal a potential 
therapeutic strategy of targeting obesity
mediators including lifestyle changes and/or drugs that promote IRS2 
expression. 
 
: Propose model of the role of OPN in regulation of WAT.
 
itivity, reduces inflammation, 
-associated inflammatory 
 DISCUSSION
179
 
 
pulation of 
 
 
  
 
  
 
 
 
 
 
 
CHAPTER 
CONCLUSIONS 
 
 
 
 
6 
  
 
 
 CONCLUSIONS  
183 
 
6. CONCLUSIONS 
I. Deletion of Irs2 causes increased accumulation of both 
visceral and subcutaneous adipose tissue in female mice. 
This adiposity may reflect a specific role for IRS2 signaling in 
the regulation of energy stores and/or the effects produced 
directly by Irs2-deficiency in pancreatic beta cells and liver.  
 
II. The expression of cytokines and adipokines are dysregulated 
in Irs2-deficient female mice, reflecting a profile consistent 
with obesity-induced inflammation. The results of this study 
suggest that Irs2 null mice represent a physiologically relevant 
model for studying the role of inflammation in the progression 
from pre-diabetes to diabetes.  
 
III. The population of adipocyte progenitor cells located within the 
stroma-vascular fraction was increased in visceral WAT of 
Irs2-deficienct mice. Irs2-deficient progenitor cells from both 
visceral and subcutaneous WAT failed to differentiate to 
adipocytes in vitro. Impaired differentiation was associated 
with reduced expression of key adipogenic transcription 
factors such as PPARγ and C/EBPα in vitro and in vivo. 
Additionally Irs2-deficient APCs proliferated more rapidly in 
culture. Collectively, these results implicate a role for IRS2 
signals in regulating the development and differentiation of 
adipocyte progenitors. IRS2 signaling may mediate the 
insulin-dependent transcriptional program of adipogenesis as 
well as in the regulation of proliferation. Maturation to 
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functional adipocytes may be particularly sensitive to loss of 
IRS2. 
 
IV. In contrast to the Irs2 model, the expression of cytokines and 
markers of inflammation are reduced in WAT of mice deficient 
for osteopontin (Spp1). Irs2 expression was enhanced in 
Spp1-/- WAT. These observations suggest that reduced Irs2 
expression is associated with obesity and inflammation 
whereas anti-inflammatory settings such as Spp1-deficiency 
are associated with enhanced Irs2 expression.   
 
V. Adipocyte progenitors isolated Spp1-/- mice differentiate more 
efficiently to adipocytes in vitro than WT control progenitors. 
The enhanced differentiation was associated with increased 
expression of PPARγ. These findings suggest that cytokines 
such as osteopontin may negatively regulate adipocyte 
differentiation.  
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7. RESUMEN 
 
INTRODUCCIÓN 
Insulina y acciones fisiológicas 
La insulina es la hormona anabolizante más importante, es secretada 
por las células β pancreáticas de los islotes de Langerhans y es 
responsable del control de los niveles de glucosa circulantes. Además 
posee importantes acciones a nivel de desarrollo, diferenciación y 
crecimiento. A nivel de metabolismo, los órganos diana de la insulina 
son el hígado, el músculo y el tejido adiposo. Sus funciones incluyen 
la regulación de la incorporación de glucosa en el músculo y en el 
tejido adiposo, la gluconeogénesis y lipogénesis en el hígado así 
como la lipogénesis y la adipogénesis en el tejido adiposo. También 
tiene la capacidad de influir en el apetito al actuar sobre el hipotálamo 
junto con la acción de la leptina. Además, la insulina, a través de su 
ruta se señalización puede participar en la expresión de genes, en la 
síntesis de proteínas y en proliferación y supervivencia celular.  
La insulina ejerce su función a través de su interacción con el 
receptor de insulina (IR) que transmite la señal a través de la 
fosforilación, gracias a su actividad quinasa, a las proteínas IRS (del 
inglés Insulin Receptor Substrate). A partir de aquí se activan una 
serie de rutas en las que están involucradas otras proteínas tales 
como AKT y MAP quinasas entre otras, cuya consecuencia final es la 
activación de proteínas y factores de transcripción que regulan la 
expresión génica con consecuencias en el metabolismo, crecimiento, 
diferenciación y supervivencia celular. 
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Modelo deficiente en IRS2: ratón Irs2-/-. 
Los ratones deficientes en la proteína IRS2 son un 10% más 
pequeños que los silvestres, muestran un descenso en la masa de 
células β que junto con la resistencia a insulina que también 
acompaña a este modelo, desencadenan la aparición de diabetes tipo 
2. Además, las hembras deficientes en IRS2 desarrollan obesidad por 
un incremento del tejido adiposo y una desregulación del sistema 
hipotalámico que a través de la leptina regula el apetito, provocando 
una mayor ingesta de alimento en ratones deficientes para IRS2. 
Añadir además la relación entre el sistema reproductivo y la función 
de IRS2, siendo las hembras Irs2-/- infértiles.  
 
Diabetes Mellitus tipo 2 
La diabetes Mellitus (DM) es una enfermedad metabólica 
caracterizada por niveles altos de glucosa en sangre. Principalmente 
existen dos tipos de DM. La DM tipo 1 es una enfermedad 
autoinmune en la que se desarrollan anticuerpos que atacan a las 
células beta del páncreas, encargadas de la síntesis de insulina, 
resultando en una falta total de ésta, y por lo tanto, una necesidad 
absoluta de aporte exógeno. El otro tipo es la DM tipo 2, mucho más 
frecuente que la anterior, que se desarrolla por una resistencia a la 
acción de la insulina sobre los tejidos periféricos (hígado, musculo y 
tejido adiposo principalmente) que acaba por un fallo en la secreción 
de ésta, apareciendo una hiperinsulinemia inicial que trata de 
compensar la falta de acción, seguida de un fallo en la síntesis debida 
a la desaparición progresiva de las células β pancreáticas, que por 
tanto desencadena la aparición de DM. La estrategia terapéutica 
seguida en la DM tipo 1 es el aporte exógeno de insulina, mientras 
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que en la DM tipo 2, acciones en la dieta y ejercicio pueden regular 
inicialmente la glucemia de los pacientes, aunque a medida que 
aparecen las complicaciones de la resistencia a insulina, fármacos 
hipoglucemiantes e incluso en último caso, insulina exógena, acaban 
siendo necesarias para el control de la glucemia. 
El estudio “Di@betes” es el estudio epidemiológico más importante 
hecho hasta ahora en territorio español, tasa en un 13,8% la 
prevalencia de DM en población mayor de 18 años. Mientras que a 
nivel mundial los estudios estiman que en 2025 habrá 300 millones de 
personas con DM, suponiendo esto un 5,4% de la población mundial, 
siendo el aumento más pronunciado en países en desarrollo.  
La DM forma parte del conjunto de enfermedades presentes en el 
Síndrome Metabólico (SM) y, junto con la obesidad, es considerada 
por la Organización Mundial de la Salud (WHO, por sus siglas en 
inglés) como el mayor riesgo para padecer muerte cardiovascular. 
Además de las consecuencias de la glucotoxicidad y la resistencia a 
insulina presente en la DM, ésta a su vez se acompaña de un estado 
inflamatorio reactivo que causa una retroalimentación a la DM 
empeorando la deficiente señalización por insulina en los tejidos 
periféricos e impidiendo en normal funcionamiento de la célula β 
pancreática. Citoquinas como Factor de Necrosis Tumoral α (TNF-α 
por sus siglas en inglés) o las interleuquinas 1 y 6 (IL-1, IL-6) son ya 
reconocidos como agentes que entorpecen la acción de la insulina 
inhibiendo/promoviendo fosforilaciones que dificultan la transmisión 
de la señal, por ejemplo, inactivando a las proteínas IRS mediante 
fosforilación en residuos de serina/treonina. 
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Obesidad y tejido adiposo 
La obesidad ha sido descrita por la WHO como la pandemia del siglo 
XXI afectando a más de 1 billón de personas en todo el mundo. Se 
define como un exceso de masa corporal como consecuencia de un 
desequilibrio entre un mayor aporte de energía a la que es capaz de 
consumir el organismo, agravada a su vez por factores ambientales, 
genéticos y psicosociales. El índice de masa corporal (BMI por sus 
siglas en inglés) es la herramienta que ha sido utilizada para 
diagnosticar los distintos grados de obesidad, aunque hoy en día se 
encuentre en entredicho por la importancia que está adquiriendo la 
distribución de la grasa en el cuerpo. El BMI es un parámetro 
obtenido al dividir el peso en kilogramos entre el cuadrado de la altura 
en metros (BMI=kg/m2), considerando individuos con sobrepeso a 
aquellos con un BMI≥ 25 y obesidad cuando BMI ≥ 30.  
En la obesidad se produce un aumento del tejido adiposo, fenómeno 
que ha sido explicado por dos teorías, la hiperplasia y la hipertrofia de 
los adipocitos, aunque actualmente se postula que lo que ocurre es 
una combinación de ambas. La hiperplasia es un aumento del tejido 
adiposo por un aumento en el número de adipocitos tras la 
diferenciación de células progenitoras presentes en el nicho del tejido 
adiposo, sin embargo, la hipertrofia es un aumento del tamaño de los 
adipocitos ya presentes, aumentando así su capacidad para 
almacenar triglicéridos. 
El tejido adiposo es el órgano encargado de almacenar el exceso de 
energía en forma de lípidos y es uno de los tejidos más importantes 
metabólicamente hablando, tanto como almacén de lípidos como por 
ser el encargado de su movilización ante necesidades. Además de 
este papel pasivo de depósito energético, hoy en día se considera al 
tejido adiposo cómo un órgano metabólicamente activo con funciones 
 RESUMEN 
189 
 
endocrinas, paracrinas y autocrinas que influyen de una forma 
importante en la homeostasis general del organismo, influyendo en el 
metabolismo lípidos y glucosa, inflamación y regulación del apetito 
entre otros. 
El origen embrionario del tejido adiposo es el mesodermo, junto con 
músculo y huesos. Las células mesenquimales (MSC por sus siglas 
en inglés) provenientes de esta capa embrionaria son capaces de 
diferenciarse a adipocitos, osteoblastos, condrocitos y mioblastos, 
aunque el número exacto de pasos hasta que las MSC se convierten 
en adipocitos maduros no está bien establecido. 
Existen dos tipos de tejido adiposo: blanco y marrón, con un mismo 
origen embrionario pero con funciones metabólicas muy distintas. El 
tejido adiposo blanco (WAT, por sus siglas en inglés) está encargado 
principalmente para la reserva energética y el tejido adiposo marrón 
(BAT, por sus siglas en inglés), por el contrario, está encargado de 
disipar la energía que sobra en forma de calor por un proceso 
denominado termogénesis. Ambos tipos de tejido adiposo se 
distribuyen por el cuerpo de forma distinta, mientras que los mayores 
depósitos de WAT se localizan principalmente en la zona intra-
abdominal (tejido visceral) y de una forma subcutánea en nalgas, 
muslos y abdomen. Por el contrario, depósitos de BAT son más 
abundantes en la etapa postnatal reduciéndose en el etapa adulta a 
pequeños depósitos en la zona cervical, supraclavicular y 
paravertebral. Ambos no presentan diferencias única y 
exclusivamente en cuanto a coloración, sino también en cuanto a su 
morfología, distribución, expresión genes y función. También hay 
diferencias en cuanto a vascularización, tamaño celular, expresión de 
receptores de esteroides y factores de crecimiento y expresión de 
proteínas. Además, tanto WAT como BAT están enervados por 
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distintos sistemas, mientras que el sistema adrenérgico está 
encargado del control del WAT, el noradrenérgico se encarga del 
BAT. El tejido adiposo marrón posee adipocitos multiloculares con 
abundantes mitocondrias que expresan altas cantidades de proteína 
desacoplante 1 (UCP-1), la cual es responsable de la actividad 
termogénica de este tejido. Por el contrario, el tejido adiposo blanco 
está formado por adipocitos uniloculares, que al contrario que los 
adipocitos del BAT, producen por ejemplo, leptina, una hormona que 
informa al cerebro del estado nutricional para regular la ingesta y el 
gasto energético. Además de las diferencias existentes entre el WAT 
y el BAT, dentro del WAT, en función de su localización, también 
existen diferencias entre el tejido adiposo blanco visceral (V) o 
subcutáneo (SC). Adipocitos de depósitos V son menos sensibles a la 
insulina que los que se localizan en el tejido SC, y por tanto, a los 
efectos lipogénicos de ésta. La capacidad reguladora del 
metabolismo de los lípidos la ejercen los adipocitos gracias a un 
conjunto de proteínas reguladoras, entre otras cabe destacar: 
lipoproteína Lipasa (LPL), transportadores de ácidos grasos, 
proteínas de unión a ácidos grasos (FABP, por sus siglas en inglés), 
fosfoenolpiruvato carboxilasa (PEPCK, por sus siglas en inglés), 
perilipina, hormona sensible a la lipasa (HSL, por sus siglas en inglés) 
y por último, los transportadores de glucosa (GLUT), en concreto 
GLUT4. 
Cómo se ha comentado antes, la función principal del WAT es 
almacenar triglicéridos (TG) en los momentos de exceso energético o 
liberar ácidos grasos (AG) cuando las necesidades energéticas así lo 
requieran, pero además en el WAT se produce la síntesis de 
adipoquinas, hormonas y citoquinas tanto por lo adipocitos como por 
otras células presentes en el tejido adiposo, como macrófagos y 
linfocitos T, de ahí el importante papel del WAT a nivel endocrino, 
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autocrino y paracrino. Entre las adipoquinas y citoquinas que se 
sintetizan desde el WAT cabe destacar: la LEPTINA (gen ob), la 
ADIPONECTINA (gen adipoq); la RESISTINA (gen retn); la Proteína 
de unión al retinol 4 (RBP4, por sus siglas en inglés, gen rbp4); TNFα, 
(gen tnfa); IL6 (gen il6);  Proteína quimioatrayente de monocitos 1 
(MCP1, por sus siglas en inglés, gen Ccl2). Estas moleculas son el 
nexo de unión entre la obesidad, la diabetes y la inflamación que 
construyen una compleja red de retroalimentación en la que también 
se implican otros sistemas del organismo. 
Células progenitoras de adipocitos (APC) 
Son las células madre adultas presentes en el tejido adiposo 
procedentes de células mesenquimales. Aunque las células 
progenitoras son más abundantes en las etapas tempranas de la 
vida, también están presentes en la etapa adulta del organismo. Se 
pueden localizar en la fracción estroma-vascular del tejido adiposo 
(SVF, por sus siglas en inglés) tras una digestión enzimática del WAT 
y un posterior aislamiento mediante marcajes específicos con 
anticuerpos, entre ellos Sca1+ (antígeno específico de células madre 
de ratón), CD45- (antígeno común de leucocitos), CD34+ (proteína 
presente en células del estroma) y Ter119– (molécula de superficie 
de plaquetas) entre otros. Hay que destacar las diferencias existentes 
en cuanto a proliferación, capacidad de diferenciación y expresión de 
genes de APC aisladas de distintas fuentes de tejido adiposo, por lo 
que acaban siendo funcionalmente diferentes. El proceso por el cual 
los progenitores acaban siendo adipocitos maduros y funcionales se 
denomina adipogénesis y aparece tanto en etapas jóvenes como 
adultas ante la necesidad de renovación celular cómo la de nuevas 
células para aumentar la masa de tejido adiposo en obesidad. La 
adipogénesis conlleva 4 estadios: interrupción de proliferación, 
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expansión clonal, diferenciación temprana y diferenciación tardía. 
Esta última etapa ha sido ampliamente estudiada en líneas celulares 
de preadipocitos murinos como los 3T3L1 y en ella intervienen 
numerosos factores, entre los que cabe destacar: 
- PPARγ: receptor nuclear clave en la adipogénesis cuya 
expresión es obligatoria para la diferenciación completa hacia 
adipocitos maduros.  
- Familia C/EBPs: formadas por las proteínas C/EBP α, β, δ, , 
. Las isoformas α, β y δ son las implicadas en la 
adipogénesis.  
- ADD1/ SREBP1: proteína que se expresa de forma tardía en 
la diferenciación. Interactúa directamente con PPARγ y con 
ello regula la actividad de genes relacionados con el 
metabolismo de ácigos grasos y TGC.  
Osteopontina 
La osteopontina es una molécula expresada por macrófagos activos, 
linfocitos T, osteoclastos, hepatocitos y células endoteliales, 
epiteliales y de la musculatura lisa de la vasculatura. Tiene un papel 
esencial en la respuesta inmunitaria y en los procesos de inflamación 
a nivel sistémico además de estar involucrada en la patología de la 
esteatosis hepática no alcohólica asociada a la obesidad (NAFDL, por 
sus siglas en inglés). Además la OPN favorece la infiltración de 
macrófagos en obesidad que ayuda al desarrollo de resistencia a 
insulina en el tejido adiposo, con consecuencias ya mencionadas 
previamente. 
Durante la estancia en el laboratorio del Dr. Thomas Stulnig en Viena 
se utilizaron ratones deficientes en Osteopontina (OPN, gen Spp1). 
Se ha descrito que el modelo deficiente en osteopontina Spp1-/- es 
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resistente a las complicaciones metabólicas e inflamatorias que se 
desarrollan en la obesidad inducida por una dieta rica en grasa, tanto 
a nivel hepático, evitando la esteatosis, como a nivel del tejido 
adiposo, mejorando la sensibilidad a la insulina y disminuyendo la 
infiltración de macrófagos responsables del aumento de marcadores 
de inflamación. Por ello, este modelo es una importante herramienta 
para estudiar la importancia de la inflamación, o mejor dicho, la 
ausencia de ésta en el proceso de diferenciación hacia adipocitos de 
las células progenitoras residentes en el tejido adiposo. 
 
HIPÓTESIS Y OBJETIVOS 
Defectos en la señalización por insulina están implicados en la 
aparición de DM tipo 2 y obesidad. La deficiencia en Irs2 produce 
resistencia a insulina y defectos en las células beta pancreática en 
ratones. Además las hembras deficientes en Irs2 desarrollan 
obesidad y resistencia a leptina y catecolaminas. Sin embargo, la 
función exacta que desempeña IRS2 en el tejido adiposo está aún por 
esclarecer. Además, teniendo en cuenta el papel de la osteopontina 
en la inflamación del tejido adiposo, postulamos que puede existir una 
relación entre la función de la osteopontina en el WAT y la 
señalización por IRS2. Para definir el papel de IRS2 en adipogénesis 
y obesidad se proponen los siguientes objetivos: 
1. Caracterización del tejido adiposo blanco de hembras 
deficientes en Irs2 estudiando marcadores funcionales de 
adipocitos, de inflamación así como de la señalización de 
insulina. 
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2. Aislamiento y caracterización de APC de grasa y 
determinación del papel de IRS2 en la diferenciación y 
proliferación de estas células. 
3. Evaluar la posible relación fisiológica entre la señalización por 
IRS2 y la citoquina OPN mediante el estudio de tejido adiposo 
procedente de ratones hembras Irs2-/- y Spp1-/- . 
 
MATERIAL Y MÉTODOS 
Animales de estudio 
Hembras silvestres y deficientes en IRS2 (Irs2-/-) de la cepa C57BL/6J  
de 12-16 semanas de edad. Los procedimientos empleados están 
aprobados por el Comité de Ética y Bienestar Animal (CEBA) del 
CIPF. Animales silvestres y deficientes en osteopontina (Spp1-/-) de la 
cepa C57BL/6J  de 12-14 semanas de edad del laboratorio del Dr. 
Stulnig en Viena utilizados durante la colaboración científica. 
Análisis de glucosa y hormonas en sangre  
Extracción de suero de la sangre de los ratones en ayunas y posterior 
determinación de glucosa (tiras reactivas), insulina (ELISA) y 
adipoquinas y otras citoquinas por Luminex®. 
Análisis histológico del tejido adiposo 
Cortes histológicos en parafina y análisis morfológico de los 
adipocitos mediante tinción de Hematoxilina/Eosina.  
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Análisis de la grasa V y SC del modelo deficiente para Irs2 y para 
Osteopontina (Spp1-/-). 
Extracción de mRNA mediante Trizol® y posterior estudio por PCR 
cuantitativa de los genes involucrados en la señalización de insulina, 
la adipogénesis e inflamación en el tejido adiposo V y SC así como 
estudio mediante western blot de las proteínas más importantes de 
los procesos señalados anteriormente. 
Aislamiento e identificación de APC 
Para el aislamiento enzimático se siguió un protocolo modificado del 
publicado por Smith-Hall J et al. y posteriormente se identificaron 
utilizando los marcadores: Sca1, CD34, CD45, CD31 y Ter119, junto 
con DAPI para el marcaje de viabilidad. 
 Aislamiento de APC mediante MACS®: utilizando anticuerpos 
conjugados a microbolas magnéticas. Las poblaciones 
celulares se aíslan haciendo usos de imanes y las distintas 
combinaciones de los anticuerpos. 
 Aislamiento de APC mediante FACS: utilizando anticuerpos 
conjugados con fluorocromos. Las poblaciones celulares se 
aíslan utilizando un clitómetro High Speed Cell Sorter MoFlo 
equipado con 3 láseres con los que excitar los distintos 
fluorocromos y poder así aislar las poblaciones de interés. 
Cultivo de las APC 
Para el cultivo rutinario, tras su aislamiento por FACS o MACS se 
cultivaron en medio DMEM, 10% Suero Bovino Fetal de un clon 
específico (FcBS) y 10ng/mL de FGFβ. Se realizaron ensayos 
celulares de proliferación y apoptosis. 
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Para la diferenciación hacia adipocitos maduros, las APC se dejaron 
crecer hasta 100% de confluencia con el medio de cultivo descrito 
anteriormente  y luego se cultivaron en un medio formado por DMEM 
avanzado (aDMEM/F12) y suero bovino fetal (FBS, por sus siglas en 
inglés) con diferentes  factores (insulina (INS), dexametasona (DXM) 
e isobutilmetilxantina (IBMX)) para la diferenciación hacia adipocitos 
maduros como se indica en la tabla: 
día -3 a 0 día 0 a 4 día 4 a 7 día 7 a 12 
DMEM aDMEM/F12 aDMEM/F12 aDMEM/F12 
10% FcBS 5% FBS 5% FBS 5% FBS 
10ng/mL βFGF INS 20µg/mL INS 20µg/mL  
 DXM 10µM   
 IBMX 0.5mM   
Se tomaron muestras a días 0, 4 y 10 para su posterior estudio 
molecular con técnicas de inmunotinción, citometría de flujo,  western 
blot y PCR cuantitativa para evaluar la diferenciación mediante la 
expresión de marcadores clave en la adipogénesis tales como las 
proteínas relacionadas con la señalización de insulina así como 
aquellas que directamente intervienen en la adipogenesis como 
PPARγ. 
Análisis estadístico  
Para evaluar si las diferencias obtenidas en los resultados eran 
estadísticamente significativas, se utilizaron los programas GraphPad 
Prism 5 y Microsoft Excel con la función del test t de Student. 
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CONCLUSIONES 
I. La ausencia en ratones hembras de Irs2 en provoca un 
aumento del tejido adiposo tanto visceral como subcutáneo. 
Este aumento puede relacionar la señalización por IRS2 con 
la regulación de las reservas energéticas. 
II. Los niveles de expresión de citoquinas y adipoquinas en el 
tejido adiposo están alterados en hembras deficientes para 
Irs2, algo relacionado con la inflamación presente en la 
obesidad. Por ello el modelo deficiente en Irs2 podría ser 
relevante para estudiar que papel juega la inflamación en la 
progresión desde un estado prediabético a la aparición de 
diabetes. 
III. Hay un aumento de células progenitoras de adipocitos en el 
tejido adiposo visceral de ratones deficientes para Irs2 pero 
estas células tienen alterado el mecanismo molecular de la 
adipogenesis in vitro. Además los progenitores aislados del 
tejido adiposo de ratones deficientes para Irs2 proliferan más 
rápido que los controles. Todo ello indica que IRS2 está 
involucrada en la diferenciación dependiente de insulina de 
los adipocitos así como en la regulación de la proliferación. 
IV. La deficiencia de osteopontina causa una reducción en todos 
los marcadores de inflamación en el tejido adiposo. Adamas 
la expresión de Irs2 está aumentada en grasa.  
V. Celulas progenitoras de adipocitos aisladas del tejido adiposo 
de ratones deficientes para osteopontina diferencian mejor 
que los progenitores aislados de ratones controles. Por ellos 
citoquinas como la osteopontina entorpecen la diferenciación 
completa hacia adipocitos. 
 
 
 
 
 REFERENCES 
199 
 
REFERENCES 
 
ADILSON GUILHERME, J. V. V., VISHWAJEET PURI & MICHAEL P. 
CZECH 2008. Adipocyte dysfunctions linking obesity to insulin 
resistance and type 2 diabetes. Nature Reviews Molecular 
Cell Biology, 9, 367-377. 
ALARCON, B., BERKHOUT, B., BREITMEYER, J. & TERHORST, C. 
1988. Assembly of the human T cell receptor-CD3 complex 
takes place in the endoplasmic reticulum and involves 
intermediary complexes between the CD3-gamma. delta. 
epsilon core and single T cell receptor alpha or beta chains. 
Journal of Biological Chemistry, 263, 2953-2961. 
AMOS, A. F., MCCARTY, D. J. & ZIMMET, P. 1997. The rising global 
burden of diabetes and its complications: estimates and 
projections to the year 2010. Diabetic medicine, 14, S7-S85. 
ANTUNA-PUENTE, B., FEVE, B., FELLAHI, S. & BASTARD, J. P. 
2008. Adipokines: The missing link between insulin resistance 
and obesity. Diabetes & Metabolism, 34, 2-11. 
ARMULIK, A., ABRAMSSON, A. & BETSHOLTZ, C. 2005. 
Endothelial/pericyte interactions. Circulation research, 97, 
512-523. 
ASHKAR, S., WEBER, G. F., PANOUTSAKOPOULOU, V., 
SANCHIRICO, M. E., JANSSON, M., ZAWAIDEH, S., 
RITTLING, S. R., DENHARDT, D. T., GLIMCHER, M. J. & 
CANTOR, H. 2000. Eta-1 (Osteopontin): An Early Component 
of Type-1 (Cell-Mediated) Immunity. Science, 287, 860-864. 
BANEGAS, J., LOPEZ-GARCIA, E., GUTIERREZ-FISAC, J., 
GUALLAR-CASTILLON, P. & RODRIGUEZ-ARTALEJO, F. 
2003. A simple estimate of mortality attributable to excess 
weight in the European Union. European Journal of Clinical 
Nutrition, 57, 201-208. 
BARBOSA-DA-SILVA, S., FRAULOB-AQUINO, J. C., LOPES, J. R., 
MANDARIM-DE-LACERDA, C. A. & AGUILA, M. B. 2012. 
Weight Cycling Enhances Adipose Tissue Inflammatory 
Responses in Male Mice. PLoS ONE, 7, e39837. 
BASKIN, D. G., FIGLEWICZ LATTEMANN, D., SEELEY, R. J., 
WOODS, S. C., PORTE JR, D. & SCHWARTZ, M. W. 1999. 
Insulin and leptin: dual adiposity signals to the brain for the 
regulation of food intake and body weight. Brain research, 
848, 114-123. 
BASTARD, J.-P., JARDEL, C., BRUCKERT, E., BLONDY, P., 
CAPEAU, J., LAVILLE, M., VIDAL, H. & HAINQUE, B. 2000. 
Elevated levels of interleukin 6 are reduced in serum and 
subcutaneous adipose tissue of obese women after weight 
200 
 
loss. Journal of Clinical Endocrinology & Metabolism, 85, 
3338-3342. 
BASTARD, J.-P., MAACHI, M., VAN NHIEU, J. T., JARDEL, C., 
BRUCKERT, E., GRIMALDI, A., ROBERT, J.-J., CAPEAU, J. 
& HAINQUE, B. 2002. Adipose tissue IL-6 content correlates 
with resistance to insulin activation of glucose uptake both in 
vivo and in vitro. Journal of Clinical Endocrinology & 
Metabolism, 87, 2084-2089. 
BEALE, E. G., FOREST, C. & HAMMER, R. E. 2003. Regulation of 
cytosolic phosphoenolpyruvate carboxykinase gene 
expression in adipocytes. Biochimie, 85, 1207-1211. 
BELKINA, A. C. & DENIS, G. V. 2010. Obesity genes and insulin 
resistance. Current Opinion in Endocrinology, Diabetes and 
Obesity, 17, 472-477 10.1097/MED.0b013e32833c5c48. 
BELL, G. I., PICTET, R. L., RUTTER, W. J., CORDELL, B., TISCHER, 
E. & GOODMAN, H. M. 1980. Sequence of the human insulin 
gene. Nature, 284, 26-32. 
BELL, R. M. & COLEMAN, R. A. 1980. Enzymes of glycerolipid 
synthesis in eukaryotes. Annual review of biochemistry, 49, 
459-487. 
BERTOLA, A., DEVEAUX, V., BONNAFOUS, S., ROUSSEAU, D., 
ANTY, R., WAKKACH, A., DAHMAN, M., TORDJMAN, J., 
CLÉMENT, K. & MCQUAID, S. E. 2009. Elevated expression 
of osteopontin may be related to adipose tissue macrophage 
accumulation and liver steatosis in morbid obesity. Diabetes, 
58, 125-133. 
BIDDINGER, S. B. & KAHN, C. R. 2006. From mice to men: insights 
into the insulin resistance syndromes. Annu Rev Physiol, 68, 
123-58. 
BJÖRNHOLM, M., HE, A., ATTERSAND, A., LAKE, S., LIU, S., 
LIENHARD, G., TAYLOR, S., ARNER, P. & ZIERATH, J. 
2002. Absence of functional insulin receptor substrate-3 (IRS-
3) gene in humans. Diabetologia, 45, 1697-1702. 
BJÖRNTORP, P. 1974. Size, number and function of adipose tissue 
cells in human obesity. Hormone and metabolic research= 
Hormon-und Stoffwechselforschung= Hormones et 
métabolisme, 77. 
BJÖRNTORP, P. 1990. "Portal" adipose tissue as a generator of risk 
factors for cardiovascular disease and diabetes. 
Arteriosclerosis, Thrombosis, and Vascular Biology, 10, 493-
6. 
BJÖRNTORP, P. 1991a. Adipose tissue distribution and function. 
International Journal of Obesity, 15 Suppl 2, 67-81. 
BJÖRNTORP, P. 1991b. Metabolic implications of body fat 
distribution. Diabetes Care, 14, 1132-1143. 
 REFERENCES 
201 
 
BJÖRNTORP, P., KARLSSON, M. & PETTERSSON, P. 1982. 
Expansion of adipose tissue storage capacity at different ages 
in rats. Metabolism, 31, 366-373. 
BLÜHER, M., MICHAEL, M. D., PERONI, O. D., UEKI, K., CARTER, 
N., KAHN, B. B. & KAHN, C. R. 2002. Adipose tissue 
selective insulin receptor knockout protects against obesity 
and obesity-related glucose intolerance. Developmental cell, 
3, 25-38. 
BLUMBERG, R. S., LEY, S., SANCHO, J., LONBERG, N., LACY, E., 
MCDERMOTT, F., SCHAD, V., GREENSTEIN, J. L. & 
TERHORST, C. 1990. Structure of the T-cell antigen receptor: 
evidence for two CD3 epsilon subunits in the T-cell receptor-
CD3 complex. Proceedings of the National Academy of 
Sciences, 87, 7220-7224. 
BOARD, M., BOLLEN, M., STALMANS, W., KIM, Y., FLEET, G. & 
JOHNSON, L. 1995. Effects of C-1-substituted glucose 
analogue on the activation states of glycogen synthase and 
glycogen phosphorylase in rat hepatocytes. Biochemical 
Journal, 311, 845. 
BÖHNI, R., RIESGO-ESCOVAR, J., OLDHAM, S., BROGIOLO, W., 
STOCKER, H., ANDRUSS, B. F., BECKINGHAM, K. & 
HAFEN, E. 1999. Autonomous Control of Cell and Organ Size 
by CHICO, a< i> Drosophila</i> Homolog of Vertebrate IRS1–
4. Cell, 97, 865-875. 
BOUCHARD, C. 1997. Genetic determinants of regional fat 
distribution. Human reproduction, 12, 1-5. 
BOUCHARD, C., DESPRES, J.-P. & MAURIEGE, P. 1993. Genetic 
and nongenetic determinants of regional fat distribution. 
Endocrine reviews, 14, 72-93. 
BOUCHARD, C. & PERUSSE, L. 1993. Genetics of Obesity. Annual 
Review of Nutrition, 13, 337-354. 
BOURA-HALFON, S. & ZICK, Y. 2009. Phosphorylation of IRS 
proteins, insulin action, and insulin resistance. American 
Journal of Physiology-Endocrinology And Metabolism, 296, 
E581-E591. 
BRADY, M. J. 2004. IRS2 takes center stage in the development of 
type 2 diabetes. The Journal of Clinical Investigation, 114, 
886-888. 
BROWN, M. S. & GOLDSTEIN, J. L. 1997. The SREBP Pathway: 
Regulation review of cholesterol metabolism by proteolysis of 
a membrane-bound transcription factor. Cell, 89, 331-340. 
BRUNING, J. C., GAUTAM, D., BURKS, D. J., GILLETTE, J., 
SCHUBERT, M., ORBAN, P. C., KLEIN, R., KRONE, W., 
MULLER-WIELAND, D. & KAHN, C. R. 2000. Role of Brain 
Insulin Receptor in Control of Body Weight and Reproduction. 
Science, 289, 2122-2125. 
202 
 
BURKS, D. J., DE MORA, J. F., SCHUBERT, M., WITHERS, D. J., 
MYERS, M. G., TOWERY, H. H., ALTAMURO, S. L., FLINT, 
C. L. & WHITE, M. F. 2000. IRS-2 pathways integrate female 
reproduction and energy homeostasis. Nature, 407, 377-382. 
BURKS, D. J., PONS, S., TOWERY, H., SMITH-HALL, J., MYERS JR, 
M. G., YENUSH, L. & WHITE, M. F. 1997. Heterologous 
pleckstrin homology domains do not couple IRS-1 to the 
insulin receptor. Journal of Biological Chemistry, 272, 27716-
27721. 
BURKS, D. J., WANG, J., TOWERY, H., ISHIBASHI, O., LOWE, D., 
RIEDEL, H. & WHITE, M. F. 1998. IRS pleckstrin homology 
domains bind to acidic motifs in proteins. Journal of Biological 
Chemistry, 273, 31061-31067. 
BURKS, D. J. & WHITE, M. F. 2001. IRS proteins and beta-cell 
function. Diabetes, 50 Suppl 1, S140-5. 
CAI, D., DHE-PAGANON, S., MELENDEZ, P. A., LEE, J. & 
SHOELSON, S. E. 2003. Two new substrates in insulin 
signaling, IRS5/DOK4 and IRS6/DOK5. Journal of Biological 
Chemistry, 278, 25323-25330. 
CALABRO, P., SAMUDIO, I., WILLERSON, J. T. & YEH, E. T. H. 
2004. Resistin Promotes Smooth Muscle Cell Proliferation 
Through Activation of Extracellular Signal–Regulated Kinase 
1/2 and Phosphatidylinositol 3-Kinase Pathways. Circulation, 
110, 3335-3340. 
CALLE, M. C. & FERNANDEZ, M. L. 2012. Inflammation and type 2 
diabetes. Diabetes & Metabolism, 38, 183-191. 
CAMPBELL, I. W. 2000. Antidiabetic Drugs Present and Future. 
Drugs, 60, 1017-1028. 
CANCELLO, R., HENEGAR, C., VIGUERIE, N., TALEB, S., POITOU, 
C., ROUAULT, C., COUPAYE, M., PELLOUX, V., HUGOL, 
D., BOUILLOT, J.-L., BOULOUMIÉ, A., BARBATELLI, G., 
CINTI, S., SVENSSON, P.-A., BARSH, G. S., ZUCKER, J.-D., 
BASDEVANT, A., LANGIN, D. & CLÉMENT, K. 2005. 
Reduction of Macrophage Infiltration and Chemoattractant 
Gene Expression Changes in White Adipose Tissue of 
Morbidly Obese Subjects After Surgery-Induced Weight Loss. 
Diabetes, 54, 2277-2286. 
CANNON, B., HEDIN, A. & NEDERGAARD, J. 1982. Exclusive 
occurrence of thermogenin antigen in brown adipose tissue. 
FEBS letters, 150, 129-132. 
CANNON, B. & NEDERGAARD, J. 2004. Brown adipose tissue: 
function and physiological significance. Physiological reviews, 
84, 277-359. 
CAO, Z., UMEK, R. M. & MCKNIGHT, S. L. 1991. Regulated 
expression of three C/EBP isoforms during adipose 
 REFERENCES 
203 
 
conversion of 3T3-L1 cells. Genes & development, 5, 1538-
1552. 
CARMELIET, P. 2003. Angiogenesis in health and disease. Nature 
medicine, 9, 653-660. 
CASES, S., SMITH, S. J., ZHENG, Y.-W., MYERS, H. M., LEAR, S. 
R., SANDE, E., NOVAK, S., COLLINS, C., WELCH, C. B. & 
LUSIS, A. J. 1998. Identification of a gene encoding an acyl 
CoA: diacylglycerol acyltransferase, a key enzyme in 
triacylglycerol synthesis. Proceedings of the National 
Academy of Sciences, 95, 13018-13023. 
CINTI, S. 2001a. The adipose organ: endocrine aspects and insights 
from transgenic models. Eating and weight disorders: EWD, 6, 
4. 
CINTI, S. 2001b. The adipose organ: morphological perspectives of 
adipose tissues. Proceedings of the Nutrition Society, 60, 319-
328. 
CINTI, S. 2005. The adipose organ. Prostaglandins, Leukotrienes and 
Essential Fatty Acids, 73, 9-15. 
COFFER, P. J., JIN, J. & WOODGETT, J. R. 1998. Protein kinase B 
(c-Akt): a multifunctional mediator of phosphatidylinositol 3-
kinase activation. Biochemical Journal, 335, 1. 
CONSIDINE, R. V. & CARO, J. F. 1997. Leptin and the regulation of 
body weight. The international journal of biochemistry & cell 
biology, 29, 1255-1272. 
CONSIDINE, R. V., NYCE, M. R., MORALES, L., MAGOSIN, S. A., 
SINHA, M. K., BAUER, T. L., ROSATO, E. L., COLBERG, J. 
& CARO, J. 1996. Paracrine stimulation of preadipocyte-
enriched cell cultures by mature adipocytes. American Journal 
of Physiology-Endocrinology And Metabolism, 270, E895-
E899. 
COPPS, K. & WHITE, M. 2012. Regulation of insulin sensitivity by 
serine/threonine phosphorylation of insulin receptor substrate 
proteins IRS1 and IRS2. Diabetologia, 55, 2565-2582. 
COPPS, K. D., HANCER, N. J., OPARE-ADO, L., QIU, W., WALSH, 
C. & WHITE, M. F. 2010. Irs1 serine 307 promotes insulin 
sensitivity in mice. Cell Metab, 11, 84-92. 
CRAIG, A. M. & DENHARDT, D. T. 1991. The murine gene encoding 
secreted phosphoprotein 1 (osteopontin): promoter structure, 
activity, and induction in vivo by estrogen and progesterone. 
Gene, 100, 163-171. 
CROSS, D. A., ALESSI, D. R., COHEN, P., ANDJELKOVICH, M. & 
HEMMINGS, B. A. 1995. Inhibition of glycogen synthase 
kinase-3 by insulin mediated by protein kinase B. Nature, 378, 
785-789. 
204 
 
CHANG, L., CHIANG, S.-H. & SALTIEL, A. R. 2004. Insulin signaling 
and the regulation of glucose transport. Molecular medicine, 
10, 65. 
CHOUDHURY, A. I., HEFFRON, H., SMITH, M. A., AL-QASSAB, H., 
XU, A. W., SELMAN, C., SIMMGEN, M., CLEMENTS, M., 
CLARET, M., MACCOLL, G., BEDFORD, D. C., HISADOME, 
K., DIAKONOV, I., MOOSAJEE, V., BELL, J. D., SPEAKMAN, 
J. R., BATTERHAM, R. L., BARSH, G. S., ASHFORD, M. L. J. 
& WITHERS, D. J. 2005. The role of insulin receptor substrate 
2 in hypothalamic and beta cell function. The Journal of 
Clinical Investigation, 115, 940-950. 
CHOY, L. N., ROSEN, B. & SPIEGELMAN, B. M. 1992. Adipsin and 
an endogenous pathway of complement from adipose cells. 
Journal of Biological Chemistry, 267, 12736-12741. 
DANDONA, P., ALJADA, A. & BANDYOPADHYAY, A. 2004. 
Inflammation: the link between insulin resistance, obesity and 
diabetes. Trends in immunology, 25, 4-7. 
DANDONA, P., ALJADA, A., CHAUDHURI, A., MOHANTY, P. & 
GARG, R. 2005. Metabolic Syndrome A Comprehensive 
Perspective Based on Interactions Between Obesity, 
Diabetes, and Inflammation. Circulation, 111, 1448-1454. 
DANI, C. & BILLON, N. 2012. Adipocyte Precursors: Developmental 
Origins, Self-Renewal, and Plasticity 
Adipose Tissue Biology. In: SYMONDS, M. E. E. (ed.). Springer New 
York. 
DARZYNKIEWICZ, Z., HALICKA, H. D. & ZHAO, H. 2010. Analysis of 
Cellular DNA Content by Flow and Laser Scanning Cytometry 
Polyploidization and Cancer. In: POON, R. Y. C. (ed.). Springer New 
York. 
DEREK LEROITH  MD, P., JERROLD M OLEFSKY  MD ,  SIMEON I 
TAYLOR  MD, PHD 2003. Diabetes Mellitus A Fundamental 
and Clinical Text. 
DI GREGORIO, G. B., YAO-BORENGASSER, A., RASOULI, N., 
VARMA, V., LU, T., MILES, L. M., RANGANATHAN, G., 
PETERSON, C. A., MCGEHEE, R. E. & KERN, P. A. 2005. 
Expression of CD68 and macrophage chemoattractant 
protein-1 genes in human adipose and muscle tissues 
association with cytokine expression, insulin resistance, and 
reduction by pioglitazone. Diabetes, 54, 2305-2313. 
DONG, X., PARK, S., LIN, X., COPPS, K., YI, X. & WHITE, M. F. 
2006. Irs1 and Irs2 signaling is essential for hepatic glucose 
homeostasis and systemic growth. Journal of Clinical 
Investigation, 116, 101-114. 
DONG, X. C., COPPS, K. D., GUO, S., LI, Y., KOLLIPARA, R., 
DEPINHO, R. A. & WHITE, M. F. 2008. Inactivation of hepatic 
 REFERENCES 
205 
 
Foxo1 by insulin signaling is required for adaptive nutrient 
homeostasis and endocrine growth regulation. Cell 
metabolism, 8, 65-76. 
DORHEIM, M. A., SULLIVAN, M., DANDAPANI, V., WU, X., 
HUDSON, J., SEGARINI, P. R., ROSEN, D. M., 
AULTHOUSE, A. L. & GIMBLE, J. M. 1993. Osteoblastic gene 
expression during adipogenesis in hematopoietic supporting 
murine bone marrow stromal cells. Journal of cellular 
physiology, 154, 317-328. 
DUCKWORTH, W. C. 1988. Insulin degradation: mechanisms, 
products, and significance. Endocrine reviews, 9, 319-345. 
DULL, T. J., GRAY, A., HAYFLICK, J. S. & ULLRICH, A. 1984. 
Insulin-like growth factor II precursor gene organization in 
relation to insulin gene family. 
ENGELMAN, J. A., LUO, J. & CANTLEY, L. C. 2006. The evolution of 
phosphatidylinositol 3-kinases as regulators of growth and 
metabolism. Nature Reviews Genetics, 7, 606-619. 
ENGFELDT, P., HELLMÉR, J., WAHRENBERG, H. & ARNER, P. 
1988. Effects of insulin on adrenoceptor binding and the rate 
of catecholamine-induced lipolysis in isolated human fat cells. 
Journal of Biological Chemistry, 263, 15553-15560. 
EPSTEIN, F. H., MOLLER, D. E. & FLIER, J. S. 1991. Insulin 
resistance—mechanisms, syndromes, and implications. New 
England Journal of Medicine, 325, 938-948. 
EXCELLENCE, N. I. F. H. A. C. 2006. Obesity: The Prevention, 
Identification, Assessment and Management of Overweight 
and Obesity in Adults and Children London. 
FAIN, J. N., MADAN, A. K., HILER, M. L., CHEEMA, P. & BAHOUTH, 
S. W. 2004. Comparison of the release of adipokines by 
adipose tissue, adipose tissue matrix, and adipocytes from 
visceral and subcutaneous abdominal adipose tissues of 
obese humans. Endocrinology, 145, 2273-2282. 
FAJAS, L., AUBOEUF, D., RASPÉ, E., SCHOONJANS, K., 
LEFEBVRE, A.-M., SALADIN, R., NAJIB, J., LAVILLE, M., 
FRUCHART, J.-C. & DEEB, S. 1997. The organization, 
promoter analysis, and expression of the human PPARγ 
gene. Journal of Biological Chemistry, 272, 18779-18789. 
FAJAS, L., SCHOONJANS, K., GELMAN, L., KIM, J. B., NAJIB, J., 
MARTIN, G., FRUCHART, J.-C., BRIGGS, M., 
SPIEGELMAN, B. M. & AUWERX, J. 1999. Regulation of 
peroxisome proliferator-activated receptor γ expression by 
adipocyte differentiation and determination factor 1/sterol 
regulatory element binding protein 1: implications for 
adipocyte differentiation and metabolism. Molecular and 
cellular biology, 19, 5495-5503. 
206 
 
FALCÃO-PIRES, I., CASTRO-CHAVES, P., MIRANDA-SILVA, D., 
LOURENÇO, A. P. & LEITE-MOREIRA, A. F. 2012. 
Physiological, pathological and potential therapeutic roles of 
adipokines. Drug Discovery Today, 17, 880-889. 
FANTIN, V. R., LAVAN, B. E., WANG, Q., JENKINS, N. A., GILBERT, 
D. J., COPELAND, N. G., KELLER, S. R. & LIENHARD, G. E. 
1999. Cloning, tissue expression, and chromosomal location 
of the mouse insulin receptor substrate 4 gene. 
Endocrinology, 140, 1329-1337. 
FASSHAUER, M., KLEIN, J., UEKI, K., KRIAUCIUNAS, K. M., 
BENITO, M., WHITE, M. F. & KAHN, C. R. 2000. Essential 
role of insulin receptor substrate-2 in insulin stimulation of 
Glut4 translocation and glucose uptake in brown adipocytes. 
Journal of Biological Chemistry, 275, 25494-25501. 
FAVELYUKIS, S., TILL, J. H., HUBBARD, S. R. & MILLER, W. T. 
2001. Structure and autoregulation of the insulin-like growth 
factor 1 receptor kinase. Nature Structural & Molecular 
Biology, 8, 1058-1063. 
FAVRE, C., GERARD, A., CLAUZIER, E., PONTAROTTI, P., OLIVE, 
D. & NUNES, J. 2003. DOK4 and DOK5: new Dok-related 
genes expressed in human T cells. Genes and immunity, 4, 
40-45. 
FINUCANE, O. M., REYNOLDS, C. M., MCGILLICUDDY, F. C. & 
ROCHE, H. M. 2012. Insights into the role of macrophage 
migration inhibitory factor in obesity and insulin resistance. 
Proceedings of the Nutrition Society, FirstView, 11. 
FISHER, L., TORCHIA, D., FOHR, B., YOUNG, M. & FEDARKO, N. 
2001. Flexible structures of SIBLING proteins, bone 
sialoprotein, and osteopontin. Biochemical and Biophysical 
Research Communications, 280, 460-465. 
FRIED, S. K., BUNKIN, D. A. & GREENBERG, A. S. 1998. Omental 
and subcutaneous adipose tissues of obese subjects release 
interleukin-6: depot difference and regulation by 
glucocorticoid. Journal of Clinical Endocrinology & 
Metabolism, 83, 847-850. 
FRIED, S. K., RUSSELL, C. D., GRAUSO, N. L. & BROLIN, R. E. 
1993. Lipoprotein lipase regulation by insulin and 
glucocorticoid in subcutaneous and omental adipose tissues 
of obese women and men. Journal of Clinical Investigation, 
92, 2191. 
FRIEDMAN, J. E., ISHIZUKA, T., LIU, S., FARRELL, C. J., BEDOL, 
D., KOLETSKY, R. J., KAUNG, H. L. & ERNSBERGER, P. 
1997. Reduced insulin receptor signaling in the obese 
spontaneously hypertensive Koletsky rat. Am J Physiol, 273, 
E1014-23. 
 REFERENCES 
207 
 
FRIEDMAN, J. M. & HALAAS, J. L. 1998. Leptin and the regulation of 
body weight in mammals. Nature, 395, 763-770. 
GAO, C., GUO, H., DOWNEY, L., MARROQUIN, C., WEI, J. & KUO, 
P. C. 2003. Osteopontin-dependent CD44v6 expression and 
cell adhesion in HepG2 cells. Carcinogenesis, 24, 1871-1878. 
GAO, G. F. & JAKOBSEN, B. K. 2000. Molecular interactions of 
coreceptor CD8 and MHC class I: the molecular basis for 
functional coordination with the T-cell receptor. Immunology 
today, 21, 630-636. 
GARCIA-BARRADO, M. J., IGLESIAS-OSMA, M. C., MORENO-
VIEDMA, V., PASTOR MANSILLA, M. F., GONZALEZ, S. S., 
CARRETERO, J., MORATINOS, J. & BURKS, D. J. 2011. 
Differential sensitivity to adrenergic stimulation underlies the 
sexual dimorphism in the development of diabetes caused by 
Irs-2 deficiency. Biochemical pharmacology, 81, 279-288. 
GAVIN, J. R., ROTH, J., NEVILLE, D. M., DE MEYTS, P. & BUELL, D. 
N. 1974. Insulin-dependent regulation of insulin receptor 
concentrations: a direct demonstration in cell culture. 
Proceedings of the National Academy of Sciences, 71, 84-88. 
GERDES, J., LEMKE, H., BAISCH, H., WACKER, H.-H., SCHWAB, 
U. & STEIN, H. 1984. Cell cycle analysis of a cell proliferation-
associated human nuclear antigen defined by the monoclonal 
antibody Ki-67. The Journal of Immunology, 133, 1710-1715. 
GERIN, I., CHA, H. C. & MACDOUGALD, O. A. 2006. Chapter 8 
Regulation of adipocyte differentiation and metabolism by Wnt 
signaling and C/EBP transcription factors. In: JACOB, E. F. 
(ed.) Advances in Molecular and Cellular Endocrinology. 
Elsevier. 
GESTA, S., BLUHER, M., YAMAMOTO, Y., NORRIS, A. W., 
BERNDT, J., KRALISCH, S., BOUCHER, J., LEWIS, C. & 
KAHN, C. R. 2006. Evidence for a role of developmental 
genes in the origin of obesity and body fat distribution. Proc 
Natl Acad Sci U S A, 103, 6676-81. 
GESTA, S., TSENG, Y. H. & KAHN, C. R. 2007. Developmental origin 
of fat: tracking obesity to its source. Cell, 131, 242-56. 
GIACHELLI, C. M., LOMBARDI, D., JOHNSON, R. J., MURRY, C. E. 
& ALMEIDA, M. 1998. Evidence for a role of osteopontin in 
macrophage infiltration in response to pathological stimuli in 
vivo. The American journal of pathology, 152, 353. 
GLASS, C. K., ROSE, D. W. & ROSENFELD, M. G. 1997. Nuclear 
receptor coactivators. Current opinion in cell biology, 9, 222-
232. 
GLASS, C. K. & ROSENFELD, M. G. 2000. The coregulator exchange 
in transcriptional functions of nuclear receptors. Genes & 
development, 14, 121-141. 
208 
 
GLATZ, J. F. & STORCH, J. 2001. Unravelling the significance of 
cellular fatty acid-binding proteins. Current opinion in 
lipidology, 12, 267-274. 
GOCZE, P. M. & FREEMAN, D. A. 1994. Factors underlying the 
variability of lipid droplet fluorescence in MA‐10 leydig tumor 
cells. Cytometry, 17, 151-158. 
GÓMEZ-AMBROSI, J., CATALÁN, V., RAMÍREZ, B., RODRÍGUEZ, 
A., COLINA, I., SILVA, C., ROTELLAR, F., MUGUETA, C., 
GIL, M. J., CIENFUEGOS, J. A., SALVADOR, J. & 
FRÜHBECK, G. 2007. Plasma Osteopontin Levels and 
Expression in Adipose Tissue Are Increased in Obesity. 
Journal of Clinical Endocrinology & Metabolism, 92, 3719-
3727. 
GREENBERG, A. S., EGAN, J. J., WEK, S. A., MOOS JR, M. C., 
LONDOS, C. & KIMMEL, A. R. 1993. Isolation of cDNAs for 
perilipins A and B: sequence and expression of lipid droplet-
associated proteins of adipocytes. Proceedings of the 
National Academy of Sciences of the United States of 
America, 90, 12035. 
GREGOIRE, F. M., SMAS, C. M. & SUL, H. S. 1998. Understanding 
Adipocyte Differentiation. Physiological Reviews, 78, 783-809. 
GRIGORIADIS, A. E., HEERSCHE, J. & AUBIN, J. E. 1988. 
Differentiation of muscle, fat, cartilage, and bone from 
progenitor cells present in a bone-derived clonal cell 
population: effect of dexamethasone. The Journal of cell 
biology, 106, 2139-2151. 
GUNTON, J. E., KULKARNI, R. N., YIM, S., OKADA, T., 
HAWTHORNE, W. J., TSENG, Y.-H., ROBERSON, R. S., 
RICORDI, C., O'CONNELL, P. J. & GONZALEZ, F. J. 2005. 
Loss of ARNT/HIF1beta mediates altered gene expression 
and pancreatic-islet dysfunction in human type 2 diabetes. 
Cell, 122, 337-349. 
GUO, S., COPPS, K. D., DONG, X., PARK, S., CHENG, Z., POCAI, 
A., ROSSETTI, L., SAJAN, M., FARESE, R. V. & WHITE, M. 
F. 2009. The Irs1 branch of the insulin signaling cascade 
plays a dominant role in hepatic nutrient homeostasis. 
Molecular and cellular biology, 29, 5070-5083. 
HANKE, S. & MANN, M. 2009. The phosphotyrosine interactome of 
the insulin receptor family and its substrates IRS-1 and IRS-2. 
Mol Cell Proteomics, 8, 519-34. 
HAUNER, H. & ENTENMANN, G. 1991. Regional variation of adipose 
differentiation in cultured stromal-vascular cells from the 
abdominal and femoral adipose tissue of obese women. 
International journal of obesity, 15, 121. 
HAUNER, H., ENTENMANN, G., WABITSCH, M., GAILLARD, D., 
AILHAUD, G., NEGREL, R. & PFEIFFER, E. 1989. Promoting 
 REFERENCES 
209 
 
effect of glucocorticoids on the differentiation of human 
adipocyte precursor cells cultured in a chemically defined 
medium. Journal of Clinical Investigation, 84, 1663. 
HAUNERLAND, N. H. & SPENER, F. 2004. Fatty acid-binding 
proteins–insights from genetic manipulations. Progress in lipid 
research, 43, 328-349. 
HAUSMAN, D. B., DIGIROLAMO, M., BARTNESS, T. J., HAUSMAN, 
G. J. & MARTIN, R. J. 2001. The biology of white adipocyte 
proliferation. Obesity Reviews, 2, 239-254. 
HAUSMAN, G., WRIGHT, J., DEAN, R. & RICHARDSON, R. 1993. 
Cellular and molecular aspects of the regulation of 
adipogenesis. Journal of Animal Science, 71, 33-55. 
HENRY, R. R., PHILLIPS, S. A., MUDALIAR, S. R. & CIARALDI, T. P. 
2006. Chapter 6 The adipocyte and adipose tissue as 
endocrine organs: Impact on the insulin resistance phenotype. 
In: JACOB, E. F. (ed.) Advances in Molecular and Cellular 
Endocrinology. Elsevier. 
HENRY, S. L., BENSLEY, J. G., WOOD-BRADLEY, R. J., CULLEN-
MCEWEN, L. A., BERTRAM, J. F. & ARMITAGE, J. A. 2012. 
White adipocytes: More than just fat depots. The International 
Journal of Biochemistry &amp; Cell Biology, 44, 435-440. 
HIBUSE, T., MAEDA, N., NAGASAWA, A. & FUNAHASHI, T. 2006. 
Aquaporins and glycerol metabolism. Biochimica et 
Biophysica Acta (BBA) - Biomembranes, 1758, 1004-1011. 
HIJIYA, N., SETOGUCHI, M., MATSUURA, K., HIGUCHI, Y., 
AKIZUKI, S. & YAMAMOTO, S. 1994. Cloning and 
characterization of the human osteopontin gene and its 
promoter. Biochemical Journal, 303, 255. 
HILL, M. M., CLARK, S. F., TUCKER, D. F., BIRNBAUM, M. J., 
JAMES, D. E. & MACAULAY, S. L. 1999. A role for protein 
kinase Bβ/Akt2 in insulin-stimulated GLUT4 translocation in 
adipocytes. Molecular and cellular biology, 19, 7771-7781. 
HIROSUMI, J., TUNCMAN, G., CHANG, L., GÖRGÜN, C. Z., UYSAL, 
K. T., MAEDA, K., KARIN, M. & HOTAMISLIGIL, G. S. 2002. 
A central role for JNK in obesity and insulin resistance. 
Nature, 420, 333-336. 
HIRSCH, J. & BATCHELOR, B. 1976. Adipose tissue cellularity in 
human obesity. Clinics in Endocrinology and Metabolism, 5, 
299-311. 
HOFBAUER, K. G. 2002. Molecular pathways to obesity. International 
Journal of Obesity, International Journal of Obesity (2002) 26, 
Suppl 2, S18-S27. . 
HOLM, C. 2003. Molecular mechanisms regulating hormone-sensitive 
lipase and lipolysis. Biochemical Society Transactions, 31, 
1120-1124. 
210 
 
HORWITZ, D. L., STARR, J., MAKO, M., BLACKARD, W. & 
RUBENSTEIN, A. 1975. Proinsulin, insulin, and C-peptide 
concentrations in human portal and peripheral blood. Journal 
of Clinical Investigation, 55, 1278. 
HOSOGAI, N., FUKUHARA, A., OSHIMA, K., MIYATA, Y., TANAKA, 
S., SEGAWA, K., FURUKAWA, S., TOCHINO, Y., KOMURO, 
R. & MATSUDA, M. 2007. Adipose tissue hypoxia in obesity 
and its impact on adipocytokine dysregulation. Diabetes, 56, 
901-911. 
HOTAMISLIGIL, G. 2003. Inflammatory pathways and insulin action. 
International journal of obesity, 27, S53-S55. 
HOTAMISLIGIL, G. S. 2006. Inflammation and metabolic disorders. 
Nature, 444, 860-867. 
HOTAMISLIGIL, G. S., PERALDI, P., BUDAVARI, A., ELLIS, R., 
WHITE, M. F. & SPIEGELMAN, B. 1996. IRS-1-Mediated 
Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF- 
-and Obesity-Induced Insulin Resistance. SCIENCE-NEW 
YORK THEN WASHINGTON-, 665-667. 
HOTAMISLIGIL, G. S., SHARGILL, N. S. & SPIEGELMAN, B. M. 
1993. Adipose expression of tumor necrosis factor-alpha: 
direct role in obesity-linked insulin resistance. Science, 259, 
87-91. 
HU, E., LIANG, P. & SPIEGELMAN, B. M. 1996. AdipoQ is a novel 
adipose-specific gene dysregulated in obesity. Journal of 
Biological Chemistry, 271, 10697-10703. 
IKEDA, H., WEST, D., PUSTEK, J., FIGLEWICZ, D., GREENWOOD, 
M., PORTE JR, D. & WOODS, S. 1986. Intraventricular insulin 
reduces food intake and body weight of lean but not obese 
Zucker rats. Appetite, 7, 381-386. 
ISAKSON, P., HAMMARSTEDT, A., GUSTAFSON, B. & SMITH, U. 
2009. Impaired Preadipocyte Differentiation in Human 
Abdominal Obesity Role of Wnt, Tumor Necrosis Factor-α, 
and Inflammation. Diabetes, 58, 1550-1557. 
JAMES, P. T., LEACH, R., KALAMARA, E. & SHAYEGHI, M. 2012. 
The worldwide obesity epidemic. Obesity Research, 9, 228S-
233S. 
JENSEN, M. D. 2008. Role of body fat distribution and the metabolic 
complications of obesity. Journal of Clinical Endocrinology & 
Metabolism, 93, s57-s63. 
JO, J., GAVRILOVA, O., PACK, S., JOU, W., MULLEN, S., SUMNER, 
A. E., CUSHMAN, S. W. & PERIWAL, V. 2009. Hypertrophy 
and/or Hyperplasia: Dynamics of Adipose Tissue Growth. 
PLoS Comput Biol, 5, e1000324. 
JOE, A. W. B., YI, L., EVEN, Y., VOGL, A. W. & ROSSI, F. M. V. 
2009. Depot-Specific Differences in Adipogenic Progenitor 
 REFERENCES 
211 
 
Abundance and Proliferative Response to High-Fat Diet. 
STEM CELLS, 27, 2563-2570. 
JOHNSON, P., STERN, J., GREENWOOD, M. & HIRSCH, J. 1978. 
Adipose tissue hyperplasia and hyperinsulinemia in Zucker 
obese female rats: a developmental study. Metabolism, 27, 
1941-1954. 
JONO, S., PEINADO, C. & GIACHELLI, C. M. 2000. Phosphorylation 
of osteopontin is required for inhibition of vascular smooth 
muscle cell calcification. Journal of Biological Chemistry, 275, 
20197-20203. 
KABON, B., NAGELE, A., REDDY, D., EAGON, C., FLESHMAN, J. 
W., SESSLER, D. I. & KURZ, A. 2004. Obesity decreases 
perioperative tissue oxygenation. Anesthesiology, 100, 274. 
KAHN, A. R. S. C. R. 2001. Insulin signalling and the regulation of 
glucose and lipid metabolism. Nature 414, 799-806. 
KAHN, B. B. 1998. Type 2 Diabetes: When Insulin Secretion Fails to 
Compensate for Insulin Resistance. Cell, 92, 593-596. 
KAHN, C., WHITE, M., SHOELSON, S., BACKER, J., ARAKI, E., 
CHEATHAM, B., CSERMELY, P., FOLLI, F., GOLDSTEIN, B. 
& HUERTAS, P. 1993. The insulin receptor and its substrate: 
molecular determinants of early events in insulin action. 
Recent progress in hormone research, 48, 291. 
KANDA, H., TATEYA, S., TAMORI, Y., KOTANI, K., HIASA, K.-I., 
KITAZAWA, R., KITAZAWA, S., MIYACHI, H., MAEDA, S. & 
EGASHIRA, K. 2006. MCP-1 contributes to macrophage 
infiltration into adipose tissue, insulin resistance, and hepatic 
steatosis in obesity. Journal of Clinical Investigation, 116, 
1494-1505. 
KAZANECKI, C. C. 2007. Osteopontin and cell adhesion: Role of 
post-translational modifications and the C-terminal region. 
Doctor of Philosophy, ProQuest. 
KAZANECKI, C. C., UZWIAK, D. J. & DENHARDT, D. T. 2007. 
Control of osteopontin signaling and function by 
post‐translational phosphorylation and protein folding. Journal 
of cellular biochemistry, 102, 912-924. 
KEOPHIPHATH, M., ACHARD, V., HENEGAR, C., ROUAULT, C., 
CLÉMENT, K. & LACASA, D. 2009. Macrophage-secreted 
factors promote a profibrotic phenotype in human 
preadipocytes. Molecular Endocrinology, 23, 11-24. 
KERN, P. A., RANGANATHAN, S., LI, C., WOOD, L. & 
RANGANATHAN, G. 2001. Adipose tissue tumor necrosis 
factor and interleukin-6 expression in human obesity and 
insulin resistance. American Journal of Physiology - 
Endocrinology And Metabolism, 280, E745-E751. 
KHAN, S. A., COOK, A. C., KAPPIL, M., GÜNTHERT, U., 
CHAMBERS, A. F., TUCK, A. B. & DENHARDT, D. T. 2005. 
212 
 
Enhanced cell surface CD44 variant (v6, v9) expression by 
osteopontin in breast cancer epithelial cells facilitates tumor 
cell migration: novel post-transcriptional, post-translational 
regulation. Clinical and Experimental Metastasis, 22, 663-673. 
KIEFER, F. 2010. Osteopontin in obesity-associated adipose tissue 
inflammation and insulin resistance and its interaction with 
monocyte chemoattractant protein-1. Degree ‘Doctor of 
Philosophy - PhD’ Doctoral Thesis at the Medical University of 
Vienna for obtaining the Degree ‘Doctor of Philosophy - PhD’, 
Medical University of Vienna. 
KIEFER, F., NESCHEN, S., PFAU, B., LEGERER, B., NEUHOFER, 
A., KAHLE, M., HRABÉ DE ANGELIS, M., SCHLEDERER, 
M., MAIR, M., KENNER, L., PLUTZKY, J., ZEYDA, M. & 
STULNIG, T. 2011. Osteopontin deficiency protects against 
obesity-induced hepatic steatosis and attenuates glucose 
production in mice. Diabetologia, 54, 2132-2142. 
KIEFER, F. W., ZEYDA, M., GOLLINGER, K., PFAU, B., NEUHOFER, 
A., WEICHHART, T., SÄEMANN, M. D., GEYEREGGER, R., 
SCHLEDERER, M. & KENNER, L. 2010. Neutralization of 
osteopontin inhibits obesity-induced inflammation and insulin 
resistance. Diabetes, 59, 935-946. 
KIEFER, F. W., ZEYDA, M., TODORIC, J., HUBER, J., 
GEYEREGGER, R., WEICHHART, T., ASZMANN, O., 
LUDVIK, B., SILBERHUMER, G. R. & PRAGER, G. 2008. 
Osteopontin expression in human and murine obesity: 
extensive local up-regulation in adipose tissue but minimal 
systemic alterations. Endocrinology, 149, 1350-1357. 
KIGUCHI, N., MAEDA, T., KOBAYASHI, Y., FUKAZAWA, Y. & 
KISHIOKA, S. 2009. Leptin enhances CC-chemokine ligand 
expression in cultured murine macrophage. Biochemical and 
biophysical research communications, 384, 311-315. 
KIM, J. B., SARRAF, P., WRIGHT, M., YAO, K. M., MUELLER, E., 
SOLANES, G., LOWELL, B. B. & SPIEGELMAN, B. M. 1998. 
Nutritional and insulin regulation of fatty acid synthetase and 
leptin gene expression through ADD1/SREBP1. Journal of 
Clinical Investigation, 101, 1. 
KIM, J. B. & SPIEGELMAN, B. M. 1996. ADD1/SREBP1 promotes 
adipocyte differentiation and gene expression linked to fatty 
acid metabolism. Genes & development, 10, 1096-1107. 
KIM, J. B., SPOTTS, G. D., HALVORSEN, Y.-D., SHIH, H.-M., 
ELLENBERGER, T., TOWLE, H. C. & SPIEGELMAN, B. M. 
1995. Dual DNA binding specificity of ADD1/SREBP1 
controlled by a single amino acid in the basic helix-loop-helix 
domain. Molecular and cellular biology, 15, 2582-2588. 
 REFERENCES 
213 
 
KING, H., AUBERT, R. E. & HERMAN, W. H. 1998. Global Burden of 
Diabetes, 1995–2025: Prevalence, numerical estimates, and 
projections. Diabetes Care, 21, 1414-1431. 
KISSEBAH, A. H. & KRAKOWER, G. R. 1994. Regional adiposity and 
morbidity. Physiol Rev, 74, 761-811. 
KLAMMT, J., GARTEN, A., BARNIKOL-OETTLER, A., BECK-
SICKINGER, A. G. & KIESS, W. 2005. Comparative analysis 
of the signaling capabilities of the insulin receptor-related 
receptor. Biochem Biophys Res Commun, 327, 557-64. 
KLIP, A. & PÂQUET, M. R. 1990. Glucose transport and glucose 
transporters in muscle and their metabolic regulation. 
Diabetes Care, 13, 228-243. 
KOOPMAN, G., REUTELINGSPERGER, C., KUIJTEN, G., 
KEEHNEN, R., PALS, S. & VAN OERS, M. 1994. Annexin V 
for flow cytometric detection of phosphatidylserine expression 
on B cells undergoing apoptosis. Blood, 84, 1415-1420. 
KRISTIANSEN, O. P. & MANDRUP-POULSEN, T. 2005. Interleukin-6 
and Diabetes. Diabetes, 54, S114-S124. 
KUBOTA, N., TERAUCHI, Y., MIKI, H., TAMEMOTO, H., YAMAUCHI, 
T., KOMEDA, K., SATOH, S., NAKANO, R., ISHII, C., 
SUGIYAMA, T., ETO, K., TSUBAMOTO, Y., OKUNO, A., 
MURAKAMI, K., SEKIHARA, H., HASEGAWA, G., NAITO, M., 
TOYOSHIMA, Y., TANAKA, S., SHIOTA, K., KITAMURA, T., 
FUJITA, T., EZAKI, O., AIZAWA, S., NAGAI, R., TOBE, K., 
KIMURA, S. & KADOWAKI, T. 1999. PPARγ Mediates High-
Fat Diet–Induced Adipocyte Hypertrophy and Insulin 
Resistance. Molecular cell, 4, 597-609. 
KUBOTA, N., TERAUCHI, Y., TOBE, K., YANO, W., SUZUKI, R., 
UEKI, K., TAKAMOTO, I., SATOH, H., MAKI, T., KUBOTA, T., 
MOROI, M., OKADA-IWABU, M., EZAKI, O., NAGAI, R., 
UETA, Y., KADOWAKI, T. & NODA, T. 2004. Insulin receptor 
substrate 2 plays a crucial role in beta cells and the 
hypothalamus. The Journal of Clinical Investigation, 114, 917-
927. 
KUBOTA, N., TOBE, K., TERAUCHI, Y., ETO, K., YAMAUCHI, T., 
SUZUKI, R., TSUBAMOTO, Y., KOMEDA, K., NAKANO, R., 
MIKI, H., SATOH, S., SEKIHARA, H., SCIACCHITANO, S., 
LESNIAK, M., AIZAWA, S., NAGAI, R., KIMURA, S., 
AKANUMA, Y., TAYLOR, S. I. & KADOWAKI, T. 2000. 
Disruption of insulin receptor substrate 2 causes type 2 
diabetes because of liver insulin resistance and lack of 
compensatory beta-cell hyperplasia. Diabetes, 49, 1880-1889. 
LACASA, D., TALEB, S., KEOPHIPHATH, M., MIRANVILLE, A. & 
CLEMENT, K. 2007. Macrophage-secreted factors impair 
human adipogenesis: involvement of proinflammatory state in 
preadipocytes. Endocrinology, 148, 868-877. 
214 
 
LAFONTAN, M. & BERLAN, M. 2003. Do regional differences in 
adipocyte biology provide new pathophysiological insights? 
Trends in pharmacological sciences, 24, 276-283. 
LANG, D., MATTHEWS, D., PETO, J. & TURNER, R. 1979. Cyclic 
oscillations of basal plasma glucose and insulin 
concentrations in human beings. New England Journal of 
Medicine, 301, 1023-1027. 
LAU, D., SCHILLABEER, G., LI, Z., WONG, K., VARZANEH, F. & 
TOUGH, S. 1996. Paracrine interactions in adipose tissue 
development and growth. International journal of obesity and 
related metabolic disorders: journal of the International 
Association for the Study of Obesity, 20, S16. 
LAUSTSEN, P. G., MICHAEL, M. D., CRUTE, B. E., COHEN, S. E., 
UEKI, K., KULKARNI, R. N., KELLER, S. R., LIENHARD, G. 
E. & KAHN, C. R. 2002. Lipoatrophic diabetes in 
Irs1−/−/Irs3−/− double knockout mice. Genes & development, 
16, 3213-3222. 
LAVAN, B. E., LANE, W. S. & LIENHARD, G. E. 1997. The 60-kDa 
phosphotyrosine protein in insulin-treated adipocytes is a new 
member of the insulin receptor substrate family. Journal of 
Biological Chemistry, 272, 11439-11443. 
LEE, Y. H., GIRAUD, J., DAVIS, R. J. & WHITE, M. F. 2003. c-Jun N-
terminal kinase (JNK) mediates feedback inhibition of the 
insulin signaling cascade. Journal of Biological Chemistry, 
278, 2896-2902. 
LIEBERMAN, L. S. 2003. DIETARY, EVOLUTIONARY, AND 
MODERNIZING INFLUENCES ON THE PREVALENCE OF 
TYPE 2 DIABETES. Annual Review of Nutrition, 23, 345-377. 
LIN, X., TAGUCHI, A., PARK, S., KUSHNER, J. A., LI, F., LI, Y. & 
WHITE, M. F. 2004. Dysregulation of insulin receptor 
substrate 2 in beta cells and brain causes obesity and 
diabetes. The Journal of Clinical Investigation, 114, 908-916. 
LISTENBERGER, L. L. & BROWN, D. A. 2007. Fluorescent detection 
of lipid droplets and associated proteins. Current Protocols in 
Cell Biology, 24.2. 1-24.2. 11. 
LITTHAUER, D. & SERRERO, G. 1992. The primary culture of mouse 
adipocyte precursor cells in defined medium. Comparative 
Biochemistry and Physiology Part A: Physiology, 101, 59-64. 
LIVAK, K. J. & SCHMITTGEN, T. D. 2001. Analysis of Relative Gene 
Expression Data Using Real-Time Quantitative PCR and the 
2−ΔΔCT Method. Methods, 25, 402-408. 
LONDOS, C., BRASAEMLE, D. L., SCHULTZ, C. J., SEGREST, J. P. 
& KIMMEL, A. R. Year. Perilipins, ADRP, and other proteins 
that associate with intracellular neutral lipid droplets in animal 
cells. In:  Seminars in cell & developmental biology, 1999. 51. 
 REFERENCES 
215 
 
LOWELL, B. B., NAPOLITANO, A., USHER, P., DULLOO, A. G., 
ROSEN, B. S., SPIEGELMAN, B. M. & FLIER, J. S. 1990. 
Reduced Adipsin Expression in Murine Obesity: Effect of Age 
and Treatment with the Sympathomimetic-Thermogenic Drug 
Mixture Ephedrine and Caffeine. Endocrinology, 126, 1514-
1520. 
M ZEYDA, D. F., J TODORIC, O ASZMANN, M SPEISER, G GYÖRI, 
G J ZLABINGER AND T M STULNIG 2007. Human adipose 
tissue macrophages are of an anti-inflammatory phenotype 
but capable of excessive pro-inflammatory mediator 
production. International Journal of Obesity, 31, 1420–1428. 
MARCUELLO, C., CALLE-PASCUAL, A. L., FUENTES, M., RUNKLE, 
I., SORIGUER, F., GODAY, A., BOSCH-COMAS, A., BORDI, 
#XFA, , E., CARMENA, R., CASAMITJANA, R., CASTA, 
#XF1, O, L., CASTELL, C., CATAL, #XE1, , M., DELGADO, 
E., FRANCH, J., GAZTAMBIDE, S., GIRB, #XE9, S, J., 
GOMIS, R., GUTI, RREZ, G., #XF3, PEZ-ALBA, A., MART, 
#XED, NEZ-LARRAD, M. T., MEN, NDEZ, E., MORA-PECES, 
I., ORTEGA, E., PASCUAL-MANICH, G., ROJO-MART, NEZ, 
G., SERRANO-RIOS, M., VALD, S, S., ZQUEZ, J. A. & 
VENDRELL, J. 2012. Evaluation of Health-Related Quality of 
Life according to Carbohydrate Metabolism Status: A Spanish 
Population-Based Study (Di@bet.es Study). International 
Journal of Endocrinology, 2012, 6. 
MARDILOVICH, K., PANKRATZ, S. L. & SHAW, L. M. 2009. 
Expression and function of the insulin receptor substrate 
proteins in cancer. Cell Commun Signal, 7, 14. 
MAURIEGE, P., DESPRES, J., MARCOTTE, M., FERLAND, M., 
TREMBLAY, A., NADEAU, A., MOORJANI, S., LUPIEN, P., 
THERIAULT, G. & BOUCHARD, C. 1990. Abdominal fat cell 
lipolysis, body fat distribution, and metabolic variables in 
premenopausal women. Journal of Clinical Endocrinology & 
Metabolism, 71, 1028-1035. 
MAZZALI, M., KIPARI, T., OPHASCHAROENSUK, V., WESSON, J. 
A., JOHNSON, R. & HUGHES, J. 2002. Osteopontin a 
molecule for all seasons. QJM, 95, 3-13. 
MENDEZ, M. A., MONTEIRO, C. A. & POPKIN, B. M. 2005. 
Overweight exceeds underweight among women in most 
developing countries. The American journal of clinical 
nutrition, 81, 714-721. 
MERRY, K., DODDS, R., LITTLEWOOD, A. & GOWEN, M. 1993. 
Expression of osteopontin mRNA by osteoclasts and 
osteoblasts in modelling adult human bone. Journal of cell 
science, 104, 1013-1020. 
MOHAMED-ALI, V., PINKNEY, J. & COPPACK, S. 1998. Adipose 
tissue as an endocrine and paracrine organ. International 
216 
 
journal of obesity and related metabolic disorders: journal of 
the International Association for the Study of Obesity, 22, 
1145. 
MONTAGUE, C. T., PRINS, J. B., SANDERS, L., DIGBY, J. E. & 
O'RAHILLY, S. 1997. Depot-and sex-specific differences in 
human leptin mRNA expression: implications for the control of 
regional fat distribution. Diabetes, 46, 342-347. 
MORAS, D. & GRONEMEYER, H. 1998. The nuclear receptor ligand-
binding domain: structure and function. Current opinion in cell 
biology, 10, 384-391. 
MYERS JR, M. G. & WHITE, M. F. 1996. Insulin signal transduction 
and the IRS proteins. Annual review of pharmacology and 
toxicology, 36, 615-658. 
MYERS, M. G., MENDEZ, R., SHI, P., PIERCE, J. H., RHOADS, R. & 
WHITE, M. F. 1998. The COOH-terminal tyrosine 
phosphorylation sites on IRS-1 bind SHP-2 and negatively 
regulate insulin signaling. Journal of Biological Chemistry, 
273, 26908-26914. 
NEGANOVA, I., AL-QASSAB, H., HEFFRON, H., SELMAN, C., 
CHOUDHURY, A. I., LINGARD, S. J., DIAKONOV, I., 
PATTERSON, M., GHATEI, M., BLOOM, S. R., FRANKS, S., 
HUHTANIEMI, I., HARDY, K. & WITHERS, D. J. 2007. Role of 
central nervous system and ovarian insulin receptor substrate 
2 signaling in female reproductive function in the mouse. Biol 
Reprod, 76, 1045-53. 
NELMS, K., O'NEILL, T. J., LI, S., HUBBARD, S. R., GUSTAFSON, T. 
A. & PAUL, W. E. 1999. Alternative splicing, gene localization, 
and binding of SH2-B to the insulin receptor kinase domain. 
Mammalian genome, 10, 1160-1167. 
NICHOLLS, D. G. & LOCKE, R. M. 1984. Thermogenic mechanisms 
in brown fat. Physiological reviews, 64, 1-64. 
NOMIYAMA, T., PEREZ-TILVE, D., OGAWA, D., GIZARD, F., ZHAO, 
Y., HEYWOOD, E. B., JONES, K. L., KAWAMORI, R., 
CASSIS, L. A. & TSCHOP, M. 2007. Osteopontin mediates 
obesity-induced adipose tissue macrophage infiltration and 
insulin resistance in mice. Journal of Clinical Investigation, 
117, 2877. 
NUSSEY S, W. S. 2001. Endocrinology: An Integrated Approach. 
Oxford: BIOS Scientific Publishers. 
O'CONNELL, J., LYNCH, L., CAWOOD, T. J., KWASNIK, A., NOLAN, 
N., GEOGHEGAN, J., MCCORMICK, A., O'FARRELLY, C. & 
O'SHEA, D. 2010. The relationship of omental and 
subcutaneous adipocyte size to metabolic disease in severe 
obesity. PloS one, 5, e9997. 
O’REGAN, A. W., HAYDEN, J. M. & BERMAN, J. S. 2000. 
Osteopontin augments CD3-mediated interferon-γ and CD40 
 REFERENCES 
217 
 
ligand expression by T cells, which results in IL-12 production 
from peripheral blood mononuclear cells. Journal of leukocyte 
biology, 68, 495-502. 
OBSTFELD, A. E., SUGARU, E., THEARLE, M., FRANCISCO, A.-M., 
GAYET, C., GINSBERG, H. N., ABLES, E. V. & FERRANTE, 
A. W. 2010. CC chemokine receptor 2 (CCR2) regulates the 
hepatic recruitment of myeloid cells that promote obesity-
induced hepatic steatosis. Diabetes, 59, 916-925. 
OFEI, F., HUREL, S., NEWKIRK, J., SOPWITH, M. & TAYLOR, R. 
1996. Effects of an engineered human anti–TNF-α antibody 
(CDP571) on insulin sensitivity and glycemic control in 
patients with NIDDM. Diabetes, 45, 881-885. 
ORGANIZATION, W. H. 2010. Obesity and overweight. Fact Sheet No 
311. September 2006. Online document at: www. who. 
int/mediacentre/factsheets/fs311/en/index. html Accessed 
September, 13. 
ORGANIZATION, W. H. 2011. Obesity and overweight. 2011. URL 
http://www. who. int/mediacentre/factsheets/fs311/en/index. 
html (accessed June 2011). 
ORGANIZATION, W. H. 2012. Obesity and overweight [Online]. 
Available: 
http://www.who.int/mediacentre/factsheets/fs311/en/index.htm
l [Accessed Fact sheet N°311]. 
PASARICA, M., SEREDA, O. R., REDMAN, L. M., ALBARADO, D. C., 
HYMEL, D. T., ROAN, L. E., ROOD, J. C., BURK, D. H. & 
SMITH, S. R. 2009. Reduced adipose tissue oxygenation in 
human obesity evidence for rarefaction, macrophage 
chemotaxis, and inflammation without an angiogenic 
response. Diabetes, 58, 718-725. 
PATTI, M.-E., SUN, X.-J., BRUENING, J. C., ARAKI, E., LIPES, M. A., 
WHITE, M. F. & KAHN, C. R. 1995. 4PS/insulin receptor 
substrate (IRS)-2 is the alternative substrate of the insulin 
receptor in IRS-1-deficient mice. Journal of Biological 
Chemistry, 270, 24670-24673. 
PAWSON, T. & SCOTT, J. D. 1997. Signaling through scaffold, 
anchoring, and adaptor proteins. Science, 278, 2075-2080. 
PERMANA, P. A., NAIR, S., LEE, Y. H., LUCZY-BACHMAN, G., DE 
COURTEN, B. V. & TATARANNI, P. A. 2004. Subcutaneous 
abdominal preadipocyte differentiation in vitro inversely 
correlates with central obesity. American Journal of 
Physiology-Endocrinology And Metabolism, 286, E958-E962. 
PESSIN, J. E. & SALTIEL, A. R. 2000. Signaling pathways in insulin 
action: molecular targets of insulin resistance. The Journal of 
Clinical Investigation, 106, 165-169. 
PHILIP, S. & KUNDU, G. C. 2003. Osteopontin induces nuclear factor 
κB-mediated promatrix metalloproteinase-2 activation through 
218 
 
IκBα/IKK signaling pathways, and curcumin 
(diferulolylmethane) down-regulates these pathways. Journal 
of Biological Chemistry, 278, 14487-14497. 
PHILIPPE, J. 1991. Structure and Pancreatic Expression of the Insulin 
and Glucagon Genes. Endocrine reviews, 12, 252-271. 
PICKUP, J., MATTOCK, M., CHUSNEY, G. & BURT, D. 1997. NIDDM 
as a disease of the innate immune system: association of 
acute-phase reactants and interleukin-6 with metabolic 
syndrome X. Diabetologia, 40, 1286-1292. 
PITTAS, A. G., JOSEPH, N. A. & GREENBERG, A. S. 2004. 
Adipocytokines and insulin resistance. Journal of Clinical 
Endocrinology & Metabolism, 89, 447-452. 
PITTENGER, M. F., MACKAY, A. M., BECK, S. C., JAISWAL, R. K., 
DOUGLAS, R., MOSCA, J. D., MOORMAN, M. A., 
SIMONETTI, D. W., CRAIG, S. & MARSHAK, D. R. 1999. 
Multilineage potential of adult human mesenchymal stem 
cells. Science, 284, 143-147. 
POPKIN, B. M. & GORDON-LARSEN, P. 2004. The nutrition 
transition: worldwide obesity dynamics and their determinants. 
International journal of obesity, 28, S2-S9. 
POWELKA, A. M., SETH, A., VIRBASIUS, J. V., KISKINIS, E., 
NICOLORO, S. M., GUILHERME, A., TANG, X., 
STRAUBHAAR, J., CHERNIACK, A. D. & PARKER, M. G. 
2006. Suppression of oxidative metabolism and mitochondrial 
biogenesis by the transcriptional corepressor RIP140 in 
mouse adipocytes. Journal of Clinical Investigation, 116, 125-
136. 
PREVIS, S. F., WITHERS, D. J., REN, J.-M., WHITE, M. F. & 
SHULMAN, G. I. 2000. Contrasting Effects of IRS-1 Versus 
IRS-2 Gene Disruption on Carbohydrate and Lipid Metabolism 
in Vivo. Journal of Biological Chemistry, 275, 38990-38994. 
PUIGSERVER, P. & SPIEGELMAN, B. M. 2003. Peroxisome 
proliferator-activated receptor-γ coactivator 1α (PGC-1α): 
transcriptional coactivator and metabolic regulator. Endocrine 
reviews, 24, 78-90. 
QIN YANG, T. E. G., NIMESH MODY, FREDERIC PREITNER, ODILE 
D. PERONI, JANICE M. ZABOLOTNY, KO KOTANI, 
LOREDANA QUADRO, & BARBARA B. KAHN 2005. Serum 
retinol binding protein 4 contributes to insulin resistance in 
obesity and type 2 diabetes. Nature 436, 356-362. 
RAJALA, M. W. & SCHERER, P. E. 2003. Minireview: the adipocyte—
at the crossroads of energy homeostasis, inflammation, and 
atherosclerosis. Endocrinology, 144, 3765-3773. 
RANGASWAMI, H., BULBULE, A. & KUNDU, G. C. 2006. 
Osteopontin: role in cell signaling and cancer progression. 
Trends in cell biology, 16, 79-87. 
 REFERENCES 
219 
 
RANGWALA, S. M. & LAZAR, M. A. 2004. Peroxisome proliferator-
activated receptor γ in diabetes and metabolism. Trends in 
Pharmacological Sciences, 25, 331-336. 
REAVEN, G. 2004a. The metabolic syndrome or the insulin resistance 
syndrome? Different names, different concepts, and different 
goals. Endocrinology and metabolism clinics of North 
America, 33, 283-303. 
REAVEN, G. M. 2004b. Insulin Resistance, Cardiovascular Disease, 
and the Metabolic Syndrome. Diabetes Care, 27, 1011-1012. 
RESHEF, L., OLSWANG, Y., CASSUTO, H., BLUM, B., CRONIGER, 
C. M., KALHAN, S. C., TILGHMAN, S. M. & HANSON, R. W. 
2003. Glyceroneogenesis and the triglyceride/fatty acid cycle. 
Journal of Biological Chemistry, 278, 30413-30416. 
RINDERKNECHT, E. & HUMBEL, R. E. 1978. The amino acid 
sequence of human insulin-like growth factor I and its 
structural homology with proinsulin. Journal of Biological 
Chemistry, 253, 2769-2776. 
RODEHEFFER, M. S., BIRSOY, K. & FRIEDMAN, J. M. 2008. 
Identification of white adipocyte progenitor cells in vivo. Cell, 
135, 240-9. 
ROSEN, E. D. & MACDOUGALD, O. A. 2006. Adipocyte 
differentiation from the inside out. Nat Rev Mol Cell Biol, 7, 
885-96. 
ROSEN, E. D. & SPIEGELMAN, B. M. 2000. Molecular regulation of 
adipogenesis. Annu Rev Cell Dev Biol, 16, 145-71. 
RUBENSTEIN, A., BLOCK, M., STARR, J., MELANI, F. & STEINER, 
D. 1972. Proinsulin and C-peptide in blood. Diabetes, 21, 661. 
RUI, L., AGUIRRE, V., KIM, J. K., SHULMAN, G. I., LEE, A., 
CORBOULD, A., DUNAIF, A. & WHITE, M. F. 2001. 
Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of 
IRS-1 at inhibitory Ser^ 3^ 0^ 7 via distinct pathways. Journal 
of Clinical Investigation, 107, 181-189. 
RUI, L. & WHITE, M. F. 2003. The role of insulin receptor substrate 
proteins in insulin signaling and metabolic regulation. 
Diabetes Mellitus: A Fundamental and Clinical Text, 207. 
RUI, L., YUAN, M., FRANTZ, D., SHOELSON, S. & WHITE, M. F. 
2002. SOCS-1 and SOCS-3 block insulin signaling by 
ubiquitin-mediated degradation of IRS1 and IRS2. Science 
Signalling, 277, 42394. 
SAHAI, A., MALLADI, P., MELIN-ALDANA, H., GREEN, R. M. & 
WHITINGTON, P. F. 2004a. Upregulation of osteopontin 
expression is involved in the development of nonalcoholic 
steatohepatitis in a dietary murine model. American Journal of 
Physiology-Gastrointestinal and Liver Physiology, 287, G264-
G273. 
220 
 
SAHAI, A., MALLADI, P., PAN, X., PAUL, R., MELIN-ALDANA, H., 
GREEN, R. M. & WHITINGTON, P. F. 2004b. Obese and 
diabetic db/db mice develop marked liver fibrosis in a model of 
nonalcoholic steatohepatitis: role of short-form leptin receptors 
and osteopontin. American Journal of Physiology-
Gastrointestinal and Liver Physiology, 287, G1035-G1043. 
SAMANNA, V., WEI, H., EGO-OSUALA, D. & CHELLAIAH, M. 2006. 
Alpha-V-dependent outside-in signaling is required for the 
regulation of CD44 surface expression, MMP-2 secretion, and 
cell migration by osteopontin in human melanoma cells. 
Experimental cell research, 312, 2214-2230. 
SAMBROOK, J. & RUSSELL, D. W. 1989. SDS-polyacrylamide gel 
electrophoresis of proteins. Molecular cloning: a laboratory 
manual, 3, 18.47-18.59. 
SARTIPY, P. & LOSKUTOFF, D. J. 2003. Monocyte chemoattractant 
protein 1 in obesity and insulin resistance. Proceedings of the 
National Academy of Sciences, 100, 7265-7270. 
SAWKA-VERHELLE, D., BARON, V., MOTHE, I., FILLOUX, C., 
WHITE, M. F. & VAN OBBERGHEN, E. 1997. Tyr624 and 
Tyr628 in insulin receptor substrate-2 mediate its association 
with the insulin receptor. Journal of Biological Chemistry, 272, 
16414-16420. 
SCHÄGGER, H. 2006. Tricine–SDS-PAGE. Nature protocols, 1, 16-
22. 
SCHOLZEN, T. & GERDES, J. 2000. The Ki-67 protein: From the 
known and the unknown. Journal of Cellular Physiology, 182, 
311-322. 
SCHUBERT, M., BRAZIL, D. P., BURKS, D. J., KUSHNER, J. A., YE, 
J., FLINT, C. L., FARHANG-FALLAH, J., DIKKES, P., 
WAROT, X. M. & RIO, C. 2003. Insulin receptor substrate-2 
deficiency impairs brain growth and promotes tau 
phosphorylation. The Journal of neuroscience, 23, 7084-7092. 
SCHWARTZ, D. R. & LAZAR, M. A. 2011. Human resistin: found in 
translation from mouse to man. Trends in Endocrinology 
&amp; Metabolism, 22, 259-265. 
SCHWARTZ, M., SIPOLS, A., MARKS, J., SANACORA, G., WHITE, 
J., SCHEURINK, A., KAHN, S., BASKIN, D., WOODS, S. & 
FIGLEWICZ, D. 1992. Inhibition of hypothalamic neuropeptide 
Y gene expression by insulin. Endocrinology, 130, 3608-3616. 
SEALE, P., BJORK, B., YANG, W., KAJIMURA, S., CHIN, S., 
KUANG, S., SCIME, A., DEVARAKONDA, S., CONROE, H. 
M., ERDJUMENT-BROMAGE, H., TEMPST, P., RUDNICKI, 
M. A., BEIER, D. R. & SPIEGELMAN, B. M. 2008. PRDM16 
controls a brown fat/skeletal muscle switch. Nature 454, 961-
967. 
 REFERENCES 
221 
 
SEALE, P., KAJIMURA, S., YANG, W., CHIN, S., ROHAS, L. M., 
ULDRY, M., TAVERNIER, G., LANGIN, D. & SPIEGELMAN, 
B. M. 2007. Transcriptional control of brown fat determination 
by PRDM16. Cell metabolism, 6, 38-54. 
SEMENZA, G. L. 2000. HIF-1 and human disease: one highly 
involved factor. Genes & development, 14, 1983-1991. 
SENGER, D. R., ASCH, B. B., SMITH, B. D., PERRUZZI, C. A. & 
DVORAK, H. F. 1983. A secreted phosphoprotein marker for 
neoplastic transformation of both epithelial and fibroblastic 
cells. 
SERRERO, G. & LEPAK, N. 1996. Endocrine and paracrine negative 
regulators of adipose differentiation. International journal of 
obesity, 20, S58-S64. 
SHAPSES, S., CIFUENTES, M., SPEVAK, L., CHOWDHURY, H., 
BRITTINGHAM, J., BOSKEY, A. & DENHARDT, D. 2003. 
Osteopontin facilitates bone resorption, decreasing bone 
mineral crystallinity and content during calcium deficiency. 
Calcified tissue international, 73, 86-92. 
SHARFI, H. & ELDAR-FINKELMAN, H. 2008. Sequential 
phosphorylation of insulin receptor substrate-2 by glycogen 
synthase kinase-3 and c-Jun NH2-terminal kinase plays a role 
in hepatic insulin signaling. American Journal of Physiology-
Endocrinology And Metabolism, 294, E307-E315. 
SHAW, J. E., SICREE, R. A. & ZIMMET, P. Z. 2010. Global estimates 
of the prevalence of diabetes for 2010 and 2030. Diabetes 
Research and Clinical Practice, 87, 4-14. 
SHIMOMURA, I., MATSUDA, M., HAMMER, R. E., BASHMAKOV, Y., 
BROWN, M. S. & GOLDSTEIN, J. L. 2000. Decreased IRS-2 
and Increased SREBP-1c Lead to Mixed Insulin Resistance 
and Sensitivity in Livers of Lipodystrophic and ob/ob Mice. 
Molecular cell, 6, 77-86. 
SIMON, G. 1965. Histogenesis. Handbook of physiology. Section, 5, 
101-107. 
SØRENSEN, E. S., PETERSEN, T. E. & HØJRUP, P. 1995. 
Posttranslational modifications of bovine osteopontin: 
Identification of twenty‐eight phosphorylation and three 
O‐glycosylation sites. Protein Science, 4, 2040-2049. 
SORIGUER, F., GODAY, A., BOSCH-COMAS, A., BORDIÚ, E., 
CALLE-PASCUAL, A., CARMENA, R., CASAMITJANA, R., 
CASTAÑO, L., CASTELL, C., CATALÁ, M., DELGADO, E., 
FRANCH, J., GAZTAMBIDE, S., GIRBÉS, J., GOMIS, R., 
GUTIÉRREZ, G., LÓPEZ-ALBA, A., MARTÍNEZ-LARRAD, M. 
T., MENÉNDEZ, E., MORA-PECES, I., ORTEGA, E., 
PASCUAL-MANICH, G., ROJO-MARTÍNEZ, G., SERRANO-
RIOS, M., VALDÉS, S., VÁZQUEZ, J. A. & VENDRELL, J. 
2012. Prevalence of diabetes mellitus and impaired glucose 
222 
 
regulation in Spain: the Di@bet.es Study. Diabetologia, 55, 
88-93. 
SPALDING, K. L., ARNER, E., WESTERMARK, P. O., BERNARD, S., 
BUCHHOLZ, B. A., BERGMANN, O., BLOMQVIST, L., 
HOFFSTEDT, J., NÄSLUND, E. & BRITTON, T. 2008. 
Dynamics of fat cell turnover in humans. Nature, 453, 783-
787. 
SPANGRUDE, G., HEIMFELD, S. & WEISSMAN, I. 1988. Purification 
and characterization of mouse hematopoietic stem cells. 
Science, 241, 58-62. 
SPIEGELMAN, B. 1998. PPAR-gamma: adipogenic regulator and 
thiazolidinedione receptor. Diabetes, 47, 507-514. 
SPIEGELMAN, B., CHOY, L., HOTAMISLIGIL, G., GRAVES, R., 
TONTONOZ, P., PUTKEY, J., DOTSON, D., MOUAWAD, P., 
JONES, G. & TAN, X. 1993. Regulation of adipocyte gene 
expression in differantiation and syndromes of 
obesity/diabetes. J Biol Chem., 268. 
SPIEGELMAN, B. M. & FLIER, J. S. 1996. Adipogenesis and Obesity: 
Rounding Out the Big Picture. Cell, 87, 377-389. 
SPIEGELMAN, B. M. & FLIER, J. S. 2001. Obesity and the Regulation 
of Energy Balance. Cell, 104, 531-543. 
STAHL, A. 2004. A current review of fatty acid transport proteins 
(SLC27). Pflügers Archiv, 447, 722-727. 
STANDAL, T., BORSET, M. & SUNDAN, A. 2004. Role of osteopontin 
in adhesion, migration, cell survival and bone remodeling. Exp 
Oncol, 26, 179-84. 
STARR, R., WILLSON, T. A., VINEY, E. M., MURRAY, L., RAYNER, 
J. R., JENKINS, B. J., GONDA, T. J., ALEXANDER, W. S., 
METCALF, D. & NICOLA, N. A. 1997. A family of cytokine-
inducible inhibitors of signalling. Nature, 387, 917-921. 
STEPPAN, C. M., BAILEY, S. T., BHAT, S., BROWN, E. J., 
BANERJEE, R., WRIGHT, C. M., PATEL, H. R., AHIMA, R. S. 
& LAZAR, M. A. 2001. The hormone resistin links obesity to 
diabetes. Nature, 409, 307-312. 
STEPPAN, C. M., WANG, J., WHITEMAN, E. L., BIRNBAUM, M. J. & 
LAZAR, M. A. 2005. Activation of SOCS-3 by Resistin. 
Molecular and cellular biology, 25, 1569-1575. 
SUGII, S., OLSON, P., SEARS, D. D., SABERI, M., ATKINS, A. R., 
BARISH, G. D., HONG, S.-H., CASTRO, G. L., YIN, Y.-Q. & 
NELSON, M. C. 2009. PPARγ activation in adipocytes is 
sufficient for systemic insulin sensitization. Proceedings of the 
National Academy of Sciences, 106, 22504-22509. 
SUN, X. J., WANG, L.-M. & ZHANG, Y. 1995. Role of IRS-2 in insulin 
and cytokine signalling. Nature, 377, 173. 
SUZUKI, K. & KONO, T. 1980. Evidence that insulin causes 
translocation of glucose transport activity to the plasma 
 REFERENCES 
223 
 
membrane from an intracellular storage site. Proceedings of 
the National Academy of Sciences, 77, 2542-2545. 
TAGUCHI, A., WARTSCHOW, L. M. & WHITE, M. F. 2007. Brain 
IRS2 signaling coordinates life span and nutrient 
homeostasis. Science Signaling, 317, 369. 
TANG, W., ZEVE, D., SUH, J. M., BOSNAKOVSKI, D., KYBA, M., 
HAMMER, R. E., TALLQUIST, M. D. & GRAFF, J. M. 2008. 
White fat progenitor cells reside in the adipose vasculature. 
Science, 322, 583-586. 
TANIGUCHI, C. M., EMANUELLI, B. & KAHN, C. R. 2006. Critical 
nodes in signalling pathways: insights into insulin action. Nat 
Rev Mol Cell Biol, 7, 85-96. 
TANSEY, J., SZTALRYD, C., HLAVIN, E., KIMMEL, A. & LONDOS, 
C. 2004. The central role of perilipin a in lipid metabolism and 
adipocyte lipolysis. IUBMB life, 56, 379-385. 
TAYLOR, S. I. 1992. Lilly Lecture: molecular mechanisms of insulin 
resistance: lessons from patients with mutations in the insulin-
receptor gene. Diabetes, 41, 1473-1490. 
TCHKONIA, T., GIORGADZE, N., PIRTSKHALAVA, T., 
TCHOUKALOVA, Y., KARAGIANNIDES, I., FORSE, R. A., 
DEPONTE, M., STEVENSON, M., GUO, W., HAN, J., 
WALOGA, G., LASH, T. L., JENSEN, M. D. & KIRKLAND, J. 
L. 2002. Fat depot origin affects adipogenesis in primary 
cultured and cloned human preadipocytes. Am J Physiol 
Regul Integr Comp Physiol, 282, R1286-96. 
TCHKONIA, T., GIORGADZE, N., PIRTSKHALAVA, T., THOMOU, T., 
DEPONTE, M., KOO, A., FORSE, R. A., CHINNAPPAN, D., 
MARTIN-RUIZ, C., VON ZGLINICKI, T. & KIRKLAND, J. L. 
2006. Fat depot-specific characteristics are retained in strains 
derived from single human preadipocytes. Diabetes, 55, 2571-
8. 
TCHKONIA, T., LENBURG, M., THOMOU, T., GIORGADZE, N., 
FRAMPTON, G., PIRTSKHALAVA, T., CARTWRIGHT, A., 
CARTWRIGHT, M., FLANAGAN, J., KARAGIANNIDES, I., 
GERRY, N., FORSE, R. A., TCHOUKALOVA, Y., JENSEN, 
M. D., POTHOULAKIS, C. & KIRKLAND, J. L. 2007. 
Identification of depot-specific human fat cell progenitors 
through distinct expression profiles and developmental gene 
patterns. Am J Physiol Endocrinol Metab, 292, E298-307. 
TCHKONIA, T., TCHOUKALOVA, Y. D., GIORGADZE, N., 
PIRTSKHALAVA, T., KARAGIANNIDES, I., FORSE, R. A., 
KOO, A., STEVENSON, M., CHINNAPPAN, D., 
CARTWRIGHT, A., JENSEN, M. D. & KIRKLAND, J. L. 2005. 
Abundance of two human preadipocyte subtypes with distinct 
capacities for replication, adipogenesis, and apoptosis varies 
224 
 
among fat depots. American Journal of Physiology - 
Endocrinology And Metabolism, 288, E267-E277. 
TONTONOZ, P., HU, E., GRAVES, R. A., BUDAVARI, A. I. & 
SPIEGELMAN, B. M. 1994a. mPPAR gamma 2: tissue-
specific regulator of an adipocyte enhancer. Genes & 
development, 8, 1224-1234. 
TONTONOZ, P., HU, E. & SPIEGELMAN, B. M. 1994b. Stimulation of 
adipogenesis in fibroblasts by PPARγ2, a lipid-activated 
transcription factor. Cell, 79, 1147-1156. 
TONTONOZ, P., KIM, J., GRAVES, R. & SPIEGELMAN, B. 1993. 
ADD1: a novel helix-loop-helix transcription factor associated 
with adipocyte determination and differentiation. Molecular 
and cellular biology, 13, 4753-4759. 
TSENG, Y.-H., KRIAUCIUNAS, K. M., KOKKOTOU, E. & KAHN, C. R. 
2004. Differential roles of insulin receptor substrates in brown 
adipocyte differentiation. Molecular and cellular biology, 24, 
1918-1929. 
ULDRY, M. & THORENS, B. 2004. The SLC2 family of facilitated 
hexose and polyol transporters. Pflügers Archiv, 447, 480-
489. 
ULLRICH, A. & SCHLESSINGER, J. 1990. Signal transduction by 
receptors with tyrosine kinase activity. Cell, 61, 203. 
VAISSE, C., HALAAS, J. L., HORVATH, C. M., DARNELL, J. E., 
STOFFEL, M. & FRIEDMAN, J. M. 1996. Leptin activation of 
Stat3 in the hypothalamus of wild–type and ob/ob mice but not 
db/db mice. Nature genetics, 14, 95-97. 
VALVERDE, A. M., FABREGAT, I., BURKS, D. J., WHITE, M. F. & 
BENITO, M. 2004. IRS‐2 mediates the antiapoptotic effect of 
insulin in neonatal hepatocytes. Hepatology, 40, 1285-1294. 
VAN HARMELEN, V., RÃ¶HRIG, K. & HAUNER, H. 2004. 
Comparison of proliferation and differentiation capacity of 
human adipocyte precursor cells from the omental and 
subcutaneous adipose tissue depot of obese subjects. 
Metabolism, 53, 632-637. 
VÁZQUEZ-VELA, M. E. F., TORRES, N. & TOVAR, A. R. 2008. White 
Adipose Tissue as Endocrine Organ and Its Role in Obesity. 
Archives of Medical Research, 39, 715-728. 
VEGA, G. L. & GRUNDY, S. M. 2013. Metabolic Risk Susceptibility in 
Men Is Partially Related to Adiponectin/Leptin Ratio. Journal 
of Obesity, 2013, 9. 
VOLIOVITCH, H., SCHINDLER, D. G., HADARI, Y. R., TAYLOR, S. I., 
ACCILI, D. & ZICK, Y. 1995. Tyrosine phosphorylation of 
insulin receptor substrate-1 in vivo depends upon the 
presence of its pleckstrin homology region. J Biol Chem, 270, 
18083-7. 
 REFERENCES 
225 
 
VYKOUKAL, D. & DAVIES, M. G. 2011. Vascular biology of metabolic 
syndrome. Journal of Vascular Surgery, 54, 819-831. 
WALKEY, C. J. & SPIEGELMAN, B. M. 2008. A Functional 
Peroxisome Proliferator-activated Receptor-γ Ligand-binding 
Domain Is Not Required for Adipogenesis. Journal of 
Biological Chemistry, 283, 24290-24294. 
WANG, B., JENKINS, J. R. & TRAYHURN, P. 2005. Expression and 
secretion of inflammation-related adipokines by human 
adipocytes differentiated in culture: integrated response to 
TNF-alpha. Am J Physiol Endocrinol Metab, 288, E731-40. 
WANG, K. X. & DENHARDT, D. T. 2008. Osteopontin: Role in 
immune regulation and stress responses. Cytokine & Growth 
Factor Reviews, 19, 333-345. 
WANG, Y., BEYDOUN, M. A., LIANG, L., CABALLERO, B. & 
KUMANYIKA, S. K. 2008. Will all Americans become 
overweight or obese? Estimating the progression and cost of 
the US obesity epidemic. Obesity, 16, 2323-2330. 
WANG, Y., MONTEIRO, C. & POPKIN, B. M. 2002. Trends of obesity 
and underweight in older children and adolescents in the 
United States, Brazil, China, and Russia. The American 
journal of clinical nutrition, 75, 971-977. 
WASSERMANN, F. 1965. The development of adipose tissue. 
Comprehensive Physiology. 
WEISBERG, S. P., MCCANN, D., DESAI, M., ROSENBAUM, M., 
LEIBEL, R. L. & FERRANTE, A. W. 2003. Obesity is 
associated with macrophage accumulation in adipose tissue. 
Journal of Clinical Investigation, 112, 1796-1808. 
WHITE, M. F. 1997. The insulin signalling system and the IRS 
proteins. Diabetologia, 40, S2-S17. 
WHITE, M. F. 2002. IRS proteins and the common path to diabetes. 
American Journal of Physiology - Endocrinology And 
Metabolism, 283, E413-E422. 
WHITE, M. F. 2003. Insulin Signaling in Health and Disease. Science, 
302, 1710-1711. 
WHITE, M. F. 2006. Regulating insulin signaling and beta-cell function 
through IRS proteins. Can J Physiol Pharmacol, 84, 725-37. 
WHITE, M. F., MARON, R. & KAHN, C. R. 1985. Insulin rapidly 
stimulates tyrosine phosphorylation of a Mr-185,000 protein in 
intact cells. 
WHITE, M. F. & YENUSH, L. 1998. The IRS-signaling system: a 
network of docking proteins that mediate insulin and cytokine 
action. Protein modules in signal transduction. Springer. 
WITHERS, D. J. 2001. Insulin receptor substrate proteins and 
neuroendocrine function. Biochem Soc Trans, 29, 525-9. 
WITHERS, D. J., GUTIERREZ, J. S., TOWERY, H., BURKS, D. J., 
REN, J. M., PREVIS, S., ZHANG, Y., BERNAL, D., PONS, S., 
226 
 
SHULMAN, G. I., BONNER-WEIR, S. & WHITE, M. F. 1998. 
Disruption of IRS-2 causes type 2 diabetes in mice. Nature, 
391, 900-4. 
WON PARK, K., HALPERIN, D. S. & TONTONOZ, P. 2008. Before 
They Were Fat: Adipocyte Progenitors. Cell Metabolism, 8, 
454-457. 
WOOD, I. S., DE HEREDIA, F. P., WANG, B. & TRAYHURN, P. 2009. 
Cellular hypoxia and adipose tissue dysfunction in obesity. 
Proceedings of the Nutrition Society, 68, 370-377. 
WOODS, S. C., LOTTER, E. C., MCKAY, L. D. & PORTE, D. 1979. 
Chronic intracerebroventricular infusion of insulin reduces 
food intake and body weight of baboons. 
WU, Z., BUCHER, N. & FARMER, S. R. 1996. Induction of 
peroxisome proliferator-activated receptor gamma during the 
conversion of 3T3 fibroblasts into adipocytes is mediated by 
C/EBPbeta, C/EBPdelta, and glucocorticoids. Molecular and 
cellular biology, 16, 4128-4136. 
WU, Z., PUIGSERVER, P. & SPIEGELMAN, B. M. 1999. 
Transcriptional activation of adipogenesis. Current Opinion in 
Cell Biology, 11, 689-694. 
XIE, Y., SAKATSUME, M., NISHI, S., NARITA, I., ARAKAWA, M. & 
GEJYO, F. 2001. Expression, roles, receptors, and regulation 
of osteopontin in the kidney. Kidney international, 60, 1645-
1657. 
YASUKAWA, H., SASAKI, A. & YOSHIMURA, A. 2000. Negative 
regulation of cytokine signaling pathways. Annual review of 
immunology, 18, 143-164. 
YEAMAN, S. J. 2004. Hormone-sensitive lipase--new roles for an old 
enzyme. Biochemical Journal, 379, 11. 
YENUSH, L., MAKATI, K. J., SMITH-HALL, J., ISHIBASHI, O., 
MYERS, M. G. & WHITE, M. F. 1996. The pleckstrin 
homology domain is the principle link between the insulin 
receptor and IRS-1. Journal of Biological Chemistry, 271, 
24300-24306. 
YKI-JÄRVINEN, H. 2004. Thiazolidinediones. New England Journal of 
Medicine, 351, 1106-1118. 
YOKOMORI, N., TAWATA, M. & ONAYA, T. 1999. A transcriptional 
repressor regulates mouse GLUT4 gene expression during 
the differentiation of 3T3-L1 cells. Diabetes, 48, 2471-2474. 
YUAN, M., KONSTANTOPOULOS, N., LEE, J., HANSEN, L., LI, Z.-
W., KARIN, M. & SHOELSON, S. E. 2001. Reversal of 
obesity-and diet-induced insulin resistance with salicylates or 
targeted disruption of Ikkbeta. Science Signaling, 293, 1673. 
ZEYDA, M., GOLLINGER, K., TODORIC, J., KIEFER, F. W., KECK, 
M., ASZMANN, O., PRAGER, G., ZLABINGER, G. J., 
PETZELBAUER, P. & STULNIG, T. M. 2011. Osteopontin Is 
 REFERENCES 
227 
 
an Activator of Human Adipose Tissue Macrophages and 
Directly Affects Adipocyte Function. Endocrinology, 152, 
2219-2227. 
ZHANG, G., GURTU, V., KAIN, S. R. & YAN, G. 1997. Early detection 
of apoptosis using a fluorescent conjugate of annexin V. 
Biotechniques, 23, 525-531. 
ZHANG, Y., PROENCA, R., MAFFEI, M., BARONE, M., LEOPOLD, L. 
& FRIEDMAN, J. M. 1994. Positional cloning of the mouse 
obese gene and its human homologue. Nature, 372, 425-432. 
ZHU, Y., QI, C., KORENBERG, J. R., CHEN, X.-N., NOYA, D., RAO, 
M. S. & REDDY, J. K. 1995. Structural organization of mouse 
peroxisome proliferator-activated receptor gamma (mPPAR 
gamma) gene: alternative promoter use and different splicing 
yield two mPPAR gamma isoforms. Proceedings of the 
National Academy of Sciences, 92, 7921-7925. 
ZUK, P. A., ZHU, M., ASHJIAN, P., DE UGARTE, D. A., HUANG, J. I., 
MIZUNO, H., ALFONSO, Z. C., FRASER, J. K., BENHAIM, P. 
& HEDRICK, M. H. 2002. Human adipose tissue is a source of 
multipotent stem cells. Mol Biol Cell, 13, 4279-95. 
ZUK, P. A., ZHU, M., MIZUNO, H., HUANG, J., FUTRELL, J. W., 
KATZ, A. J., BENHAIM, P., LORENZ, H. P. & HEDRICK, M. 
H. 2001. Multilineage Cells from Human Adipose Tissue: 
Implications for Cell-Based Therapies. Tissue Engineering, 7, 
211-228. 
ZULET, M. A., MORENO-ALIAGA, M. J. & MARTÍNEZ, J. A. 2012. 
Dietary Determinants of Fat Mass and Body Composition 
Adipose Tissue Biology. In: SYMONDS, M. E. E. (ed.). Springer New 
York. 
 
 
 
